var title_f10_20_10560="Synchronous lung ca PA";
var content_f10_20_10560=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Synchronous squamous cell carcinomas of the lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows a right upper lobe solid nodule partially hidden by the right clavicle (thin arrow) and a cavitary lingular mass (thick arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_20_10560=[""].join("\n");
var outline_f10_20_10560=null;
var title_f10_20_10561="Ca oxalate monohydrate crystals";
var content_f10_20_10561=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F67694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F67694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urinary calcium oxalate monohydrate crystals under polarized light",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine sediment viewed under polarized light showing coarse, needle-shaped calcium oxalate monohydrate crystals. These crystals have a similar appearance to hippurate crystals.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of W Merrill Hicks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_20_10561=[""].join("\n");
var outline_f10_20_10561=null;
var title_f10_20_10562="Swan neck deformity scleroderma";
var content_f10_20_10562=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F64627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F64627&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Swan neck deformity and scleroderma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Picture showing hyperextension of the proximal interphalangeal joint resulting from the development of metocarpophalangeal joint subluxation in flexion. This condition is similar to the swan neck deformity observed in patients with rheumatoid arthritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nalebuff EA. Surgery in patients with systemic sclerosis of the hand. Clin Orthop Rel Res 1999; 91:366. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_20_10562=[""].join("\n");
var outline_f10_20_10562=null;
var title_f10_20_10563="Child vs adult airway 1";
var content_f10_20_10563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Anatomic differences between the pediatric and adult airway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 390px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relative to adults, children have 1) large tongues relative to the size of the oral cavity 2) larger tonsils and adenoids 3) a more superior location of the larynx in the neck 4) a larger and floppy epiglottis and 5) the narrowest portion of the airway functionally occuring below the vocal cords. All of these differences make endotracheal intubation in children potentially more difficult than in adults.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_20_10563=[""].join("\n");
var outline_f10_20_10563=null;
var title_f10_20_10564="HEp-2 cells stained speckled";
var content_f10_20_10564=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F59033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F59033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Anti-Sm antibodies stain the nuclei of HEp-2 cells in a finely speckled pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 511px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Human serum containing anti-Sm antibodies stain the nuclei of HEp-2 cells in a finely speckled pattern (A and C). DAPI staining in panels B and D indicate the location of nuclei. In contrast to anti-DNA antibodies, in dividing cells (indicated by white arrow in C and D), anti-Sm antibodies do not stain the chromosomes. The anti-Sm antibody reference serum was obtained from the Centers for Disease Control repository of ANA standards.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_20_10564=[""].join("\n");
var outline_f10_20_10564=null;
var title_f10_20_10565="Hydrochlorothiazide: Patient drug information";
var content_f10_20_10565=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hydrochlorothiazide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     see \"Hydrochlorothiazide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/29/42454?source=see_link\">",
"     see \"Hydrochlorothiazide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F179599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Microzide&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F179600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Hydro&reg;;",
"     </li>",
"     <li>",
"      Bio-Hydrochlorothiazide;",
"     </li>",
"     <li>",
"      Dom-Hydrochlorothiazide;",
"     </li>",
"     <li>",
"      Novo-Hydrazide;",
"     </li>",
"     <li>",
"      Nu-Hydro;",
"     </li>",
"     <li>",
"      PMS-Hydrochlorothiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get rid of extra fluid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hydrochlorothiazide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703777",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), this drug may sometimes raise blood sugar. Talk with your doctor about how to fine tune this.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11757 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-42B8F45CE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_20_10565=[""].join("\n");
var outline_f10_20_10565=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179599\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F179600\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019461\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019463\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019462\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019467\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019468\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019470\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019465\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019466\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019471\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019472\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=related_link\">",
"      Hydrochlorothiazide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/29/42454?source=related_link\">",
"      Hydrochlorothiazide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_20_10566="Fetal response to stress";
var content_f10_20_10566=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Sequence of fetal response to stress",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 424px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGoAhMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooqC/vLbT7Oa7v7iK2tYVLySyuFRAO5J4FAE9U9U1Sw0m0a61W9trK2UZaW4lWNR+JIFfLnxW/acn+1XOm/D+GNYUJQ6nOu4ue5jQ8Aehb8hXzh4i8Rax4kvTd69qd3qFwf4p5C2PYDoB7CgD7p1v4//DrSWZP7c+2yLj5bOB5Afo2Av61i/wDDTfw//vat/wCAn/2VfDVFAH39of7QHw61ZkT+2zZSNnC3kDxgfVsFR+demabqNlqlql1pl5b3ls4yssEgkU/iDivy1rW8O+I9Z8N3gutB1O70+cHO6CUqG+o6EexoA/T6uF8bXGpWV9eXzy350W1tBIzaZcRJLaspdnkdJOHG3bgZP3SNpPXw34U/tOOZYdO+IMIKsQq6lbpjH/XRB291/KvpU6doWum11VrLTdQLIrwXbQpKdvUFXIPHfigDl28b6ibzULmDSmm0eylnhlIXa6+XGzb9xb+JgAE2ZwwbPapIfFupwXv2a+jsZmcabIr24ZVVbuaSMryTuK+WCG4znoK619H0x9SGovp1m2oDgXRgUyjjH38Z6HHXpWfbeEdDt7q/ki061EF7BDbzWnkIICInkdTs24zmU5Jz91emOQDnbzxrqct2llpVgkt20t8AdpkDLbyrGABuXltwycnb6HPE48Wam1/lrS2gtI7yztJYWJaXdcRxnhgdo2NJ6HcB2rpZPD2iy2MdlJo+nPZxuZEga2QxqxzlguMAnJ596sLplgoIWxtQC6SYES/eQAI3TqoVQD2wMdKAOMl8X6qNEsdUjhs3j1ScW9pAiM0kBLEAyZcBzhTlRswxC571uJreoQ+DNQ1XULEQX1nDcSGFjgP5e4qcAnaGABxkkZxk4zWg3h/Rma6ZtI08td/8fBNsmZuc/Px83IB5rM1fU9B8Ow2+i/YA/wBrSTy9NsbPzN6fxkxqMbeTnPXJ61UYuTtFClJRV2ZE3inWrWe4FxHpzR2zWUkmxHBeO5k2BVy3DJhjuOQ3A2r1qP8A4TLVZNQuI7CyivreW3u7ixYRGLzTA6goMuSxYMRu2oM4xuByNqz1rwzqN+LIC2F9PbR3LQXFsY38tGOzcGUcqwJCnkdcd6siDw3YNPqcI0iymkzvvkWJGy/OS+OSevPX3ocJJ2aEpxeqYvhXXl8Rw3d9ZBG0vzBHaTjOZwFG9segcsv1Q1z8Pjiea2m3RQW9xZwrFe5VpRHePP5EcSqCCwZlc8kcNGeA2a6TTW0fw7pOnadHe20Fusax2/nTKGlH97JxuJzkkdSaeyaFcXN7prLpks90d91akRs0x2gZkTq3yqoyR0Apcr7D5kctp3i3W724ttPWwtI9QN7PaTNOxRVEcaSbgqM/JDgbdx+vatXw34muNX1h9Na2jjuLKOQajgn91KJNsSr6h1V39l2+tbllo+mWOz7Fp1nbeWxZPJgVNpICkjA4JAA+gFJpulwafcahPEXee+n+0TO+CSdqooGAOAqqAPbuSTSGcrqnjK6svEIiitxd6V9qazdo4drJKsDSkBi/znK4wExz97IwZIPEGsyWeiMX0oTa20ZtmVXZLdTC8p3fN+9OEwCCmck4GOelOi6W2pf2idNsjqGQ32kwJ5uQNoO/Gc4469KiHhvQxBPANG00QzsHljFqm2RgSQWGMEgk8n1oAwH8TanDfTLLHYtBZ39pps6IH8yV5hF+9jOcBFMw4IOdj8jHMOl+J9a1JdMQQ6ZayakZnhdt8qpHEcNuGVyzZXAB4G48456qPRNKjube5j0yxW4t0EcMq26BolAwFU4yBgngetOm0fTJ7SK1n06zktoX8yOJ4FKI3PzAEYB5PPuaAPPPDvivU49E0cb/ALTdT6RojF7lyVMl08qO5xyT8gJ559up0j4v1R4nt4ksUvbeO/lmleNzHItrKI8Iu7ILbgcljt/2s12MekabEsax6fZosSRRoFgUBFiJMSjjgISSo/hycYrM8ReEtO121S3mH2eEPJIywwQHez/ebLxsVY8/MuDyeaAKniXWNQTwdpuo6ZJFb3dzc6epLrvULNcRIy49CHIz1xnGDgiOy8SahJqtsk8VobSbUJNLMaBhKskcbuZOTjafLOFxwpDbj0rppNPs5dOFhNbQy2QQR+RKodCo6Ag5z0HWorfRtMt70Xlvp1lFdhBEJ0gVXCAABdwGcYAGPagDm/E2p6tD4hvbW0uYo7GPRZbooU+cSBmG5WHQ/d9qyIvGOr6faW9ldQwXV/LBYPBLGjED7R5ww4LDew8g8gruLgcV395ptjezRTXllbXEsQZY3liV2QMMMASOAR19abNpOnTRSxzafaSRyxJBIjwqQ8aElEIxyqlmIHQZOOtAGM3iG8sfBOoa1qunmO7sYp5HtwwXzBHu2nq2wMADgk7c98ZOFP4g8TvLpkBht7OSbUIohNLDhJ43hlYrs3sRhkHzBueOnIru7KxtLG0FrZWsFtajOIYYwiDJyflHHJJqjH4a0KO0ltY9F0xbWVg0kK2sYRyOhK4wSO1AHIDxjqKWeqPbpbn+zhqF3KbokmaOG7niEaFcbeIvvENjKjBzmrFrr2pv4m1fTLOSNZJtRIhe9VmSCNLG0kMYUEHJaRjjIx855xiusn0PSbjyvP0uxl8mVpo99ujbJGbczjI4YsSxI5JOade6Lpd9HNHe6bZXCTSCaRZYFcPIFCh2BHLbVUZPOAB2oA4y18cX1/aW1/bW1rDaiXTYZ4ZdzSObt4hlGBACqJRglTuwelbGheJrjU9dfSWto0urLzv7QwTiLDgQ4/66KS49AD3qxqnhHT9T1mz1C6LE2piaOFYYQoMb70+fZ5gAYA4DgcdOTnT0/S4LG91G7jLvcX0olld8Z+VAiqMAYUBenqSe9AHN6z4qurLxJHa2sSXNil7BYXREW0wyShSP3hcZOHRtqo3B5IrMHjrUobaC5ubWzZL20nnt0TcvlNHcQwfvGJOVJnViQBtCnr1rtp9F0u41Bb+402ylvl27bh4FaQbTlcMRng8j0p50nTjGsZsLTy1ieEL5K4EbkF0xj7rFVJHQ4GelAGL4MuNQmv8AxRFql0lzLbamsSGJCkar9ktmwqlmKjLMcZPJJ71gS+OdUt9KN/Na2Uiz2F1eQQoWUxmCREw7ZOQ28HIA2nj5s5rvNO06x0yJ4tNs7a0jdt7JBEsYZsBckADJwqj6ADtWZovhPRdIsJbS3sLZ1mDLO8kKF5wWLYkIA3DJPWgDFvPEusWVxdLdQaeP7P8Asxuooy7NL58hUeUTjGBjGQdzAj5cZqs/jTUI4GvTBZtaTWeoXUEIDCRPsxAAds4O7PIAG3pz1rtLnS9Pur2C8ubG1mu4P9TPJCrPH/usRkfhWPa+DtMh1u71SZftM9yssbJLDCqbJSC6nYil8hVGXLHA68nIBhX3izxDBdC0h0q2uLyOyTUJIoCXWRHZwsauzJtI8s5cgj5l+UZqa48Va1Df6na/YYftaiY2NqY2BmVJVTzBLu2P8rhjH8rAkLz1rrNR0XS9TWFdR02yuxD/AKoTwLJ5f+7kcdB09KjPh/Rmku3OkacXuwRcMbZMzZOTvOPm55570AcZP42uYTaSApcSfZbwSL5T2yLKlxaxL5iPll2+cSeSMZPOQRoHxHrB1NNHVbA3/wBvaya68t/KwLUThhHuznB2ld3vnnFdPFo2lwwpDFptlHCkbwqiwKFVHILqBjhWKqSOhIGelLaaRptlHBHZ6fZ28cDM8KxQqgjZgQSoA4JBIJHqaAIfC2pvrXhzTdSljWKS6gSV0U5CsRyB7ZrUqK2t4bW3jgtYo4YIxtSONQqqPQAcAVLQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRUV3cQ2ltLc3UqQwRIXkkc4VVAyST6UAZvi3xHpnhPQLrWNcuRb2NuuWbGSx7Ko7kngCvhH4z/F7WPiNqckQeSz8Pxv/o9irY3AdHkx95v0Hb1q5+0L8U5viF4la2sJGXw9YOy2qZ/1zdDKfr2HYfU15JQAUUUUAFFFFABRXZ+E/hh4y8WWiXWhaDdz2b/duGAjjbtwzEA/hXolj+y946nGbifR7Xjo9wzH/wAdU0AeEV6z8EPjHqnw7v0s7pnvPDk0gM9sxy0Xq8fofUdD+tO8dfALxn4Q0mbU54rTULKEbpWsnZ2Re7FSoOB615JQB+ofh3W9P8RaLa6ro9ylzY3Kb45F7+oPoQeCK0a+Ef2b/iq3gPxGNP1m5ceHL47ZAeRbydpAPTscdue1fdcMiTRJLE4eN1DKynIIPIIoAfRRRQAVw/xG8J3HiWW0a3stMnMCMEmuLia3mhc/xI8YOR/skfjXcUVdOo6cuaO5FSCqR5ZHmNp4A1S11azvJbmw1KX+xzp1xc3W4TCXLESqdp3cMEySDtHfpVa6+GE66B4ZhsE0xL/TUYXcYzHHdsyBS5cITuGOCVPBPSu0sZHPxE1uMuxjXSrBgueATNeZOPU4H5CpvG+oXGmeHJri0lEEhmghM5APkJJMkby4PHyKzNzx8vPFb/XKt73/AK1/zMvqtO1v6/rQ88u/hlqx/sr+zn060ktrZLZpWnecKgkZ9pjkjIkAB45T8q2fDfgjU9L8dS6t5tjDpzzTzPCjmZpGkzgjegMR5ycO2enArQ8QxXmkLp8emaxdSz3F/bRlLuXzAoO8EnGGIbHIzg7ONvJpLDxVq15daXaQ2tk00v8AaP2pyXAxZ3SQExqMkltxIUnjjk45JYypJOL6/qCwtNO6O4orzxfG2pppdtdSW9jK99Z297bLEXCxLLNHHskPO4/vQQwxna3yjFN1Lxpe6Z9oe9ijmk097xJRATHHN5UCSqcNuKj5wDycYJ56VynQei0VQ0g6h5LDVJrOabIKtaoyLgjoQzN3zznn0FcLa+NPEF3pugvDptobzVrA6lEkIaULGFiIQ5ZPmJl5IJ2jHDZzQB6TRXCSeMNSgv3GoWUdlBJAz2sTxtJ5zrb+cR5ykoGBVwUIBwhYE8Coh4r1IyW0F2kAeZtNuFa1yoRLmYoY33ZyRsPzDG4E8LjkA9AorgIPFetXWl2c0UFil3fPIbW3ijadmjjJDltzxqv8PJbAz3qnp/jXVbmG71YJbfYG0vTruK1cHMT3O4ZLj+EHBJI6LxjmgD0uiuHk8Ta0uoppEMGnTaiL9rJp2LxwkfZhPuC/MQQDgrk+uRni9oXia41PXX0lraNLqy87+0ME4iw4EOP+uikuPQA96AOqorjNZ8VXVl4kjtbWJLmxS9gsLoiLaYZJQpH7wuMnDo21Ubg8kVmDx1qUNtBc3NrZsl7aTz26JuXymjuIYP3jEnKkzqxIA2hT160AejUVzHgy41Ca/wDFEWqXSXMttqaxIYkKRqv2S2bCqWYqMsxxk8knvWB/wnOpw2sN1c21m0d1Zz3UMce4GPybiGIhmJ+bImDcAY24560AejUVw2s+ItUk1X7Hpb21uYNdTTWaRd4ljNks5z6Hc+OMfdHvSQ+I9Wu5bOV4rWC2m1q402Hy3ZmYRNcpukBGMExKcA++e1AHdUV5lpPirXV8PeG7668u/vLnw/LqkqRrsEuz7IT8oH+s2yyYxgZOMel658b3d1NAmiW0U8F7czRWVwE80SRwou9tu5ckuXUAMOELc9KAO/ormdV1i8i8G2uoz272d7I9qJYBIGMTPNGrLuwQcbiP8Kx/+Eu1ks7w2NncCaTUre1tlYo7SWsrou52O3D7DxgYOOewAO+oriNJ8YTz3MdrcCF5lW688m3ktmieJInCsjk4JWUHOSCMEHmuX1fWte1RLjULW8W0j+waY0cSPIBGbpysh+VgCcHAJBIwCuDkkA9forgNK1rUxqraBayQi6WeZftF2zzIEhityVUbgzFmn43MSArEk9Kin8XaomqzaZY26z3kl1OFfb5qKkUNuxVV3ITkzcc8AMeelAHolFcIfF2q+cskljbW0MUunRXFu7F5Q126IQGB2jYz9cHdjt1qWHxRqf8Awj6+IZY7E6W5EjQKG86CASBXZmzhiq5ZhgY2kc9aAO2orK8M6nJrGlC/eJY4J5Ha2wSd8IYhHP8AvKA30YVq0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfNP7XfxL/ALO04eCtIl/0q8QPqDgfciPSPPq2Mn2+te++MfENp4U8L6lrmo5+zWUJlZR1Y9Ao9ySB+Nfm14q1y78S+I9R1nUGzc3szTNzkLk8KPYDA/CgDJooooAKKK0vDmi33iLXLLSNKi829u5RFEpOBk9yewHUmgCTwt4f1LxRrtrpGiWz3N7cNtVVHAHdmPZR1Jr0X41/B64+Gel6FdG6kvxdqyXcqx4iimGCFU9cEZ6+hr6j+B/wz0b4a6Yym9trzX7wAXNwGHb/AJZoOoUH8/yA7T4heFbTxr4Q1LQb/CpdR4SQrkxSDlXHuDigDM+D3irSvF3gHSr3RdkaQwrby2y4zbuoAKEdumR6gg12tfA174e+I3wM11dTiWe3tVcA3NuxktbgdlcdOfRgD6V9jfCbx/Y/EbwnHrFjE1vKrmG4t2YExSDtkdQQQR7GgDsmUOpVwGUjBBGQRXxf+1J8J4fCuop4l8PQCPR7x9txAgOIJTk5A7K36H619o1neI9HtPEGg3+kaim+0vYWgkHfBGMj3HWgD8vK+yP2R/iQda0Z/COqys2oaem+0d2yZIP7v1X+RHpXzJ8UPBV74C8YXmi3uWRDvt5sYEsR+6w/kfcGs/wP4kvPCPirTtc05iJ7SUOV7OvRlPsRkUAfpvRWZ4Y1u08R+H9P1jTX32l7Cs0ZPUA9j7g5B+ladABRRRQB8++E/FXi25/aK1PQ7uS3NsuYbhhAATaw+a8J9ifOGT/tV9ASxpLG8cqK8bgqysMhgeoI7iuV0/wjDafEvV/FShN97YQ2ox97crHeT7bVh/I11lAGbZaDo9iu2y0nT7cb1kxDbInzLna3A6jJwe2asw2FnBKssFpbxyr5m10jAI8xw8mCB/EwDN6kAnmrNFAGdBoekwLOsGl2MazuskwS3QeY4O4M2ByQeQT35qY6bYmZpTZW3mszOX8pclmUKxJx1KgA+oAFW6KAKmm6ZYaVC0OmWVrZws24pbxLGpPTOFA54FQ3OiaVdWFvY3WmWM1lbgLDbyW6NHEANoCqRgYHHHatGigDJm8OaRJ9odNOtILieFrdriGBFlCFduA2M9AB+Ao0nw7pGlafFZ2Wn2kcMZR+IEBZ0xtc4AywwDn1rWooAoXGi6Xc20NtcabZS28Lb4ongRljbnlQRgHk8j1NINE0oeXjTLEeVB9lT/R0+SHGPLHHCYONvStCigCjaaRptlHBHZ6fZ28cDM8KxQqgjZgQSoA4JBIJHqaTT9Lgsb3UbuMu9xfSiWV3xn5UCKowBhQF6epJ71fooAz59F0u41Bb+402ylvl27bh4FaQbTlcMRng8j0p50nTjGsZsLTy1ieEL5K4EbkF0xj7rFVJHQ4GelXaKAKunadY6ZE8Wm2dtaRu29kgiWMM2AuSABk4VR9AB2qNtI01oRE2n2ZiEUkAQwrgRuQXTGPusVUkdDgZ6VeooAzF8P6MtjJZLpGnCzkcSvALZPLZwAAxXGCQFUZ9h6VaWws1WNVtLcLHM1wgEa/LKxYs444Yl2JPU7j6mrNFAFKy0nTrGRXstPtLZ13gNDCqEbypfoP4iiE+u0Z6CmS6JpUumxafLpli9hFjy7ZoEMSY6YTGBj6VoUUAVvsFn9ijs/slv9kjChIPLGxdpBXC4wMEAj0wKjk0jTZYjFLp9m8RMh2NCpGZCTIcY/iJJb1yc5q7RQBlnw7ojWkVo2j6abWJzLHCbVNiOerBcYB96sDStOWMxrYWgjKxptEK42xnMYxjop5A7dquUUAZ95omlXqOl5pljcI8nnMssCOGkwF3nI5bAAz1wKS50PSbq3a3utLsJoGkErRyW6MpcAKGIIxnAAz6DFaNFAFNdK09U2LYWgTMR2iFQMxkGM4x/CVBX0wMYqne+G9LubbUo4rSGzl1CJori4tYkjmdW+9lsZyfU1sUUAMhijghjhhRUijUIiKMBQBgAU+iigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigD5k/bU8WG20jSPC1tJh7tjeXIH9xThAfq2T/wGvkavSv2ifEX/AAknxc12dH3W9rILOHB42x/KcfVtx/GvNaACiivaf2fvgzceP7pdW1jfb+HLeTBI+9csDyi+g9TQB5Q2ialHosWsTWU8elSymBLpkIR3AyVU9zVCKV4X3wuyN03KcGvUf2gvGi+IvFp0bSVig8N6ETZ2FvCNqfLwz49yMD2AryugCQTSBgwkcMDkHceK9Y+Ffxz8TeCr2CG/u7jVtDDASWlw+90X/pm55B9s4ryOigD9Hdfj034pfCq/i0ieO4tNWs28h8/dkxlc+hDAZ9MV8ofs2eJ9V8F/FmPw3cOEtNQuTZXkDEbRKu4KwPqG4465+lbH7H/jmfSvF7+Frudjp2phngRjxHOozx6bgCPqBVf9p7wZd+CfiJb+LtLKraajc/aIyo/1VwmGIP1PzfnQB9rUVx/wp8cWXj/wbZ6zZsizlRHdQA5MMwHzKfbuD3BFdhQB4N+1x4IHiDwTHr1nGpv9Hy7YXl4T94Z9uv518SV+p17bRXtnNbXKLJDMhjdGGQwIwQa/Nv4oeFpPBvjvV9EkyUt5iYWxjdG3Kn8jj8KAPpr9jTxkl94avvCl04+06e5uLcf3oXPzD8GP/jwr6Qr85vgh4o/4RD4n6HqcjbbYzC3uP+uUnysfwyD+FfoyDkZHSgAooooAKKKKACiiigDzj4p6xqdh4h8MWOmXeowRXq3hlTT4kkmkZI1ZMBlPQnn2JqXw74i8UyatpGhajZWJ1A6bFfX0sshRlBmZGCqqkFtoBxwMk84rpfFc8Gnw2OptZW1xdxXttawySoC0IuJ44XKt1Hyv264ANa32S2F6bz7PD9sMfkmfYN+zOdu7rjPOOmaq6tY5vYz53NS36eWh5Vp/jvV4/C+gtp1rbzT3en3d67308jlRC3TIGWJHrircHxHv1s72bULbT7UnT7XULQq0kg2zttCOAAS30wPfvXX6m3hPQktIdUOhaavlSx2yXPlQjyzjzFQNj5fmXcBxyM9avJo+i3NqNmnadLbTW6QjECMjwjlE6YKDqB09KLrsQqNZfb/q3+ZwOn/ETWbu3ggGl2X9pPqx0wq8rJH/AKreGONxHoRzWl/wmupxeL4fDNxp9v8A2pJcRHcjMYzbGMvJICR1UqVAOM8V1troOj2gjFrpOnwCOTzkEdsi7ZMbd4wOGxxnriol8P2n/CVN4gd5nvjaizRWI2Rx7tx2jGcknkkmi6GqdZJe91/AwPiN4vu/Db20OmJazXLQS3LwzKxJRMcgggAcnJJz0wDXIeKvH+q6loF8+l+RpscFvp08jea32hmuDG+I8YG0A7ST15r1jU9I03VfK/tTTrO88rPl/aIFk2Z643A4qvP4b0O4MJuNG02UwxrFHvtY22Iv3VXI4AxwBwKE0gq0as2+WVk/8jjv+E/u/wDhOIdLjgtLjTZL99PMsYZXjkVSSCSfmII5wuPesq2+I2tX+k200dvp0UuoaZd3UHkyM72zwj70gIxg9uOo716Fead4fs9Rh1C6sNNjv551SO5a3TzHlIIX5sZ3YzzWZoei+GvBNtY6ZAkKXN0DbpJJErXFyN3O4qoLAFgMkYGRmi6E6Vdv4tNf0/4JzWh+J9buTorSCG81K40CS9VY5mEcrgIVDoAAHOecdM8cUwfFKe40G51ax0+J7QSWlpFIzHaJ5UDSbv8AZTIHue9eg22l6LpLwPbWOnWLgmGJo4UiOWOSq4A6kZwOuKdJp2k2Wk3UL2NlDppDSzxCFRGe7My4wemTRddhqjWSsp/1Yx/DPiK/1Dw1qN9qVlHb3dk8qbFb5ZAqhlbGSVyCODzXM3Hj/W4tC0G7k02wSbWmBttsjyKi+XuO8YX5ieAoP48V6BpNjpcGlrFpNnZw6fOvmCOCFUjcMOu0DByMU6bSNNn05NPn06zlsEACWzwKYlA6AKRgY+lF0W6dVxSUtbHmt98StXtYNOmutMtbGF4Q11LIzzLFJ5rR7T5eSg+XIJB64xkVfh8f351pIpLOzazbWp9H8qJ2Nwdm7EoXpt45+tdmvhvQ1ktnGi6YHthiBhax5iGc4Q4+Xkk8VS0rwzonh25v9TEcIubm5lupLy5VN8ZlbJQPgEJk8DPei6M1Srpr3tDkNO+JV/PYyXc1lYtHPpV1qdtHBKzNF5Ofkm+vqMc5GKH+IGv26XCXGlafNdSabBqVpHBO3KSSBNrbgNzDk4XrjA613NpYaC15qlta2Oni5cBb5EgUGQOCcScfMCM9c1YuNC0m4XbcaXYSr5K2+Ht0YeUpyqcj7oPIHQGi67D9lWt8Z5u3xN1GS0sIrO1tJtRuZ7iJsxyosZiVCUKNht53juQBzz0Ho/hzUJdV0Kyvbm3+zTzRhpIdwbY3cZHXmorvRtBj0lbW807S10yI7hDLBGIUJPXaRtHJrStreG1gjgtYo4YIxtSONQqqPQAcCk2uhdKFSLvOVyWiiikdAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWX4q1RNE8M6rqkpCpZ2sk5J/2VJ/pWpXlH7UWqnSvgvrYQ4e8MVov/AnG7/x0NQB8D3U8lzcyzzHdLK5dz6knJqKirWmWFxqmo2thYxNLdXMixRIoyWZjgCgD0z4CfCi5+I+vGa73weHrJx9rmHBkPXykPqR1PYfhX198VtVg+H/AMItVn0eKO0W1tfs1oiAKI2b5Fx9M5rX+GfhG18EeDNO0S0RA8KBp3UY8yU/eY+vP6AV57+17MI/g3cIQf3t7Agx9S3/ALLQB8MOSzFmOSeST3NNoooAKKKKANnwbqkmieLNH1OFyj2t3FLuHoGGf0zX6IfEjwdp/wAQPBt1o9+q4mTzLaYjJhlx8rj8+fUE1+a1fpl8OriW78A+HJ7jmWTT4Gb6+WKAPkf9n/WdT+Gnxom8J6y4igvJvsN1HuBQSjPluD9Tj6NX21XyR+2R4XOleItG8ZaaxhmuCLeZkGCJY/mR8+uOP+Aivor4TeJJfF3w50LW7lQLm6t/32O8ikox/EqT+NAHW18k/tp+FDDqmk+KbdDsuE+x3B4wGXJQ+vTI/CvravNP2jNAHiD4Q69EsZee1jF3DjqGjOT/AOO7qAPz3BwcjrX6P/BrxEPFPwy8P6oXDzPbLFNg5xInyNn3ytfm/X2D+xPrguPC+u6I7sXtLlbhFPQJIuOPxQ/nQB9J0UUUAFFFFABRRRQBwfxa8SaPoul2Ftqt/Dazy6jYzokmQWjjvIXkYeyqCTXZ6Zf2uqafBfafMs9pOgeKVejqehFePftSeGJtd8J6RdWUXmXlrfpAv+7MQmPxcR169ounxaRo9jptt/qLOBLeP/dRQo/lQBz3iIXlr450PVINNvL61h02+tpPs2wsskktoyA7mXgiJ+fauFvvCfiNILeMxXkVhJHdSQ22nsjvp80tw8ihcyxqGVHVVYEqpVgMKQT7PRQB5Vq2ja1JYeJEbTtUm1+4882mpQ3SogiZMRoMSDaR93aFxuy3fdS+JvC2rxa8iac2qvpUdtELOSCXz5YJxK7yMWlmUgtuT5juBClTgABvVKKAPHJND8SXWsahNJZ6rZLdW19Fc/YHjVWZpUMRQtLl22hjk7MAkDbkgMn0DxPcWNglzYzQ6bG12jQWS4fcxj8qbymuPkOBIBtkO0kNgbjt9mooA8o/4R/WZdcsJdRsNQvLqHU7S4jv5ZoysdssCK6lQ/DeYJCwUEEnIJ4xueO/Duo6t4jtb3SQ0V1BompQW10ZSqw3TtbGAkA8jKuehHy89q7uigDxpPCupS6cjXOnaxJDBfWVzJZM6RnKeYsrRkTsWfDruJYBtoIyc1PfaN4juvEdzOmm3Vusv26CURsnkywNDIINzGQs7EiI4wApJHbJ9eooA4PxNFPY+BdAju8pbW72qahAJ1iaWMJtaMMWUH5tpK5+YAjnODheDNLvdbGgXLNqEekw/wBtOn+mOFDHUIzaB9j/ALxRGrbeWXA4OCM+ryRpKhSVFdD1VhkGlACgAAADgAUAeSWGheJYdHd7a01K2v7SwgkuUlvA51C/ilSQlDvPDhHUs23cJFB6ECK98JeJ7vRtdsNUa5v1js42tcXP/HzLJKk84GWGCrxlUzgBWABAzXsNFAHl9x4avW1a71TT7C8glF5pDWu+c71gWWMXAI3kf6reGzkkcc11HiTR7jVfFegsxuxpcEVy1wILl4VMmYvLD7GBYcPxyOOa6iigDw6Xwz4m1Gz1VLnS7uE3enFrm1SREhe6SeJwsbeaWY7RIA7Fc+3Qbx0PWn8YxXXlarDYfaLSSxMZR2t4FVBLDIzTDbkiQt8rFlcYJYAL6nRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV83/tt6i0Pg/wAP6crYFzevMw9QiY/m9fSFfI37cF0W13wvaZ4jtppcf7zKP/ZaAPmWvpP9jPwXHqGu6j4qvYd8OngW9oWHHnMMs31Ckf8AfVeY/Ar4dH4keMxp88zwabax/aLuRPvbMgBV9yTjPbmvvrwz4f0vwxo0GlaFZxWdjCPljjHUnqSepJ7k80AaleGftirM3wkUxAmNb+EyH0GGA/Uivc684/aGs7S/+EHiKC9nggIg8yFpmCgyIQyqM9zggfWgD88qKKKACiiigB8UbSypHGMu5CqPUmv1B8PWzWegabbOoVobaKMqOgIUCvzc+Hujya/450LS4VLNc3kSED+7uBY/kDX6ZKAqhQMADAoA8C/bPjZvhjYOAxVdSTJGcDKP1rof2VLxLv4K6OiNua3lnhYeh8xmx+TCu5+I3ha28ZeDNT0S7HFxEfLb+5IBlG/A4rwL9izWZYf+Em8M3PDwSLdIpPIP3HGPqFoA+oap6xZrqGk3lm4ytxC8RB9wRVyigD8uNasX0vWL6wmGJLWd4W+qsR/Svcf2MtW+x/Eq+04g7b+xYDn+JGDDj6bq4f8AaG0w6V8Y/EsO3CSTidPo6hv6mrX7NN99g+NXhxs4EzyQHP8AtxsP54oA/QSiiigAooooAKKKKAMLxLrmkaa9raamJJ7idhLDaw273EjGNgwcIgJ+UgHPqKv2erWN3aWtzFcKsVyP3Xm5jZvba2Dn2xmuU+Ivhi61+4s5rOwtZpYEZY7j7dLaTwMe4ZFYMvsfwrldY+Guu3rWz393DrUhsI7WZ5rjyXR1YtuVzFISORyNrHGTVJI5J1asZNKN1/X9aHrzXMC3CwNNGJ2GVjLjcR6gdaal3bSLI0dxEwjO1yHB2n0PpXn6eDdRj1nVne20y6GoXBnTVZZG+1Wg8sKFQbedpHykMOvPpWC3w11l9A1C0SPSrOZtKi01Ut5GK3UiSq5nkOwYbAI7nk80WXcJV6i2h3PXvtlt5Ukv2iHy4iQ77xhCOxPas3TPEml6jb3U8N0iQ211JZu8rBAZEODgk8j3rhNX+HVyNT1WXR7XTY9NlvLC7i08kxxTiFXEiOApC7iynocleRVSXwBrraX9mFtpAhl1O7u5bRXAVUlC7AjmI7QpByAoJGBxRZdxSrVk/g/q562Zoh1kQcBuWHQ8A0qzRsVCyISwyoDDkeorzbwl8P57TV9GutegsrpNP0iK0TJLlLhJmcMuR0CkYNM+FHhy4sNb1m6uhL9ksJJNM0sSxlCsAlaRiM9QSygN3C+lFl3LjWqNxTja56Q13bLci3a4hFwRkRFxuI+nWqF34g0611uw0mScNe3rSLGifNtKJvO7+7x61wfivwTrmr+MhqUS6ebeO8triGbeI5ESPbvUgRksxwcEvgDjFV9J8A63Y61pswi0oGymv5G1DeWmujOjhDIhQfdLAEbjxn8Sy7kSrVeayh1/U9ShvrSdHeG6gkSM4dkkBCn3x0qtqGt6bp8Cz3l5DHE062wbO4eYTgLx0Oa8U1bwJrul+GfEFzPa2zPPpcVs0Vk28yzLOrFgixoAMZwADgdzXRX/AMO7+9tdWuDp+jW8txfWlzDpsbFoFWEYYbvLGC4JzhOmM9TT5V3J+s1Xooa/8P8A5fiem22owXFzcQgSIYXCbpF2rISMjYf4utTS3dtDHvluIUTds3M4A3emfX2rzq68D6lLaa7LbpY2t9JeWt/pqo5McMkKKNpwBxwy8Doe1Z+o/DTUG0rQkRre9ktoZhfQSSiMSyzHc7o7RuM5yM7QcAYIpWXct1qq+x/V/wCmetO6ou52VV9SajkureJo1kniQyHagZwNx9B6muO17wrd3/w7sNBi8nz4PsocSSll2xupYbtoJ4BAOBn2rn/GHw1mvdXMmlW1m+mPaJbJamYW/wBmKsWyh8p+CTk7dpz3oSRU6tSO0b7HqDXdslx5D3EKzbd3llwGx6464p0dzBIZBHNE5jAL7WB25GRn045ryPW/A2sR6vrOqQR2YgljuZpCzi4kmJhZVEamIOjdM4kI64Haq+jfD/VtT8NFxDY6M9xoVvYpFGWzO4ZJC84CrtJ27SPmI3NyccnKu5H1ipe3J3PY47q3lhWWOeJ4mOA6uCpP1pjX1otsLhrqAW5OBKZBtJ+vSvNJPAF/dxuZ7XTLa3udZtL6TTIXLQRQxLtcD5ACzdSNoFUdT+GupGC4j063sVVdUu7qzQThEgjlSNVGxonQj5WyuBjjB5NFl3G69VK/J/X3HrjXVukkSNPEry8xqXGX+g71NXj9/wDDbV5dUjuJWsrxWgtIwY5Ra/ZXhUD92BE5CZGQFKdSK9gpNJGtKpOd+aNgooopGwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfFf7aM/mfEzTos58rTUGPTLua+1K+Hv2xGJ+LgBPA0+H+bUAdj+w7GPtfi2TAzstlz36yV9YV8q/sOqP+Kubac/6MM/9/K+qqAMrxVr1l4Y8O3+s6o+y0s4mlf1bHRR7k4A+tfnr8VPiJq/xE8Qy3+pytHaKSLWzVj5cKduOhbHVu9e7fto+MyBpnhCzlIzi8vFHftGp/U/lXypQAUUUUAFFFLQB9G/sZeERqHinUfE1yoMWmR+RBkdZZAckfRQf++q+xq/Mfwr4s17wne/avDuq3VhL38p/lb/eU/K34ivoy2/aqNp4TsI5dGe/8QiPbcys4igLf3gACeeMjigD6qkdY42eRlRFBZmY4AA6kmvjj9mPUo4/2gNdhtiklvepdhHU5GBJvBB9CBXKal8Sfip8TWuNOsGvZ7S6Bjez021xHtI5UsBnGPVq9s/Zf+D+o+D7i78ReKrYW+qSx+Ta2/mBmiQ8szY4ycAY7DPrQB9EUUUUAfDX7YFmLf4vPMox9psoZD7kAr/7KK4D4P3AtPin4UnJwE1KDP8A32BXq37asAT4haRMGBMunDI9MSNXi3gNinjfw+wOCNQg/wDRi0AfpvRRRQAUUUUAFFFFAGD41u57LRreW1laKRtS0+IsvUo95Cjj6FWYfjW9XNfEL/kA2v8A2FtM/wDS+CuloA4Hxxa3eo+PPDtlahJI203UJnhlupYUJWWzAY+XySN7AZ7MayB4j1yfxRfaXHe2dmIp57OOwknQTmFYm8uWNCvmO5O1t24rtyMZBNeq1meJdXj0HQ7rUpYZJ0gAPlxkBmJYKAM4HU0AeO3/AI8v9J+H+l3Fl4gW51G30Q6g8l1NCsdxIiAtCSUZ5JAQQyrtb5gWYZFei+F55on8bSwxtcSxarIY4s/eItoCFHpk/wA6uxeLLWGa6g1u3n0m5t4lnKTlXEqM2wGMoW3HcQu372WUY+ZcyP4v0RLaGY3bnzXdFiW3laYFPv7ogu9duRuyBjIzjIoA860fxl4gvLGA/wBr6a8t3NYxusbxyTWjyzKkimIKNgAbAWTLBlOS3OJdT8Ya9bw21o2o29qi3GowNqd08UCyPBMEiRmZDGCVJLABS20lSuDXfv4y8PrNdRDU4ZJrVgkscQZ3ViQAm1QSWJYYUZJzwKdN4u0WGyhvJLqT7JIHJmFvKyRbG2v5pC/utpBB37cEHOMGgDi7jxP4iNvrV8b6yitrJ7GFkht96RCdIDNP5hPKRiV3GQOF5OOjR43v9N0y+1UXZ1zSLDVJLB3hjRpJlaGMwsDGApPnME4AH7zPauz1DX9Cuk1Gxub6WOOBXFxNGZYVTZjcFnXA3rkZCtuFZUFz4Qh0mBFM7xJfiXyZEuZLlrpQJAZI2BlZgNr/ADg4AVugUgAn8Ralq2i+DdOlvbuGK+eS2gv79Yx5dsHYCWUA8AAkgFsgZBbIBrmtU8W3lrO6WPiKC8ENtFLp42Qn+2ZGmlR4wQMMVCIv7vbgtuPBArqX8Z28Xw2tfF81rKsE9hBei2U7mBlVSqZx6uBnHvVnTvF2mztBb3U8cV84+aONZHjV9u/yxIUUb9nzbCA2OdtAHJ/8JLriX3n/ANoW/lT3+p2McM8IEMQgWVo5GZRvJzEA3OCDwM81jReOtWfSoI01LIN79nu9UkmtfJi/cbwsc6KYsM3ALrkfdPLKa73T/Hmh3nhvTtc33kFjewC4UyWkhMSbVYmQqpCBQ4yxO33IrW0bWE1O/wBbtkiKf2ZeLaF92RJut4Ztw9OJgP8AgOe9AHD6Jq/izXZL6K01XSlntdLhmjFvCJoZ7iQTgMJM/czGh4H0OKpz+PLzU9Lh1GC5fSLHULpbeykmMUCoY4S03myyo4X95ujACEkwnHUkdgfH3hoRNL/aWYlj87esEpBj5zICF5RcfMwyq/xEVem8UaNDqMljJfILhMhvkYqGCeYU34279nzbM7tvOMUAeTTeKtVudD13Vb7VhDNN4Kiv4LENtimnCXhlaMZDAjbGSVIOCuTgLXVSeKtSXxLJbrfRG5F9cW0mkeWm6G2SGR0uc/f+Yqh3E7SHCgbua7G48S6PbxLJJfxbXgS5Tbli8bttQqACW3McADkngA1WuPGegW9tDPLf4WZJXVBDIZAIiol3IF3LsLDdkDb3xg0AYvw91rVb+8hi1W8F2LrRbPVB+6WPypJTIGRdo+78q4zk9eecDu6wU8XaHJBcypfBltzGGAifc/mEiMxrjMgcghSgIbBxnFRT+NvD0EEcsuoqEdGkOInJjRWKOzgLlArAhi2NpGDigDo6KxtI8R2Oq6zq+l2wnF1pc4gm3xEKxMccmVboRiVRzg5B4xgnZoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr4f/bFQr8W1bHDafCf1avuCvjH9tW3MfxE0ibHEumjn3EjigDpv2HWXZ4tTI3Ztjj2/eV9UMcAk9ua+UP2HrlRd+LLbI3lLeQDHOAXHX8RX094j1D+yfD2p6jwTaW0k4B7lVJ/pQB+d/xj11vEfxM8Q6h83ltdNHGG6hEO0fyrjKluZmuLmWaT78jl2+pOaioAKKKKAPv34RaV4N1v4T+HtTbQNGaKKzCytNaRuUdBiQkkE9QT+NfG3xd8UWnivxxfXuk2lvZ6TEfIsoIIhGoiXo2B3Y5b8asaJ8UfEGifDm/8HadLHDYXkrO8wH7wIy4eMHsG4569fWqvwh8J/wDCbfEPR9Ek3/ZppN9wydREo3N+YGPxoA0vhX8JvEXxEukfT4Ps+lK+2a/m4jXHUL3Y+wqHUtIb4W/FdLbxHpcOqW+nXAlNvICI7qLqpGQcj6g8jmv0M0zT7TSrCCx022itbOBQkcMShVUDsAK4/wCLvh7whrnhe5/4TVtPtIVjKRX9wVR7dj0KueevbvQBN8JPGGheNPCEGoeHIIbOJT5c1kgVTbOP4SAAOnIOORXaV8Tfse3dza/Fq6sractZz2UvmgfdfaQVbH1/ma+2aACiiigD47/bcCf8Jn4eIYbzYNuUDkDzDg/z/KvDvAKGTxz4eQck6hAP/Ii17T+2vJu+IOipxlNNH6yPXk/wet/tfxT8KQYzu1KDP4OD/SgD9JKKKKACiiigAooooA5r4hf8gG1/7C2mf+l8FdLXNfEL/kA2v/YW0z/0vgrpaACsjxbo7694evNNjuFtnnC7Zmj8wKQwYZXIz09RWvXK/FKc23gLVpRO0AVU3SrIUKr5igncCMcZ5oAo634Gm8QJPNrupwz3+2JbZ4bQxwwhJVlwYy7F9zIobLjIUbdp5osPBV5pl3b3+lX2lWeoIs8Unl6a3kSJIYicp527eDCvzbzkZBHTHOatr0mkNqM/gi9+36OsEC3ExuWuYLSVrhULpIxYDEZkZhyq7VZhgndJZ+LL+VrG31TxLp1hp7m6ZdWgmgmErIYvLhaQqIg+JHJCqCQnGMNQB0Wo+BEvtLuLaS9Rp21Q6rE8lvujDkY2Om4blwWHBU85GMVj698Ln1bRp9P+36ZDFPZ3Fq0Q0xmhieUsfPijM3yS/NyxLE4GNtV9U8TeIoLDU79L+3+xpq39mhhAsQtYuCZmkbcAc/Lll2jcCQcVkeJPiBq+m+GTcx6vYNqFrZ3V6kiXMP2a9WN22IG8smWTaoDLFsAJ+8uQAAdXrXw4/tbUNSll1JLW2vA5MNnbtGHkLo6PMDIUkKlByEUnueTmxp/gi50+8tb+yvNKtdQgkkJa301likjdEVgyGYsX/drht3AGMGuc1zxtrOm6xr8Fvcx31zCszQW9r5UsNvGrou6VQPOR1VmY7so2DjHFS6f4s1GVrO2vfEenxafPdSINWt54J2G2JGSF3CCIOzM5GFztUDGTmgDrU8I7Phxp/hT7dn7LZW1n9q8r73lBBu2buM7OmeM9TVWHwNHb+Kp9WiksZIprwXrJcWRkmjk2gHy5fMAUcZ5RiMnnpjnt9w/7N+jGG5lgmk0SwUyqfmwyRBvzBI/Gm6RrGrWfiv8AsGK802xtrW6FnHZSNFA0sBjBE0cITczFjkFTswCpXIJoAtXvwyurvwzYaJNrNpNa2WmtpcS3GnGRBHtVUlCeaB5yhfv8jnhV5z2fhvQv7Fn1eT7R5/8AaF1Hc42bfL220EG3qc58jdnj72O2T5EnjfUtN+G3h9ofERl1hNGN3NJeTQqrzxxR7reQsju8oYnKDDnd8zLwa9I8BXD3OreMpXz82qwsFzkLnTrI4H4k0AVIvAHl6NBYf2lnytCn0XzPI6+bs/e43dtn3e+eoqxaeDJbfUYT/aSNpcd6uo/Zvs5EhnEez/Wb8bM/Nt25zxuxxXBaN4i17QfBmlLaXJvRPosd0qyxLi0AuIYncEDJVY5Wc7t33M8DIq9d+NNTTRo4xr1j58k9x9lv4ry3MLpHHEwjml8ooZS0hwkaAsq54waAN6P4Y20ej3ll9vMjtdxTWjSwBktoYWJhtigI3xrucdQcOcEHBq5a+BPKZH+02ULCwv7Jks7IxRk3LQHzMGRjlfI5yTu3dRjFcnqniHxHrnhHxDfW+pCwjttGtrtY7SD94JJbfzGIkzkAHpgZ967fxNq91Y+BVv8ARtSt7u5eS3iivSiyRv5k6RltqEAjDHoR9aAM3VPhzHfvHK1+nmw2lhBCJLffHvtTcfM67huVxcMNoIIxkN6Nm+HYm0nV7P7ZZ2x1DSbnTG+yWJjjQzMxMoQyEkjdyC3JycjOBmat4s1PTPGFnpi6qk0kN7aWV1BcGKE3CzbcyxRBC7AeYPn3qoZSMNg1i2PinWbHw9otu/iBCZZLtL2/u5oo2tZo3UJbu7qyqzBnbDDcQmARQB6npOjTabr2t3qXcb2mqTpdNAYSHjlWGKHh92CpWFTjbnJPPatquO13WtWg8AaVqFvPYx6tdy6bC8sama3DT3EMblRkFlxI2OQcY5Fc8PE2vW3jRtMu9RslFrdQ24t53jhe9haNS0qR7S7uWZguxtvybSMgmgD1KivFbD4g6tMt00GpQS2c1vaz/aJGill05ZLhY5DKsaKqFEbcUYvtK5ZsZFWvEOtz299eTW/i03tkfD93JbHdGI7yWMuSAUwC6gjJTBwvbmgD2CivP9N8Q6xJ4rtvDrbfMYpqBn8olfsBi6Z6b/P+Trnb81cv4N1jXbqxWW01YnUZfDGmX9npkxDJcSGJ2kCbiW5K7SwJPzDOcCgD2iiub8Ca3P4k0ufWSCmnXc5bT0ePY4twAoZvdmDsP9llrpKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK+Tv24bIi+8KX2OGjnhJ+hQ/+zGvrGvnr9tPTDc/D3SdQUZ+x6gFY+iujD+aigDzL9i688n4k6nbGUqJ9OYhMffZXT+QJr6c+Nl+2mfCbxTdIMsti6D/gXy/+zV8d/st6l/Z3xo0YELtulltjn/aQkY98gV9Q/tTSmL4J65jf8zQL8vvKvX2oA+BKKKKACiiigAr6n/Yo8LMZtb8UXEY2BRY2zEd+Gcj/AMdFfLttBJdXMVvAheaVwiKOrMTgD86/SX4XeFo/BngPR9ERVWW3hBnK/wAUrcufzJoA+d/jv8fdct/E974a8FsbGO0kNtPd7A0ssgOCEz90A8Z6n2rhNK+EHxR+IciahrC3KRyYIuNXuCDg9why2PwFN/af0rR/DvxflbQ2zJMiXl5BkkRzMxJAPbIw2O26vt3w1qKav4d0zUY43jS6to5gjjDKGUHB/OgDzv4JfBvTvhnHcXTXR1DWrlBHJclNionBKIuTxkck8nA6V6tRRQAUUUUAfC37Xl21x8YriI/dt7OCMfiC3/s1YX7Ndkb741eG1AyIpJJz/wABjY/0ql8fb46h8YfFM24sq3ZiXJ6BAFx+ld1+xpphu/ijdXpGUstPkbPozsqj9C1AH2zRRRQAUUUUAFFFFAHNfEL/AJANr/2FtM/9L4K6Wua+IX/IBtf+wtpn/pfBXS0AYmsa49pqltpen2T32pTRNceWJBGkcSkKWdj0yWAAAJPPYEivJ4tsbLzxrmNJaCC3mmFzKh2GaSSNFO0nq0RwehyO4IEus6Jd3GtW2r6RfxWd9FA9q4ntzPFLGzK3Kh0IYFeCG/ibIPGMu78G3F7q39o3uqo9yw07fstdqk2lxNNwN5wG87bjnbtzls0AaL+M9AQSs1+BHDAbiWXyZPLjQR+adz7dqt5fzbSQ2OcVLq/iO1sLu3tUxPcPeQ2kqK2DEZQSrHj0HSsnUPB1zd2viPTU1SOPRtcFx58JtS0yNND5bbJN4GM4YAoT1GcYxEPBd7cX0t7qesQyXUt5bXbNbWZhUeSjKFUGRiM7s5JOD2oAvaj460Swsbm5le7YW7Qh4vssiSFZZBGrqrhdybj95cjg4yeKvxeKNHl1GKxW8H2mXaFUxuAGZN6ozEYVypDBCQ2OcVxtp8L5YYpzJq1s109rDALmOwKySPFMsqyzsZSZWJQBuVyDxitseELp9SaW41OFrKa+h1O4gS1Ks1zGkajY5kO2MtErbSGPUbscUAamk+LtA1eZY9N1S2uGZHkUoTgqm3eQeh27lz6Z+tWbnxBpVroUWtXN9DDpUqxOt1IdqFZCoQ5PQEsvX1rkNd8DTTeDPDnh+1nleSzljglvYiIituUZJ8gkn542ZABkhmRv4cjrPEOipq+lW9jHItqkN5Z3S7Y8jEFxHMEAyMZ8vbntnODjFAEVv4r0W4vILaG9DSz7Qh8t9gZl3KjPjarleQhIYgg45rLPj/THvriG1WSe3htFu/tODGkgaQRjYXADrzkMpIPaoLjwFDJ4nu9UWSxkhu7mO7ljubMySo6oq/upBIoUYRSMqxByQegFOP4d3J08WdzrUUkUWmxaZAUstjLHHIrqz/vCGbC4OAo7gDpQBuap450TT7DULsy3E8VicSmG3chj5gjOxiAr7XODtJwc5p13420OAzxx3sct3CiSPb/cdVbaVLBsbchgRnGaxLj4eSzzayw1WK2iv4pFWC0tnji8xpVkEsiGUq7grjKhN2989RjRuvB815Ya/FdajGbjV5YJXkjtiqxmNI1OFLkkHy89eM98cgEuneOdJuJb6K8kNlLaT3UTearbGWBiHYPt2k7V3FQSQOenNWte8XaTotq89zM8uyW1jdIELuv2iURxsR6ZJPrhTgE4Bwbj4fy3v2m21DVY5NNa6vryGKK1KSpJcpLGdzlyGCrPIAAoycHtTj4Gv54L5r3WreS9nOnNFJFYlI42s5vNQlDKSwZgARuHGcEdgDabxjpESTNcztGEmMKqqNI74jSRm2KCwAVwTkDHU4qa48WaHBeQWz6hGZZhEy7FZ1AlO2IsygqoY8AkgE8CsVPBt/bavNq9jrFvFqkss7M8lkXiCTR26uoTzAc7rZGB3ccgg9aZF8PYbfTpLG1v3S3+zaZax74tzItnJuGTuGSw47Y689KAO5ooooAKKKKACiiigAqO4hS4t5YZN2yRSjbWKnBGDgggg+4OakooAhsbSCwsre0s4lhtreNYoo1GAiKMBR7AACpqKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK82/aM0g6z8G/EkKqWkghW6QDrmNg5/QGvSaq6rZx6jpl3ZTAGO5heFgfRgR/WgD80vAurSaD4z0TVIj81peRS/UBhn9M19x/tNRm5+COvlDwFhk/ASoa+Ddb0+XSNZvtOuAVmtJ3gcH1ViP6V9qeIdUbxj+yhPfxiSWeTSl3hBlt8TAP+qE/SgD4dooooAKKKKAPX/wBlrwsniX4rWU1wm600pDfOMZBZSAgP/AiD+FfV3xn+Kul/DTR0eZPter3Kt9ks1bG4j+Jz2Qevft7fGXwZl8d2/iOab4bQ3EmoCLbP5aKyeWT/AB7vlxkcZ9K7LXvhX4+8Q65d+I/ibdRaVYqokvNSupUYRoOAqIh5PYKMDJoAyfBlnr/xb+LUXiHVLOJ7QXcU+o3BTZbQxpj5STx0AGMknNfd9neWdz+7srm3l2D7sUittH0HSvzy8e+PW1XToPDXhpZdO8H2JxBaZAe4Yf8ALaYj7zk846DtVT4SeMr3wT470zVbSUiEyLDdIeRJCxAYEfTke4FAH6Q0U2J1ljSSM7kcBlPqDTqACoL+5Szsbi6mYLHBG0jE9AFGT/Kp68x/aQ8Qjw78IdbkV9txeoLGLnBJk4OPou4/hQB8D63fyarrN/qExzLdTvO3PdmJ/rX1R+xDpHl6T4m1l1P76aK1Qn0QFm/9DX8q+Sa/QL9mfQzofwd0RZFKzXge8fIwfnYlf/HQtAHqVFFFABRRRQAUUUUAc18Qv+QDa/8AYW0z/wBL4K6Wua+IX/IBtf8AsLaZ/wCl8FdLQAVyvxSkmi8Bas1rI0c21ArK5QjMij7w5HXtXVVmeJdXj0HQ7rUpYZJ0gAPlxkBmJYKAM4HU0Aee+MNVvfCGlQWdrcw6XfyxXN4rNdg28hjCAIXnR2ZjkYjQAnB+ZetZo1Ke78S2l6xKPNrEUpRWO0Z0GZ8D2zXoNp4ut5TPFdWk1nc29+lhNFNJHhXeNZFIYMQRtYe/Xiprfxbpd3FbyWMrzRzTxwI7RtEG8wEq6lwN6kA4K5B7ZoA4PSfE+tHTrC6W9CQW/wDYcJthErCUXbQxyFnbLceYSuCORznpWp4J8VXuq+KdPtbnU45nu7C9ubvTwsYNhLFPbosfA3ggSuDvJyRkYHFdPbeM/D9zDPNDqSGKGETmRkdVaMnbuQkYcbsL8ueSB1OKb4Yt9Duru61TSmu5rpWe2ka7lnZ4CSrtGEmOYgfkJUBRwvHAwAYWq+JLyHxFr0H9pR291YbRp2kbU3akDAsm4bhvbLs0Y2EY8sk5zXPaZ4w8QXWmboNZ0qeW4uLCJXVknktnmm2SB40CbVwRtVjvBDAk9vSG8UaItjHetqVuLWS0S+WUn5TA5AWT6HI/OobPxhod5eQ2sN4/2iWUwBJLeSMpJt3BH3KNjFRuAbBYcjIoA4+w8Sa6PG/9l3mo2CCC7W0a1uJI4pLmLygfOSPbvZmYlgVbYACuMgmuY8H+K9UtfAGix6LrNvqG3RdMEkjxpKthO8kMXltsILZV3JVjuBQnIyAPRdH+IGlaloCaiA8U/wBnS5a2kyhCswXKuwVXAY4JXIB4PJqzaeNLB5Z1vdlnHCb4vLLKu0JazJEzHocEyKenHQ9RkA5TVvFmp6Z4ws9MXVUmkhvbSyuoLgxQm4WbbmWKIIXYDzB8+9VDKRhsGllmuV+AN/Lb3MsFwLO4xMh+df3j9D244zXZz+L9Hgs1u55buKAl9zPYzr5QUAs0gKZjUBgdz4GDnNW9G1hNTv8AW7ZIin9mXi2hfdkSbreGbcPTiYD/AIDnvQB5na3DeGNc1TS49Sh0jS21KKGbUPKijSECxR1UAjy03N3Ix1HVgan/AOE28SxLpzTW8JWawg1WZjCV/wBHjMn2oqM5BI+zlQckeaRziu7Hi/RBHdSS3jW62wRpPtMEkJ2u2xWAdQWUtwGXIz3qO48ZaLFppu1uJZPmkjWBbeXzt6DLKY9u9cDBJK4AIJ4IoAx9U1fUG+DtxrN3hb+XTTdlQCmwuu4LwQQVBA69qz31nXbrXreGPVjb293rtxo4jjt4z5USW0swkUsCTJmLbk5XDfdJGa7TT9cgufC9lrc0csUNzaxXPlojSuu9QQoCglj8wHA5qrL4x0KKziuZL4rHIZFC+TJ5ieWQJC8e3cgQkbiwAXIzjIoA84n8eax/ZwZtWtodRi0dbu2tfLjDaldCaaPysHnD+WoITBBbIIAwbdz418RxaxrXkvYvc2jX6x6NJMgnkSGORoGjiC+YWkKRtksVKyHABArqtf8AFfhXQL/UdTnuRNqkNihmjtiZJGgG50wuduDuYg8Z9eK0ZPF+lRSSrNM6qqwmMCNmklaXftVYgDIWxGxxtzgE9AcAHnUfiQWWoeILq38SNqC3CabCuoxvbpFCzmcnc5QxxpxjLKx5UcnFOg8Y+Ib7w+Z49SghmtdN1a7aWCNJVne0ujDH8xUAqwGWIVc5429vUbvWrW30q21BSXt7ia3hQn5DmaVI1+9jHLjjr2xnis2Txz4ejkkT7ezMnmcR28r7/LbbJswp37D97bnb3xQBylz4w1HGv3EWoRLq1kkv2LQPLUtcqLcSLJjHmvkknKHGF243ZNbvw31m91ZNQ+1apYanBGY2ilt7mOaRdwO5XMaqo5AIGM4Jznqdd/Fmhrew2v8AaEbSymIKUVmQGX/VbnA2rvyAuSNx4GTQvi3Q2e6X+0I1Fsjyu7qyoyoQrsjEYcKxAO0nBIB5NAG5RXLab41sLxNVlMF9HDY3y2K4s5nllY28U2fKCb1wJCOR/DnuKtS+MdAjktkOpRt9oihnRo1Z18uZisbswBCqzKQGYgZ4oA36Kw5PFeixzXkb3oUWm4SyGN/LDKQGQSY2s4JAKglgeMZq/pOqWmrW7zWMrOqOY5FeNo3jcYJV0YBlOCDggHBB6EUAXaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+DP2qfDbaD8W764RNttqqLexntuPyv/AOPKT+Ndz+z/AOIYNU+CPjvwrfXTRtZ2k91FtGSInQ7sevzjn/eruf2yPCn9reBbPX7ePNxpE2JCBkmGTAP5MFP5180/BDX7fw/8RdPk1BlXTb1X0+7LZwIpV2EnHoSD+FAHBUVf17T5tJ1q+0+6iMU9tM8Tof4SDiqIoASiiigD6P8A2PPFGkeHZvFX9uanZ2ELwwyqbiQIW2784z169OtcP8dvi7ffEfVvs1rvtvDtrITbW/Qynp5knvjoO35mvKc8Y7UlABSg4OR1pK1fCukS6/4l0vSIB+8vbmOAe25gCfwFAH6UeD3kl8JaJJMcyNZQMx9SY1zWvUVpAtraQ28f3IkWNfoBipaACvkr9tbxSJtT0XwxbyAi3Q3tyo7M3yoD+G4/8Cr6vvbqGys57q7kWK3gRpZJGOAqqMkn6AV+a/xJ8TyeMfHOsa7JkLdzkxKf4Yxwg/75AoAzvC+kTeIPEmmaRaqWmvbiOBcdtzAZ/DrX6b6dZw6fp9rZWy7YLeJYYx6KoAH6CvjH9jvwodX+IFxrs6ZttHhyhI4M0gKr+S7z+Vfa1ABRRRQAUUUUAFFFFAHNfEL/AJANr/2FtM/9L4K6Wua+IX/IBtf+wtpn/pfBXS0AFZHi3RU8ReHrzSpJFiS5CqzNHvGAwJBXIznGPxrmPHFrd6j488O2VqEkjbTdQmeGW6lhQlZbMBj5fJI3sBnsxrIHiPXJ/FF9pcd7Z2Yinns47CSdBOYViby5Y0K+Y7k7W3biu3IxkE0AdAngOK1b7Ppl1FaaSuoJqUVktsCIZBu8xVO4DYxIOMfKd2OCAtbSPh/LYvEW1SIQxXdtdR2ltbvHbReVvyEjaV9hbeAdpC4RcL1J4i/8eX+k/D/S7iy8QLc6jb6IdQeS6mhWO4kRAWhJKM8kgIIZV2t8wLMMivRfDFxNE/jaWKNriWHVJGjizyxFtAQo+p/nQBkX/gCS30LTUt7ua5udKsEt4FigQNLLHcQTo+HkVcboFBUsMgn5hW94A0/U7O11a51uNYrvUL97rywqqUXZGgyFdwD+7zgO3BHOcgcNB421Z7C7aw121v7g2WnTl2gRltZ57kxSRlU2nCj+FjuHc1sT+IdXsfET6fcatFLewahZ2kOnmCNGvreURGW5A+8Nm+X7p2jyDkHPAA+0+G9zHpaafPrUUkFvpkOlWxSyKFIopFZWfMh3NhQCRtHfA6VuzeEfM1G8uvtuPtGswavt8r7vl28UPl53c58rdu7bsY4yeR0zxn4muNR0+xmihUz3g0lpfK+9cQShrlh2w8AlK+hiJ56VR0CTUtS1Dw/at4luGv0vtUilfEbzW213CoQwOOAMBgcDpgYwAdBb/Di5OkW1jf6zDN9jsDp9o8VkY9kbSxSOXBkbcx8iMcbQMHjmrF78Olu5XkbVGRib50KwD5XuLqC5Q8tyEa3AI/iDdu7p/FV+fg1YeJ/Mt4NQuNMtbx3Zcxo0ioWOCeg3HvWXb+ItbvtRt9N0nW4J7SfVZLWHVjbpL50S2fnEDZtRism5dwGOMEEq2QDR8V+BtT8UWzR6rrOnyl7Wa1aNtNZoE3gYkSMzcSLg/MS3XgDv0fh/QP7IfWmF20h1G4S4yqbDFttoYMDk5/1O7P8AtYxxk+Va54v8QXfh3xcZNStLOePTdTLWSzoLm0aJX8spGFDrwvLMSDuVlxkA7FtqmqaD4sj8O2t3pllZ2l1bQW9tO0VsL2GXa0sqRhNzNueRV2EDdH8wOSaAL1j8MJIA7T6rbPM0NtC88diUkm8m4SbzJXMjGSRtmC3HXIHGK1bjwTcLrV3qthqscN1cS3ORLamRBFPHbqyYDqdwNshDZ7kYPWsTSdZ8Uaho/hGQ6xax3OvSMXcWIIhQQSSbVXdycqOSce2OKy/+E68RKdRna605JEM6S2EkqGayVZQolEQUPtVMuxdiGGCuAQCAd9deF5ZPA1h4fg1ExPaQ20X2jyztlEW3KugYEo4XBUMOCRmsPTfh5c6UrSaXqtla3Un2pHEem4gEc5jYqkQkG0qYxg7iOTkHgi38MZ1nvPGLx6odWi/thNl2WQ+YPsFp08sBfUcAVg6P4p8Q6lZbtNvIb/VH0p7+5svKT/QLtHixZnbyN4aVPny2Yy2cHFAHRN4DgGi67pkF68cGo2UNlGTHuaARReWrE5+fse39aS78G31xr8eujV7ZNWj8kofsRMOUSeNsp5mSGWc4wwIKjkgkVy2o+OtWvILHUbK7h07QNUluHtL2cpBsSJY1jVnlVlBlYzOMgEqgAI6103g3Vtc1nW5vt19Yi1tbS0kkgtIt6Syyw7mKyk52BuV4zjqaAN3WtFn1jRLSzu7xBcRXdndyTJDhXaC4jmICbvlDeXt6nGc845y7DwX9kawP2/f9lTUE/wBTjd9qlEmfvcbcY9/asXVPFV9F40vdPt9Ug8621OytYdKCpvnglWIzSH+P5Fd3BGANhBznjk4fGV9o+g6VDYXywz28aTPBdSRol0r3UikICjSSMApztKBeCSelAHVaV4E1OK7n0+4vIV0SNNMUv9nzLdG1VT8pEn7sFkUEFScE4PcPtvhfFbWctnFd2SxIpFrP9hP2mMiVZE3yeZtdQUXICruAGT1Jp33i/UotK1m9g1aFtYguZIG0YxpmzgW5EXnkY8z5Yv3pZsoQQQMYzJo2v63q0+m2EWu2bRXV1cxi+snhupPLSGN1DMEEe8MzA4XG3HAJzQBp3PgS9upbue61aznmu9R+3zQyWDNayD7LFb7Gi83LY8oOCWIBPQ4BqOx+HAtdFn08aoCJdLsdN3i2wF+zSzSb8bv4vOxt7bepzgczpHjK+Nvc61qmrzQtdeHdN1COxiCbQ8qP5kkYfgKrEFm5AHLZAFW/DWv32s+IdHjvry3vBZa7cWsdxbzLKssZ00TAl0RFYgykZCgcDrjJAOku/A1xc6Je6JJqsX9kS3LXkCfZMyxym4Fwod9+HQSfw7VJXgt1J3PCWhnQbG4hb7B5k85mc2VqbdCdqrypdyThAMlugA7VyfjXxVe6Zr9zbpqcdgbd7EWto6oTfCacJK3zDcQoOPkIwRk5BAqGXxDrQjkurzWILLS5dcuNNedbdF+wwRmbbIXclSzNHHHlhgbxwSOQD06ivJpfGPihbaxWzihvJr6G4e1kEWFmW1nctJgHjz4fK29gzgjii317UNS1fRr671k2thqml31xbW+AkVyhnUwABur+SyHI56kYBIoA9Zorzv4V32oLFp2mXt613bnQLC+j3xqpiZw6lQQASuEX72TnPPOB6JQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAZ/iDSbbXdDv9Kv0D2t5C8Eg9mGK/NLxdoV14Z8Talot+pW4sp2hbP8AEAeGHsRg/jX6e18r/tk+ASwtPGunRdNtrqAUdv8AlnIf/QT/AMBoA+a/E2snXb2G9ljK3Zt0juZC2fOkUbfM+pAXPuKx6KKACiiigAooooAK9p/ZK0Aax8Wre7kTdDpdu90Tjo33V/Vs/hXi1fYn7FXh77L4T1nXpUIkvrgW8ZPeOMc4/wCBMf8AvmgD6QoorN8Sa1Z+HdBv9X1OTy7OzhaaRu+AOg9z0HuaAPE/2vvG50LwXD4ds5MXuskiXB5W3X73/fRwPoGr4qrpviP4xv8Ax34uvdc1M4aY7YYgeIYh91B9P5kmuw/Zu8Anxx8QbdruLfpGmEXV3kcPg/JH+LD8gaAPq/8AZ18Gf8IZ8MtPhuItmo34+23WRyGcDap+i4H1zXp1FFABRRRQAUUUUAFFFFAHNfEL/kA2v/YW0z/0vgrpa5r4hf8AIBtf+wtpn/pfBXS0AY2qa2bHxBpOl/YppjqHmbZldQsewZOQTnp6Cq9v408PXEE80epx+RDD9oaR0ZFaPONyEgBxu+X5c8kDqcVJq+i3V94l0XU4b2CGDT/N3wPbl2l8xdpw+8BcAf3TXON8Os6ZpFsNVKy6bYpbRS/Z+skdxDOkhXd0DQLlO4J5FAHRDxfoQntIJb8QXN2xSGCeJ4pWIYKRsYBhgsucgdc9KW28W6NdW9xNbXUkyQqjkR20rM6OdqPGoXMiseAyAg9jVYeG7m71QX2s38Nw5sJ7B0trYwKVlaM5GXYggJ6nO7PGMVz1r8NZLXSxaQ6hp8bIsMazR6cyNMkbA7LjE37xWA5C7ASScY+WgDU0XUfCmkuk1hc3UtxersLzNc3UypE5QiQvueJVdmBDbQGLZ5zWyfFOii7ubd7+ON7dZGkd1ZYv3f8ArAJCNjFP4gCSuDnGK4+L4ZSQ2Vvb22p2do8dxNP9otLBoJYhJN5hSEpMNijptYOvAJHUGST4YWzrqVubi0+yXf2srIbLN3CZ9+cS79pAMjY+TJGASeSQDqPDnia217UdUtrSGdEsTEPMmieIvvXd9x1BA9+/UVT1vx3omlafqlyZ3newhllaOONv3pjO1ljYja5DEK20naTzirfhzRLzTtT1TUNSv4Lu5v8Ayt3kWxgRPLUrwC7nn61yrfC+MWWoWUN3YrBcR3CRTtYFrmISkkgyeZhgMkcKCQBk9SQBx8ZWfiBrvSNU0xDbRyWsF1i4kUebNLEECFo0yB5kZOSrE8BW610w8X6TKVFpM04a4jtw4RkRy0gjyjsAsgDHHyk88VW1Dwj9sm1ST7ds+3anYajjys7PszwNs+9zu8jGeMbuhxzUsfBl7b6JpWjSavBJpulTWr2gFmVl2QSKyq7eYQx2oF3BV9SDQBrL4w0ApdOdRjSK3QyPJIjIjIGCl0YgB1DEAspIBI55o/4S/RPsgn+1yHM5tvJFtKZ/MC7yvlbd+QpDfd+6d3TmuV0/4Xx2OlSabDd2It1tRaW84sCLlYxJGwDyeZh+I1Bwq5IBPStifwdcx+I7vXNN1SKC/mvGuVE9qZY1R7a3gaMqHUk5t1YMCMZxgjqAbkHiHSriON4b6JhJcC0Trkyld4THXO35vpzSat4i0rSLmO31C7WGV1D42MwRCdodyAQi543NgZ4zWDZeGLj/AIWJLrV0W+yxWkRUAgRz3pVo3nCZJUiIKnJ5DEdsmfxT4Rl1q61J4NQS1g1XT10y/jaAyNJCpkI8tg67GxNKMkN1HHFAFvw74mXXdZ1mztrfZb6bObZpXZgzyLjdhduNucgEMScdAMZq6l480a30rUbuxm+2SWdtJdCIKyCZEO1ijkYYKxCkrnaSAcZFa+gaR/ZH9pfv/O+2Xsl59zbs34+Xqc4x1/SuE0v4f6lqHhlbTXb6G2lSyu7O3iit8mATyBi7t5hEhwi4xtHJzk4wAdy3iPS01GSxmuWgnQO2Z4XjjYIMttkYBGwOTgnABPY1WXxjojWiXC3M5R2CxoLSbzJcruBSPZuddoJ3KCMDOcVzGqfDFdV1K6m1DUopYZ2vQX+yH7V5dzFJGYjMXPyIJPlAUABQDk81oax4N1DWjp0+q6pp9xe2BZYi2msIXR1AYPH52S2VUgqygY6YJoAvW+v+F7LU5JLe9i+06qbeeSSPfIj+YojhcsMqgYKqqTgE+5qTTvGuk32nz3cQv9kN5NZMi2UsjmSOSRCQqKxIPlMcjoMZweKzB4CUWl1Cl5BCs8WnxhLe12Rx/ZZTJ8q7zgNnAGfl9Wplx4Fu5Lf7Kuq2slkmo3N+ltc2LSxOJ3lkdJVEqiTa8pKngDHIY8gA6DSfEVtq2tXNlZbZYI7C11CO6R8rKk7TquPp5Gc993tSSeLNEiubmGS+CtbLI0jGN9n7v/WBXxtYp/EFJK4OQMGs/wAEeDx4XdSL0XIXS7PTcCHyx+4edt/3j97z8be23qc8Z+neAn0rUbm502701WMtzPbyz6cZZ4ZJixOX80BlBduNoJXAJ6kgHRXPinRYElY38cnlyRxFYFaZmkdd6IqoCWYp821cnbz05rP07xzpN5rVzpzO8TJNFDDI0b7ZTJEsi5O3CE7toViCSDjnisrSfh6+h2VjbaLqqRJp12buy+0Wgk2s8TRyrJtZd4YuzDG0qTgEqAovt4Pmmlup7vUke4udRs9RkZLbYu6ARAqBvOA3l9cnGe+MkATVL3wtfajLc6rc3SPp8f2ho7l7mC3KQyZ80RtiOUI5U7wGwdnPC1pr4u0VrVp1upCBP9m8oW0pmMmzftEW3efkO7gfd56c1yDfC6SR7tp9XgeWfTrvTzc/YT9okE0kTiSaQyHzGXysdFHzHAXpWh4h8N39nrr+INH8+71CS9EywRwRuqIbYQsGDzR7s7AQQwIJHBGaAN9vF+hLHZyf2gjR3UaTRuiOyrG52q7kDEak5AL4BII7Gt6vLtJ+GUq6ZpTXkunNerplvZXkV3Zm6jzHuOY8OmD87A53A4U4HOfUaACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKo65pVnrmj3mmanCs1ldxNDKh7qRj86vUUAfmz8UvBN94A8Y3mi3wZo0O+2nxxNEfusP5H0INcjX6GfHP4Z2vxI8KtAmyLWbTMljcEdGxzGx/utgfQ4Pavz/wBX0280fVLrTtTt5La9tpDFLFIMFWHagCnRXpPwj8VeFtLkk0jx7oNvqWi3MqyfaQn762bGMgjBK+oB/OvpfRfgf8JPFFtFq2gwvc2Dnj7NfSGMn0OTkH2yKAPi3RdJv9c1ODT9ItJru9nYLHFEu4k/0HvXW/Ev4b6n8O7bSY9fltf7QvxJIYIX3mNF2gZPTkk/ka+7PAnw78L+BEuB4Y0xLV7gjzZGdpHYDoNzEkD2HFcr8cvg7Y/Ey3hu47prLXLWIxQTHmN1yTscemSeRyPegD4Cr9E/gP8A2dbfCzw5Y6ffWly8NmjTCCRW2u3zMCAeDkmvg3xt4O1zwVrEmm+IbGS2mBOx8ZjlX+8jdCP8ms/w/qk+j6vaXtvcXEBilR2aByrEAgnGKAP0/uJoraCSe4kSKGJS7yOcKqgZJJ7Cvib9pT4wjxtfHQPD0p/4R20ky8w/5e5B/F/uDt69fSqHxn+O2q+PI30rSVl0zw+cB4t3724/66Eds/wjj1zXi9AFjT7K51G+t7Kxhee6uJFiiiQZZ2JwAK/Q/wCCvgCH4eeCLXTMI2oy/v72Zf45SOgPoo4H0z3ryr9ln4QtokEXjDxLbFdSnT/QLeReYI2H+sI7Mw6eg+vH0lQAUUUUAFFFFABRRRQAUUUUAc18Qv8AkA2v/YW0z/0vgrpa8T/ab8S694a0vQ5tIeEWMt0rTCSINiaGRJosH0JQ5H+zXq3hKW/uPC+kz6yVOpS2sclxtXaBIygsMdsE4/CgDkfiHbX2oeMdD0/T43maXStRcJ9vktESQSWapKWjySV3nHGfmOKr6X4g1e38RWml3urR3OoRXqWE2neUivLALcM13/eGWy27OzHyY3c16ZVDXtVt9F0ua+ulkeOMqixxDLyO7BERQSBuZmVRkgZI5FAHl3gfX9attB8C6JF87arpOmz2twY9wiijhQ3Yc+u0JtJ/imHpWjZeKtRfQbnVxrMU+o2n+k6hoixR77WFJQJUAA3hhHu+8TuYAjAOK6VtQhsbubXPE2mjSfs9v5IvpbtZIkjeRcocH5WLbcnGDtHzHAp99r3hvWrc6TdXQnt9QQQuoWRUYSZCo7gAIX6BWILZ4BzQBx02s6pd6x4fvtQ1Z9OsdT0/UpobYhUSQGW3NtGwbrKYix/vD5wOM1n6b4j17Q/CNtDDd/ax/YulXSyyxqv2RZZDHK2QPuqihtz7sEFmyuQPQNT8caJplhfXErXWLJVd4RayI7IXEYZA4Xeu4gZXIH5Ve/4SnR/tsFr9rImm2BcxOFUv9xXbGEZuysQTxgGgDz6LxPr90iW8Ot2TKthqd4t3ZmG5Mn2c2vlq7BQmf37htqjIAxtPImPiLVvtkFveXYuFlOiXqnYI/L+1XEqSRrtxlAIRjcSeTkmvQtE17S9cE50i9iu1gbZI0WSFbJGM9M5BB9MVl+FvF0Wv3ECCylto7uzGoWUjurC4tywAbA+6fmQ49HHOcgAHNfDzxhea54pNs16lzYXNg94kUkkRuLV1kRfLkSNF8s4flGZ2BXkjkV6ZUV1cQ2ltLcXUqQwQoZJJJGCqigZJJPQADOaxT4u0gWP2vzLww5wcWFwWA27txXZuC4OdxG33oA36K5+68ZeHbWaSKfWLRXigF04D5CxFdwckcBSvIPepbbxXod1Zz3UGpQPbw7N7jPG9iiduQzAgY6npQBt0VzTeNtDgt1lvbsQE+YxUKZNiRyNG0jFAQqAqcscAdyKvSeJNKj1hdLa6/wBMaQQhRG5TzCm8Rl8bQ+35tuc45xQBr0Vl6tr2naTcQwX1wyzzKXWOOJ5WCAgFyFB2oCQCxwBkc1XfxXo0b3i3F21v9kieeU3EMkQ8tCAzqWUB1BIBK5AyPUUAblFYa+KtJe0kuI5bmVYpvs7xx2czyq+3eAYghcfLhs4xgg5waVfFOjSXFlDDeid7yOOWIwRvIuyQ4jZmUEIGOQCxAJBx0oA26K5Gy+IOiXFw8M0ktsUsYNQeV03RCOUyAfOuRkeUck4HIwTzjpre9tri7uraCZXntSqzIOsZZdwB9yCD9CKALFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXj/x5+DVl8RLE6hpvl2niWBMRzEYW4UdI5P6N2+lewUUAfl74h0TUvDurT6ZrVnNZ30Jw8Uq4P1HqD6jg1d8JeMNf8IXhuvDmq3VhIxG9Y3+STHZlPDfiK/Qb4i/Drw78QNOFt4gsw0yAiG6i+WaH/db09jke1fJvxD/Zv8V+HpZJ/DwGvacOR5I2zqPdD1/4CT9KAN3wz+1Xr1qqx+ItEstQA/5a27mB/wAR8wP6V1h/ay0j7OCPDN+Z+6m4TaPxxn9K+TdR0+8025a31G0uLSdesc8ZjYfgRmqtAHunxV/aAm8c6PPpK+GNNis3Pyy3RM8qf7SngK3vzXhdTW1tPdTLDawyTStwqRqWY/QCvU/A3wD8b+KZIJJtPOkWEnJuL75CB7R/eP5CgDymKN5pUihRpJHIVUUZLE9AB3NfV37PfwBe0ntvEvju2AmTElnpkgztPUPKPX0T8/SvUPhP8E/Dfw+2Xap/aetjrfXCj5P+ua9F+vJ969ToAKKKKACiiigAooooAKKKKACiiigDlPiX4Rh8aeHoNNnCbY723uPm6bVkHmfiYy4H1rq6KKACszxJpEeu6PLYyzSQFnjmimjxuiljkWSNwDwdropweDitOigDgrjwFPe3l7eXt/YJdXQtw7WWnGAOYp0m3ODIxZjs25yMA96s3ngaOXxbPrMcli6XN1BdzRXdkZnWSJY1BicSKE4iTqrYYZFdpRQB5lb/AAtkWO48/V4JJ5LBrL7UtiRPK3mRyLLO5kJlfMYz90HJxtrUbwIz+JH1ia402eW4uLe7ulm09nPnRLGoaE+b+7GIkIDB8MMg13NFAGV4W0j+wtCtdN8/z/I3fvNmzduYt0yfX1rk4fDJ8LaO9zeXF7qltpumjTbG20y3kjuRAGXC7kcsznZGNy7QApOBk16DRQByen6Qdd+HUmlahc3n+m28sLySrIJYgxYAfvlDtsyAGcZYKCc5qpr3hDVtejtf7V1fTrgwrLG0DaYxtpA4TDmIzHMilTtYkgB2+XPNdvRQBwtv4A8nw1q2k/2ln7fp9vY+b5H3PKh8vfjdznrjIx0yetWtf8Myar490TUQrpY2sLPdkOuy4eN1a3Rl6nY7SSA9AR3zx2FFAHAS/DrzNI1ex/tTH9oaZe6dv+z/AOr+0SySb8budvmYxxnGcjNQy+HtY/4Ta3W1hcaJHq51aSaZI8FjbMjBHEpcjcw4aIYw3zEBQfRaKAOf1PQ72TxCur6TqENpO9sLSdJ7Yzq6ByylcOu1gWbnkHPI4FcNrPw0v49O1W4tLy3v9Rk0q8sIibXy57kzSROrTTNId7L5WOij5jgL0r1migDg7/wLeX9xJeXmq2k95PciaeKSxY2kqLF5ao0Pm5OOWyzkZJ46Yl8J+Crzwv8AZU0zV4DALa2t7pJbIkyeTkZjIkHl7lOCCHAwCO+e3ooA4fRvA39kQmJ7qO/spNHi0m8tntsG4SIzFSh3gJnz3BB3A8cjk1o/DjQ7rQfClrBqkrz6tP8A6RfSyOHdpSAMFhw21VVM9wgrp6KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAILuytbxdt3bQTr6Sxhh+tZP/AAh3hjOf+Ec0bPr9hi/+JrdooAq2em2NioFlZW1uB0EUSp/IVaoooAKKK8X8IjxNqnjbUbizutTaysvEV3DcTTX263FsuMQLCWJ3c8EKAARzxxtSo+0Une1jKpV5Gla9z2iivJLLxp4jl8E6LrV/d6XaxardR25uRbsEskzIGd8vg5KqATgDPOaafH+rSWGhG4u9P02K7e836nNEfKnWE4TYpYAeZ9e3Fa/Uql7advu/4Yz+tQPXaK8u8J+L/EWv6po9vG2nxxzaRFqdyDAxZz57IyJ8wC5VRgnOPesLS/iV4iubS8uXl0VJTbSuLW4kSJraZXACsvmF9uDglwvOOQKawVRtrTQX1uFk9dT26ivEn+JGs/2Ak8V/Zl1u3inmlSBDtWNWIhPneVKcns2cHgHrVuLxfqoTWtWsIo5prXTLG+k8yB42ljJYyfJvIU7QSMfmRTeBqLe39OwfW4PY9ioryDU/H+ujRtLvofstrZate3It7uWMKIbdP9UG8x1UM+CckjjoM10l74r1O2+E7+IhDZzamkALCBvNhDeZsLgqTlQMtweg61nLCVI2v1dvmUsTB38lc7uivC18XanpNz4rvbHU7bVw99p9sdQjUGCJGhO6QLv2jBAXlgMnJrYg8daxLa6RDe6no+nx3M9zFLrHyTQgRhWRflfYrsG5G7HBxWksDNbP+rX/AK6+RKxcHuv6vY9coryS48fatHrMcMd3p8u2Sxjhs1gIfUUmVS80WWyFGTjggY5pU8W+KL3xCtrbXmmwW9xrF7pMQazZzGIgWWQneNxwMY4FT9Sqbtr+tR/WodD1qivEx8S9Xm0nT5ptQ0rTXm0OS/3zQ7vOnSYoI0BccsB0GT1wPSzqfxD8RRa1DA0Vhp2y2tJzbXhSP7R5qK0oDO4PyklQFDHK81X1Cre2gvrlO1z2OivKf+Ey8QpqiXLzWB03/hI5tD+zfZ2D7Ru2yGTceQF6Bf8ACsnTPiXqj2GsSajewGeC3SVTZW0U8EReVUXEizY6H7sm0jqemKSwNR7WB4uC3PbKK8Lm8a6/qGj2M8mtWNmtr4iSymvI1BieJoywZyr7SgOc4ODxyMc7Efiy9s49QWGeysIZvEk1lLqUqs8UKCJWDkM+AWPHUKPSm8DNdRLFwfQ9coryG18a+JtWttOjtJbGzmm026vXme1ZxL5Mm1WRSwwHGDznr34r0bwdqkuteFdJ1O5VEnu7WOaRU+6GKgnHtmsauHnSV5f1/VjWnXjUdkbFFFFYGwUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFUUvbVNXbTUG26aH7UQFwCu7bnPrmr1c1/wA1J/7hP/tagDohFGIvLCKI8Y244/KuA1nXPDfiKCygu5rpZTqk2li1tr0wyBkmeJiyo4JQmLIzzgivQq5CDwTDFa2kYuIzNBrM+rGb7OAzeZcSzeX17ebt3Z525xzgOMnF3T1E4qSsy1Zaz4Y0jR7A2l3aW+n/AGLz7dgTgWylF3Z64y6DnufrTz4q0AW73JnO5pjbPH9lk8/eqhirRbfM4QhuV+6QehBrj5/BGoJofi82kTfbL+62adbyurCC3WbzMDkABpHmkxkHayKcFQBuJ4N1CLVH1qHV7Ya9JO8jzNYsbco0UcewRebuGBCjZ3k5z2OANtu7BJLQ2R4g8PvGka3tm6HyDGi4beJv9UUA+8G5wRkHDehxCPFWjrbJc3ZaFJnkiaTyWkjUJI0eZJEBVBkH7xH86xrb4e/ZdR0G8t9T/faHBFbWW+2Dfu9u2bzOcszjoRt2YGBgsGztW+F0l/YS2Z1eB4JIpo9tzYmYQs88s3mQjzAEf96FLEMSEXG3nKGelGKMxeWUUx4xtxx+VO2qF2hRtxjGOMUtZ+saRbavFHHdyX0axncDaXs1qSfcxOpI9jmgBur6jpWg2RutVubSwtGZYjLMQiZPABJ4/Op7Kew1CxV7GS1urNvutCyvGfpjiuA+IPwqtPFHh46bZ6pqlrI0qOZbvUbq8QKOv7uSUqTWd4I+BWgeF7hbr+0tYubwYy8d01sp+giIb82NFwsj1nYpZW2ruUYBxyK5iHxr4Wmsor201CC5gkLOj20LykgKGZ8KpO0Bl3N0XOCQa6hRtUAZwBjk5rz+T4cJ/Y/hi1S8tZrnRNNGmb7yzMsM6bIwWMYkUq2YgRhyMEg54IANRbzws/idr2OVXv7e0NuZo0doEj4mK7wPL3Y2vjO7BB6GrK+LNFvFSS1mW5ZZ7eMBkMZAmbbHIu8DcjYOGXIbacEkVgXvgK5jmnurC7tocWckItbK2a3+1E2xhVZT5pjZQdpGUDDag3YBy7S/A99Nbafc6zqEP9oQppy7IbbYkaWshk2f6xsszMQWzjgYXrluTe7EklsbkXi3w7PBJNaXP2yOKba5tLWS42yc5OEUnI2tk9sc4qKHxl4de+v7QTKsUFrFfSXBj/cSRShirBxweF79cjGecUZvAsjaLo2nrqEEsVg0pkiu7QzW9wHJOWiDj5lzwSSBk8HIxVsPhzLZaRFp0erqYV0qwsHY2vzebaZMcy/PgAnBKENnGN1K4zcl8WeGYNPE9zewQQSTm3Mc8TRv5oXfsaNgGDbcEAjOCCOorStdW0m7+zR29xBJ9tMpjQD/AFpjOJOMfwng578Vi2PhCdNbttXvtRjnvlvnvZvKtjFG+bb7OqKpdioC4bJLEnPQYw3wr4Zk0/xd4i1adZI4J5ilhCzhhEjhXndcfd8yXLEHn5AeM4ouFjau9a0u11WGxumeO5lIiRmt38sluiebt2AnHC7sn0qmni3R2CLZSmZDcR2yssZSNi0gjyjsArgMcfIT6Vk614Fk1TxQuqyahbtGt7bXkaT2hllg8nZmOKTeAiNsJIC53MxJIwA+x8GXtvomlaNJq8Emm6VNavaAWZWXZBIrKrt5hDHagXcFX1INAFpPHWkPrMlokp+yRWct5JeurJEFSREIUlQHGX6qSMjHWrTeMtDW3SY3chLSNF5K20pmVlUMwaILvXCspJKjAZSeCM85B8OZls7Wzm1lGtrDThp1jstNrxqksUkTu28hyphQHAUNz0qTVvAF3qcN3LPqlmNUu52nku0spEMJ8pIl8jbOHjIWMEku2STkYAAAN+fxfpNtcXcNzMyvBcfZwkSNO7/uY5iwSMMwULKuSQMcE8EZ6BGDoGUgqwyCO4rgNX+Hst6NRMWqxLPeXX2kXM1s7TwH7LBb5SSOWNg37jcSODuwV4BrvLaIw28UTSPKyIFMj/efAxk47mgCSsrU/EWjaVfQWWqapZWd1Ou+KO4mWMyDOPlyRmo9V8N2Op3ZubmfVkkIC4ttVurdOP8AYjkVc++K82+IPwPtPF2sWFwmtX9raW8RR0nnmvZHJOflaWQ7B9M/SgD2FWDqGUgqRkEHIIpa4XwB8MNE8EbW0u61aWQZz516+wk9cxrtQ/ipruqAOYfx54cRZG/tEsqI0mUt5W3opw7LhfnCH7xXIX+LFX5PE2jpqKWJvVM7FVBVGaMMy7lQyAbQ5XBCk5IIIByKwrXwL5FtYxf2ju+zaZf6dnyMbvtMkT7/AL3G3ysY77uoxzV0z4dR6dq8V3FcWM8fmQTyC6sTJKJIo0TMbiQBAfLUjKsQScHoAAa2nePNEvvD1rrStex2Vwpb5rOVmjAUMxfYpCqARls7fen23jPTJPEF5pUzmKSGeKCKbDNHMZIlkX5wNqk7sAE/MRxnpXO3Xw3urjQ7HSpdYtJrSzt5rSOK508yRmNwuxynmgGZNpw54+Y4UdTdtvAdzFcGN9WhfTHuLG6lgFoRK0lqsWzEnmYCloUYjaT1Ge9AGlqHjjSIdNvbqxmF49sqv5YDJ5qGQJvRmGHUE43LkZ4zVh/F+kwKftU7Rv588IjjRpmIifa7kRhiFBxknAGRnFc8Ph1K+l22nz6ujwWFh/ZlgVtSrRQeZC58w7z5jYt4lyNvQnHNXbXwZe6bqkuo6Rq8EN3K915n2izMqFJpvNAAEikMpyM5wQeV6YAOn1bVbXSoUlvPtBVjtAgt5J26Z+6ik4464xVRPE+jyXdrbQXonkuY45YzBG0ibJP9WzOoKqG/h3EZ7Zqr4v8ADkmvvYMt1AsVszmS2u7c3FvOGGPmj3rllxwSSBk8HgjN8H+DL3wrFZW+n6vA9straW90s1mS0rQRLFvjYSDy9youQQ+O1AEl14/0yLTdIuIVknn1E2G2GMFxEt1LHGjPIoKL98kZI3bTitNvF+grJdo+oxJ9lWR5GdWVSI2CybGIw+1iFIUnBIB5OK5fTfhvcadpVhptvrMZtIf7Ke432ZLyyWLQkFD5g2BxAoIIbBJOT0q2fAUrRC2m1C0uLC2S5Syt57EuE859xE37z96AMqAAnBySTg0AbUvi/SYVikmmaC3eOaR3uEaFoxFs3AxuA+fnHb09RnW0zUbfU7bz7Qy7AxQiWF4nUjqCjgMPxFcVD8PZVtoY7jVYrsxx3cYiurZ5oAs5iwgR5S2xfK+6XPLHBXAA6Twfoc2gaU9pPfveM0zygneEiBxhEDu7BRjoWPJOMDAABuUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc1/zUn/uE/8Ataulrmv+ak/9wn/2tQB0teS2N5rhtNNkkvYjYN4tvIMAyecUF9cqELbsFQFAAx0AHavWqKAPFF8a6lbaMrtqkenyQ20M1rC4Vvt7vcypIMyZZgiqvCEEFsnggVuaDfahY+KVCXrPZaj4lvLCS1ZF2qotZZg4bG7duhA67cE8Z5rp/Fn9gLfWsniB70bdpAD3P2UYfKmZU/dY3Y5kH8qLDxtpU9/fWd5L9imtrma3DTBhG/lLvYiQgJnaGbbnIVSegzQBieNNc1DTvEl1Dp0qQu0WkxK7KXC+fqBgc7ScZ2sap2+v65aX9qJ9TN1EdXvNJKSQRruSO1nnSRiqj95mJVOMKR/DnmuxXxdozWK3Ynn8tpBEiG0mEsjFdw2R7N7fLlsqCMAnoDUd34t8PERQTajG63UMUg8tXdfKmZkR2ZRhFZlK7iQM8ZoA84t/HmtSaFHd2Op22pxz2djNd3aCMJpskz4kUsoKgBefnDbPvNlTimeIvFOo3PhS/tNR16xt4H0y/eG9tJYpReuvCQ79uzeFb5ggBJ+7twRXpfgzVtKv7Gaw0SOeGDSZG0/y5UYbfKYxjDHO4fIec59cGn/8JfoQN3u1GNFtY3lkkdGVCiEK7IxGHCkgMVJwSAcUAcO3jG9h8X6XYWl6ghF1b2NxZXMkauyvCG8yOMIZCuWHzlwuQRtPWqkHjLxDBotheTXyTNqWlx3js1uuyyzcwxPKoXBKrHMzkMTzH2BxXoa+LtFa1adbqQgT/ZvKFtKZjJs37RFt3n5Du4H3eenNO0TxJa6j4QtPEVziys57YXTeY2RGpGeTj+lAHn/iPxdqVncQ22keJNOms/s0k8GqXk8EUVxMGx5LOE2MFGCwTaxDcEbTXb+J76aG48K7MD7VqaRyAMcYMEzdsZ5UdfyqLSvGtlqN7PCkE8SJqf8AZqNMpiZmFmLot5bhWHBK4wTxnp0tDxhonkyO1zMjRuiGB7WZZmL52bYiu9t21sFVOdrehwAc58Ndf1fVG0dtWvRdf2noFtqrL5KxiGR8blTaM7TuH3iTkcEA4HN6jfajpGu69qcN2iG51z+zpb2YRJ9jtxapIqiV0YIC+1RuBXLHjc2a9CTxvoh1S5snnli+z2MWovPLEyRCF/N6sfukCFiQwHUDk5ASfxlp/maYtmHnF3evZSB1aF7dltZbj50cBhlYhgEDhwenUA4IeJtdgu7i/fV7a4u/+Efae1s7ZhLb3s0b3GWjAwXYKsbMI+T06Yq7ceMbmB44YvEtrPpD6jBbHXCIAoV4ZnkQMB5e5WRMHHG8AgkHPcWHivSr2SyhjnY3FzDFNsRGkWMSLuQO6gopI6AkZ7ZrnfiB4ssdL1iK1m0w31xpdudYy0rxBMLIi7SqkMxAk4YgY9TgUAcx/wAJTeQy/wBqXtzKJG05reO7iEaB0/tAxRXJ3goismxyxBADEgHgVZ0fxpqF4trb6t4gs9MtBLeodWjaKRLhomj8qMSOixnKyMxwilgny4wTXoU3izRIbq6glv0R7ZZGkJRtn7td0gD42syjkqCSO4qymvaU979kjv7d7nz1tvKVst5hiMwX6mMF/oCaAPN4vGeutrepJJe6dC0D3qf2fNKiy+VFHIYZki2+YS+xHJLFdrnABAqvq2va4LZYrrXpYI1XRNSkvFjSIQrc3EqSocADyh5Sn5s9SCSK9K1PxHp+l3k8OozJbpDFDK0jMMfvZTEgwOclgB071YsNasL7TJdQt5/9FiLiVpEaNoyhIcMrAMpGDkEA0AebXXjO8l8Xw6fa6lHPZXFxcWEttNJEJV2WcsolSNE3BWMQIdnwQ3C4II2U1ltH+EPh66+0SwSS2djCLlWjURF1QbneQFVXsWIOM9CcCuquvEuj2sMktxqEKJHFbzMTnhJ3McJ/4GykD3FVIPGeiXLiK1ume4YSBY3hkjPmRhi0RLKNsgCsdhw2BnGOaAOBsPFviDU9Pt4o9VghkSy1md7q2SObzjaTwJCQxQKQRIdxCDd2C8YLnxJda1rOji91FbSZNXshFpaBB5sTwJIZjkb2G92UEHb8uCCQa7TSPHWl6notpfRFkmmWyZ7aQGNkFy6ohBcKHXcxG5cglSBzxS6d430+4tXuL3FlGiyuxeQNwlw0AAA+YlmUYAHJYAZNAGX8RfEl5oWr6aI79IbNky1vA0JupnLqBtjl/wBYmMgrGQ+SMdhVS68TeIft2u6XDLZ211o0VzcTXl5Htt2RxmzyR0GC28joYTxg11svizR4YYZZpriKKQkb5LOZRF82396Sn7rnj59tM8M3FlcT6/d29qbeUX7xXMjOXMrRoqhueg2gfKOOp6k0Aef2Pie9v73w9OdcvIreO+urSaSZ7cxXb+SjxxiSP91ICSVUgA53DG5TUGleN/EVxos10+paYbqSO1MltvR5rKaS5ijdDEFVkUCRhtkJYMvU849HPjLQUtLi5ub8WsVu0ay/a4pIGTzCRGdrqDhiCAcYODg8Gq9h470K8bVAk80aafJHE7yQOBIZI4nTy8DLE+cihcbieg6EgHP2Gta3b69BBc6o11bx662kMjwRqZYzamYOxVR84YgfLhcDkEnNUfh74nudRtfD8Wp61FpjnTNOkt7NgpOoebAjO2ZMu3zEoNpyCpLZyK7j/hL9BBsVbUokkvmdLeJ1ZZHZGVHXYRuDKzqCCARnnoajtfGWjSw2Dy3Iie8jjlVcF1jEh2pvdQVQMwIUsQCRgZoAzfEGuS2/jFdOudai0SzWziuLd3WP/TZmkdWjy4OQgRPlXDHzRzxXOaP4g8QTlk0+aMpbWt9em28kyPcvHdyosYYtlQQoHQ+2K9D0rXtO1a4mh0+dpmizlvKdUbDFSUcgK4BBBKk4NalAHmmn+MUtjoNxP4qstQsbubZfzOIo0tWNvK4TK42ZdAAr5YYwSSawYPFt0Ui1i6ungub3Q9O3TxeXGkTyXMwLsZAURexYg4z0JwK9pooA8i8L+I9T1TxH4Yl1LXI4bd01S0YxSK0F7JFdW6xDO1VZ2Tfgqqk4cqACRVfwx4x1R9G8OF7+OG7e00j7PphVWbUEnSLzpAWJc7dz8g/L5ZLbga9looA888Ja/q93rul/br0T2+ojUgYBCqrD9nuFjQqQNxJUnOSc8Yx3XxHrviG1v/Fs2mSxSQaPbRvDZi1LtI7xklmYHJC/e2gZOCM816FRQB4te+NtYtdMadvEWlzWUcjt5tpe2kl3IBGCEBZFhYhsnYArFSuD1J6K38bXD6/b6XJcwJdy60lt9lkQJN9kaz80MUJyPn/i/CvR6KAPDPCur6nY6eDF4ggs2Phixms4NQkCwPLvuhI4J7qBGWI9U3cAV6H4N1yTWPCF7dme4uHheaITTGE79o6q8PyOvONy46EEAg12FFAHkek+J9aOnWF0t6Egt/7DhNsIlYSi7aGOQs7ZbjzCVwRyOc9K9coooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArmv+ak/9wn/ANrV0tc1/wA1J/7hP/tagDpaKK8d0q/tmjZ9L1aWXxZ/wkl3CbRL15GaAalKrCSHcQI1gBOSBtwpBzjIB1Xj3wLJ4ruJmOoQRwTWgtvKubQ3AgYMzebD86hHO4AkgnCrjGDkk8D3E19cG41O1l09r+fUY7ZrHJEskTRgOxkIdAHJ27VyQMnGQeStPHPiN7XULl7nThcLDKZtPd1eewYTIm7yVUPtRC7NvJ3EKVIBwXeItX8u/Nzp+vLraR6XMFukdME/arUYJh2qSNx5AHXFAG2nwzfyIfM1OCSW3uTPBA9rI9pEpi8tkETTFgD97iQAEDAxkG8fAANpqMK3lvALywtLLZbWnlxxeRPNLuVd54bz8Yzxtzk54zofEWsNqkbzXoktbnUdS08W3lKqokCysjhgN2793g84wemeaztJ8T60dOsLpb0JBb/2HCbYRKwlF20MchZ2y3HmErgjkc56UAeheG9Gm0aTU0N3HPaXV3JdxJ5JV4mkdncM24hhk8YVcDrnrXIQ/C+ODS77TobuxWCW1mtYJ/sBNzGrkHDSeZhgAADhVJwMng5XwT4qvdV8U6fa3OpxzPd2F7c3enhYwbCWKe3RY+BvBAlcHeTkjIwOKj8SeMLyy8eQWFleokcd/aWc9lcSRKZUm25kiTYZHA8wfPvVQysMNg0Abl34PnPiSbXLDUo4b1rsXCLNbGWNV+zrCyEB1JJ2hgwIweMEZzNH4RCfD+18MtfEvbwxIl2IsfPGyurFM9NyjK55GRmuNg8QeJLq1tZf7aMRvNJ1HUcJaxfuXtZYkRVyDwwl+bdk/L8u3NXYfFWtXN6Lz7WkdtHqGm2v2NYV2OtzFCXJYgtkGUlcEdOc9gDWfwNd3FzNdXetbbuXVH1NpbS2MJQtpxsgqZdtpGRIGJPIxjvWdafDJ4BfO13o7zXUVpG2NLdV3QGc+acT7zI3n/f3gjb3BwMSz8Y6pFp0WL+O2uI7WOaysmVWOqStcTI8YLkscBEGEIKltxyCBVlda1Gz1e7i/tKTULtPEcsaafI+HiiNvK8YABztbAAzleMjmgDf/wCEAuDbTQSa5LMLnSoNNuJZoS8rNC8rxyq5fjDTHIbfkKATnJNh/BVxdahDqOo6pFJfi9N3I0NqY42X7HNbKiqZGK484uSWOSMcDGLHw71f+2NMFzJr8Oq3MkMMs8EaRr9jkYEsmFG5RkY2vlhtOSa8xtpb/Q7dddtrg3OqSW+uXDSPCu5jFcIF3YGXAA4z0HAwBigD0vwp4SvfDLLHY6rA9lIlv9pjlsyXd4oI4NyOJMIGWFOCrY5weam8TeEf7bm1qT7b5H9o6YmnY8rd5e15G3/eGf8AWYxx061zWqeMpr2e9l0ia31G1tdZtbe1+zPkSq1uHKhlOGy5I7infDjU31bxfc3UmsLqckuiWkkwQIFt5TLMWiCqBtweMNlh3NAG5B4LIv4hdX0c+kQXt1qENoYCHEtwJhIHk34ZP9ImwNo+8OeKq+Ffh3DoGpaTeHUJLqWytnilLxYM8pLbJScnBVJJUxzkMORtwa1/4n1+DxFqOiWtus97ZCfUh+6OJ7Pyj5MYPQOZm2Z6kQse/GI/iC61NbSFNXTV7RL7SJjdxIieVNJckSQHZxwFU7T8y7vmJyKAO18Q+Ef7Y1h7/wC3eTu/s/5PK3f8et59p67h977vt156VdsPDyW+n63aS3DSR6pcTzMVXaUEowVHJzj1/SvPn+ImoP4Zu57e7s5NSs/DF9qNzGqgmG8h2gK65+XBLZU1p3+sa9pmrX8b6u1xDY6nplvsa3jXzUu5oonViBnC7yVxg/3i1AFy18A3hDHUNZgnk2aREphsjEAlhdNOMgyNkvu25zx1welaEvgvzJ4ZPt+PL1a41THk9fNtpoPL+9287dnvtxgZyMX4feKNY1nXzHqV3YKHjmM+mmdPtFpIrqFURhQ6gDcGLlskqVIBwfQr6eS2tJZobWa7kQZWCEoHc+gLsq5+pFAHC2fw9uRY2MOo6xDPNYx6dBA8NmYlEVpcRz4KmRss5jALZAHGB1yH4ckLG0erbZ4SZIXNtkLIL03Slhu+ZQTtIyMjkEHGNLVvFOr2+l3k8fg/XY3jhd1d5bEqpCk5IFyTj6CvJfh78bvGOuOkc3gqTV0J2m401XjC+53blz/wJaAPR/FfgHUPE6ynU9ZsZGmtfszK+nM8cLB2YSwIZv3bkMAzHcTsXG2ulsNAa0sNbtkvpUbUriecTQrseAyDHynJ5XqD+laWl3U15YxT3NjcWErjLW87Izp9SjMv6159deJtQk1+ezN/GZ2vLm0l0gIm6G1WGRkuc/f+Yqh3E7TvCgbuaAJ9K+GzWd1JcSahZCSRtOZvstgYQ5tJpJNzZkYs7+ZgsTkbe/QXtb8Ctqk+sk6hEtvf30GpJFJal/LuIo4ovmO8B4ysIyuAcsSGHGON8O+I7u0sdItJNQGm2MsGmwz6i5B+zq1i8nWTKKWdFXJGPmxySKm/4TrWH0NLt9Tghuk0v7XYxeUmNXufOmQwDPPSOIYTBzMDnAwQDt/D/hD+ytXsL/zrJWtre7gaGzszBG5nkt334LsQR9n5yTnd2xisKy+F8dkbQpd2NzstoLeb7bYGXcYs4ePEi7CQeh3jIBx1zWtLzVLPxTqJtdRZLe88RtYNbtErKoNirhwSN24Mi8ZAxnI5yIofGmt3dl511Imk2ttcwaTqF20S4gugX+0SqXyuzIiRGIK5kyemKAOs8L+FJdE1u9vzfReRcIVFnawPBDuL7jIyGRl39sqEzk5ByMdXXkvgrU9Ud9H06w1VWtJ59fvbidrdZpLgQ6mqqFwQF3CVugI54A4xQsPiBq81pq01nqFvcxnT4b23MrRSy2ztMEMcixoqoQGGULOwxy1AHtNFeaw6zrlprs0E2qvdW9nr0OklJII1M0ctrFMWcqo+ZWmwNu0YXkMTmsS38Va5L4St7q/vRdSahoFlquPLEQhkeRAypswdpDDqScjrg4oA9lorymbxfrPnXotdVsF1DOoJNY3SqsemLCXEE0hHzhW2pktkMJNy4A56v4ca2+uaLcyy3Fxcvb3TQGaYwsHwqtlJIf3ci/NjcAOQVIypoA6uiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACua/5qT/3Cf8A2tXS1zX/ADUn/uE/+1qAOlrFsvElhPol1qs7m1s7a5ubWRpf70M7wEjHXLIcDqcjvxW1XDr4N1IaXd6YdYtPsT6jLqluRYMJYpmvDdpubzsOquQCNo3Ads0AbMnjDREtY5zdyHzHeMRJbytMGQZcNEF3rtBBOVGMjOMirVj4g0y/1KWxs7hpZ49wYrE/l5XG5RJjYWGRlQSR3FcrqvgG51G1umk1O0XU7u5e6lvBZyK0bmGOFTBsmV4yEiT+NgTyR6aGieD59M8Ttqv9pKYikivDDC0RuGbb8837wo7jb94IpJPJ6ggGzceItKt9XXTJrtVvGZU27GKq7DKoz42qzDopIJ7A1neGPF0Ou6fqmorbmHT7OWVEc7zI4jZlZipQY+4SAC3B5weKivvCMtzq93MuoImm3l/banc2xgJkaeARbNsm8BVP2eLI2noeRmtLQ9C/svw9Jpf2jzd73D+bs2482V3xjJ6b8decdqAOT8H+IfDrpb63cCa0vb+MPH59zc3ZgglYEbi4226swAwMISgAZtox0Nl410m7gvZY1v8A/RLySykRbKWRjIjOpKqisSP3bHI6DrisCT4aR5sWS5sZ2i06206cX1iZ1kEIIV0AkXYTubIO4fd44ObN54Fu5jJGmq2r2J1Ca/W0urFpY383eXSVRKokAZsrwAMchjggA6DSfEVtq2tXNlZbZYI7C11CO6R8rKk7TquPp5Gc993tUM3jPQYbuS2a9Zp0d4tkdvLJukQ4eNdqnc46lFy2OcY5qp4I8Hjwu6kXouQul2em4EPlj9w87b/vH73n429tvU54dZeEfst9YXP23d9l1O81Hb5WN3niQbM7uNvmde+OgzQBd/4S7QjJZIuoxt9sjilidFZk2ynERZgMJvPC7iNx4GTU0niXRoraO4l1G3SCRpkV2bAzDu83Ppt2NnPTFcpY/DqWy0+LT4tXQ2MkFrDeo1qd83kNkGNt/wC73DCnIbgcYPNT6j8ObTUL7xBLPfTC31OF0ggSNQLN5NhmdSc7t7RRMQRjIbru4ANw+L9EFsszXbrun+yrC1vKJjLsMgTyiu/cUUsBt5HTNJaeMvD92kkkGpxGJLc3RkZWRGiGAzKxADbSyhgCSpIBweKytL8EG0vdMupJ9Ojksr/7awsrBoBN/o00G1t0rnP77Oc9FxjnNU7z4bRXml2FlPqTbLSxurQMsAG5pbiCdXwWIwrW4BXncG6juAdEfGGiC2SZruQFpjbiE28on80Jv2eVt37tmGxtzgg9KTS/F+k6prv9lWMss0rWUF/HMsZMUkUvmbcN64iJ5x1GMnIGZo/go2N/p1282nxyWl290y2Vi0Cy7oGhw26Rzkbs5z0AGB1qTwl4Pm8N3lpLBqMc0S6bb6dcI9sQZBC0zI6Hf8nM7ZBDZwMYoA6+iiigAooooAKKKKAEZQ6lWAKkYIIyCKFUIoVQAoGAAMAClooAKKKKAKeq6dBqlsILl7pEDBwba6lt3z/vRsrY56ZxUmn2Vtp1jBZ2MSw20CBI416KB/P61YooAKq6Zp9rplqbexi8uIySSkbixZ3cu7EkkklmJ59atUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc1/zUn/ALhP/taulrmv+ak/9wn/ANrUAdLXlth4vjtPCGqx2+r2j6zDrV7FIkkyyS20B1SRGlMZOdscJ3gHjCjtXqVcfaePLJ7orfWs9jZNcXtvFeTPH5bNau6y5w2VH7pyCRjA5IJAIByOs+M9Ss9Mmni1y3l022vZoor6OS2S4v4lhicGLzB5LlZHkRgu0tsG3HNbXhbxTeXvjmfTry+89ZFleKC3ERSBF2YEqf66KTnndlSTxjiujl8aeH4LMXVzqKW0Zn+zbbiN4nEuwyBCjAMCVUsBjkdM5FJJ4x0g295LbTtOLX77CNkjbDhG2yMAjYY4OCcHg80Ac/q3ibULfxdcWaX0cc0Wo2drbaUUTdeW0oi824BPz/Jvl5UgDyDkHPC/Dy0mg8G6xqDXZk1C8uL1muTEgkyk0yqSQPmxgYznA4HAxW1qnjnRNPsNQuzLcTxWJxKYbdyGPmCM7GICvtc4O0nBzmrsfijR5L+GzW7PnylVXMThQzLuVGYjarleQjEMQRxzQB5Hoes6v4f0vRbK0vtPs0l0u01BJb54rdb+eXPmh2KEyEBUB2kPlwWJyBWqPE15p8Oo2c3iOVL6TW7qFTPNBEtnGGlaNXeRH2K6hSo2kkLhRjJHbXfj/wAPwaRf6jFdSXUFnbfa2EMLZkjzjdHuADjPBIOAeDitHWPEENho1rqUUTzw3F3a2qggxn9/cRwhsEZ4MmcY5xQByXwy1e613XZtRvyn2i58OaTNII8hN7S324gds4rM03VtY0e4nlspXvku9W1eJNPMa4LR+dKm1sbtxaPb1xhumRmu01fxxo2l2WpXE73RNhC9xJF9mkR5EVgrNHvCiQAsoJUkDIyRkVbbxVoy3NvA14Vkn2bcwuApc7UDnbhCx4UMQWPAzQB5xYeONSOjTzXet2UizG2VZ7e5t99pLIX3iUmPbDH8qgb1Zw2R8xIxo+EPEfiDxFc6Nbf2naQK0eoPcyxQibzxbXvkLsb5QNy8ltuDnIUdB3HifxHY+HbJ5rxnaXypJY4Io2keQIMscKCQoyMsRgZGTzUNp4s0qZrCKW48m5uo4n8vazLG0q5RHkA2qzZ4BILcYBzQBy/g/Wr2H4HR6q2qnUdVtdG86WSYh3iuEtwzRydyysPm3fNnrWR488X614a0QSHWITqkOmS6pmVYra3uNoz5Sqyu7kYPyqVOGGXGQa79fGGhtFNKt6zRRNtDrBIVlO7biI7f3p3cfJu54qGLxlp0t+YofMltRZm6M0cbuwIl8ox+WF37wwIIxkEEYzQBwmqeJNW0jUfEESayeddWCRbiSNf7PtWtldZQXVgiM4WMMwKZfOM5rppvEOpW/wAH9X183Vhc6laafe3EVxbOJoXMQk8tsgAMcKu7GBndjittvGOgJHaPJqUcRu5HihjkVkkZ0IDpsIDBlJGQQCOtQav440bS7LUrid7omwhe4ki+zSI8iKwVmj3hRIAWUEqSBkZIyKAOQ8S+IvEmja+NOl1bTYmjt4riKa6MdpFeO0jh48MGLBVVBtRg4LgknIqlqHj/AFeDW9S/sqVL1Fh1AJp87I00MsAOwmGNA6qSpwGdmcHgLXoJ8X6ShnMsrqiNGiARs0krOpYKsSguThWONucAnoCaW78ZeH7SGCabUo/Kmh+0o8aM4EWcGRtoO1AerHAHcigDj5dXZte8LPa+Nxe6fJcTRTXCGARySGJSsLFAEySG2g/MN3c4NVdM8U63DZaPZQ7Wm1yPytPk8suIZUuGE5cnOQIWEgBP/LJx9PRrPXtOvNUm0+1naS5hLK5ET+XuXG5RJjYWGRlQSR3FalAHkmj6nqV14otI/wC3G05Lg63BDG5DRSzR6iyJw5+ZguDgcgAgYBIrqvh94g1LxL9tur2D7Lb2ojsnhKYP2xM/aSD3QMVQe6Me4rsaq6Xp9rpdklpYReVArMwXcWJZmLMSSSSSzEkk5JJoA8n1Dx9qcOs6t9gvYpIEttSItLh4jNbSW6koTEiBkUlTje7Fgc4WtC58TavYaj/Z19q4jtJZbNptTeKJPscc0VwxxkbAC8KIpcHBl5LcV6lRQBwfgQ38/wAL5DpN2kupM999muJgGV5PtEuxmA4wTjp26VjS+O7vUtEXVYp5NJsL+8jtLKSUxwCIpCzTGaWVGCDzA8f3GOY+B83HqtFAHkukeKPEGuaaZZL21hjh0H7dcJHBuM8u+dDh8jaD5QPAz6Y6Uyz8bX//AAkOh2tveoI2mtLS5sriSMMwkgVzJHHsMjLlh+8ZwMgjaeteu0UAeEeH/Et5B4Js7ey1VNThXSFmuVBXNhMs8KJGWTDZdXkyGJOYuwOKl1rUtRt7DW4tPuri3l+z+IrhZoWbehivbbBGD2V25xkdiOc+5UUAeezeItVi8Qado1leRajHq3kz2WopGrIIYyTdbivy/dCBT/emH92vQqqnT7U6qupGLN6sJt1kLE7YywYgDOBkhSSBk7RnoKtUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVzX/ADUn/uE/+1q6WuP/ALTsP+Fm+X9utfM/s3ydvnLnf533cZ+97daAOwriB8ONJbQ9YspljN5qU15I1+kKiVBPcPMFGc8KWUHs2wZHYdvXj1t4k1m28VajrqWeoXGmal9rs7FHkQ28jwJm38tQ5YFzDcnJUbvMQZOFyAdZpfgg2l7pl1JPp0cllf8A21hZWDQCb/RpoNrbpXOf32c56LjHOaqXHw9lnuNWYarFbQXyspt7W2eOIsZll8yRDKVaQbSNyhM73JzkYwrbxpfH7akHiKC9s1t9Lmm1FY4ttj9omuEmOFGAFESAb87d2WyAauw+Ita1H7Ba2uqhIZV1Jk1CKCNjdRwNGIpFyCmDuIJAw2CVwCMAGhcfDyWebWWGqxW0V/FIqwWls8cXmNKsglkQylXcFcZUJu3vnqMTweBGTxG+rTXGmXEk9zFeTiXT2ZxKiopMTeb8gOxSAwcg556Y5iL4gajc6roLRXcUTTvp0d1YzSRoJBcpGzPDHsMjKPNxv3qoZSMNg1s6dq11o/wSn1W1kRbq1tbiZHlG5QRI+CfUUAWX+HQfQrfTW1Q4i0WXSPMEHUuyMJMbuxj+73z1FdHrWjXGs6Ja2d5dxLcRXlpdvNFAVRzBcRzbQhckbvL2/eOM556VwV74xuo0uba319ZrV79YLTWRJbwwt/o/mPG8pjePhuAVQk/d6qxrCufEWuapoOuXra3PaX934MhvLS0tjt825C3hkaAfeDArGSV+YZTPRaAOp/4Vc0j3jXOrwyST6beacbhbLFxJ58kTiSaQyHzGXysYwoO4421pXPgR7nX31a4udMuJ7hoJLlZ9OZxviwA0P7393wq8NvwRn1FYMvi/VD4mhtLPXNMks0e2+zy3E8Ma6lG7DzGXCkuR8yKIyMMvzA5xVux1rxFexaG0urxxLq+tXNgPJtEDQQwx3rcFiwZyYI+SMDHQ85AOn8VeGrjWL1Luxv47Of7FcafJ5tuZlaKUoSQA64YGMYOSOTkHjGNa/DqO01iK9juLGdC9rNMt3YmV/MgSNA0TCQBMiFDyr4YZFdD4E1K51fwnp17fsr3ToVkdV2h2Viu7HbOM4HrW9QBwD+ALmTw1p2hzatbS2WktEdPDWJJURgqom/efvBsJU7dh75zTJPh3I0J8jUrWzlMIjKWlk0UL/wCkCYhk83cVbBVhvyck5GcV6FRQBxPhbwKNC1G1uxd2x8iS8k8i2s/Ii/fmI4Vd52hfK6c53e3OT/wq5pHvGudXhkkn028043C2WLiTz5InEk0hkPmMvlYxhQdxxtr0yigDip/B1/JrB1ldWtl1cTRTo/2JjACsEkLAx+bkgrISPnBBA5IyDXuPh2sujalYLqZU32j3OlvKYM4ed3d5sbum5zhPwzXe0UAcppvhSWy8YT60t9FHBL5pa1tYHiEpcjDS/vCjsMfeCKxzyeueroooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAr51k8EH/AIasWbyv9DMX9tdO4XZn/v7zX0VVT+z7X+1RqXlD7aIfs/md/L3btv50AW6R1DqVbOCMHBxS0UAZmjaHY6O88lms7TThRJNc3MtxIwXO1S8jM2BubAzgFiepNadFFABVXVdPtdW025sNQi820uEMcse4ruU9RkEEfhVqigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArwGLVbgalrh0zVL6TxUniiaC1s1uZHV7XzFyrRZ2iMfP8xAxjrxXv1FdFCuqV7q9zGtSdS1nax5JYeN9efx1NZ3kttFbxXs0DaayATNCoOx4x99icA5+6c9q5d/HXiLWNJ122ttVLgaO1/HLDGqTwskqKyny/uHDHjJI45r6DoraOKpxd/Zrp+HyMnh5tW531/rc8R1LU9WOuXGp6Nr8Mstr4U+2Nci2DrPsmkJUKWwucYLc9K9f0G8fUND069mCrJc20czBegLKCcfnV+isa1ZVEly2t/XY1pUnTbd73Ciiiuc2CiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note that the depicted sequence is an approximation and the actual course may vary depending upon the characteristics of the chronic deprivation and the individual fetal ability to cope.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Maulik, D. Doppler velocimetry for fetal surveillance: Adverse perinatal outcome and fetal hypoxia. In: Maulik, D (ed) Doppler ultrasound in obstetrics and gynecology, 1997; 349 New York, Springer Verlag. Copyright &copy; 1997 Springer-Verlag.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_20_10566=[""].join("\n");
var outline_f10_20_10566=null;
var title_f10_20_10567="E. coli asparaginase: Drug information";
var content_f10_20_10567=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   E. coli asparaginase: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/37/39508?source=see_link\">",
"    see \"E. coli asparaginase: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/1/16405?source=see_link\">",
"    see \"E. coli asparaginase: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F136999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Elspar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F137000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Kidrolase&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F137036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Miscellaneous;",
"     </li>",
"     <li>",
"      Enzyme",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F137004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols.",
"     <b>",
"      Note:",
"     </b>",
"     Dose, frequency, number of doses, and start date may vary by protocol and treatment phase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ALL:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6000 units/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose 3 times/week for ~6-9 doses",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1000 units/kg/day for 10 days",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     High-dose therapy (unlabeled dose): 10,000 units/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for ~3-12 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Single-agent therapy (rare): 200 units/kg/day for 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6000 units/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose 3 times/week for ~6-9 doses",
"     <b>",
"      or",
"     </b>",
"     6000 units/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every ~3 days for ~6-9 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     High-dose therapy (unlabeled dose): 10,000 units/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for ~3-12 doses",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Test dose:",
"     </b>",
"     A test dose is often recommended prior to the first dose of asparaginase, or prior to restarting therapy after a hiatus of several days. Most commonly, 0.1 mL of a 20 units/mL (2 units) asparaginase dilution is injected intradermally, and the patient observed for at least 1 hour. False-negative rates of up to 80% to test doses of 2-50 units are reported.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Some practitioners recommend an asparaginase desensitization regimen for patients who react to a test dose, or are being retreated following a break in therapy. Doses are doubled and given every 10 minutes until the total daily dose for that day has been administered. One schedule begins with a total of 1 unit given I.V. and doubles the dose every 10 minutes until the total amount given is the planned dose for that day. For example, if a patient was to receive a total dose of 4000 units, he/she would receive injections 1 through 12 during the desensitization. See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Asparaginase Desensitization",
"     </caption>",
"     <col align=\"center\" width=\"105\">",
"     </col>",
"     <col align=\"char\" width=\"175\">",
"     </col>",
"     <col align=\"char\" width=\"220\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Injection No.",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Elspar Dose (units)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Accumulated Total Dose",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         1",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         2",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         7",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         15",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         16",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         31",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         32",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         63",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         7",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         64",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         127",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         8",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         128",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         255",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         9",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         256",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         511",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         512",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         1023",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         11",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         1024",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         2047",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         2048",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         4095",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         13",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         4096",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         8191",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         14",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         8192",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         16,383",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         16,384",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         32,767",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         16",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         32,768",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         65,535",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         17",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         65,536",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         131,071",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         18",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         131,072",
"        </p>",
"       </td>",
"       <td>",
"        <p style=\"text-indent:0em;\">",
"         262,143",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F137023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/1/16405?source=see_link\">",
"      see \"E. coli asparaginase: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols.",
"     <b>",
"      Note:",
"     </b>",
"     Dose, frequency, number of doses, and start date may vary by protocol and treatment phase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ALL:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6000 units/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose 3 times/week for ~6-9 doses",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1000 units/kg/day for 10 days",
"     <b>",
"      or",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     High-dose therapy (unlabeled dose): 10,000 units/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every ~3 days for ~4-8 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.M.:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6000 units/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose 3 times/week",
"     <b>",
"      or",
"     </b>",
"     6000 units/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every ~3 days for ~6-9 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     High-dose therapy (unlabeled dose): 10,000 units/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose every ~3 days for ~4-8 doses",
"     <b>",
"      or",
"     </b>",
"     25,000 units/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose weekly for ~9 doses (generally used in high-risk continuation therapy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Test dose:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F137005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15673217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F136977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elspar&reg;: 10,000 units",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F136961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F136980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered I.M., I.V., or intradermal (skin test only); has been administered SubQ in specific protocols",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Doses should be given as a deep intramuscular injection into a large muscle; volumes &gt;2 mL should be divided and administered in 2 separate sites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note: I.V. administration greatly increases the risk of allergic reactions and should be avoided if possible.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: I.V. infusion in 50-250 mL of D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS over at least 30-60 minutes. The manufacturer recommends a test dose (0.1 mL of a dilute 20 unit/mL solution) prior to initial administration and when given after an interval of 7 days or more. Institutional policies vary. The skin test site should be observed for at least 1 hour for a wheal or erythema. Note that a negative skin test does not preclude the possibility of an allergic reaction. Desensitization may be performed in patients who have been found to be hypersensitive by the intradermal skin test or who have received previous courses of therapy with the drug. Have epinephrine, diphenhydramine, and hydrocortisone at the bedside. Have a running I.V. in place. A physician should be readily accessible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Gelatinous fiber-like particles may develop on standing. Filtration through a 5-micron filter during administration will remove the particles with no loss of potency.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F137042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Methotrexate, sodium bicarbonate",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F136978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment (in combination with other chemotherapy) of acute lymphoblastic leukemia (ALL)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F3881595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of lymphoblastic lymphoma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F137045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Asparaginase (",
"       <i>",
"        E. coli",
"       </i>",
"       ) may be confused with asparaginase (",
"       <i>",
"        Erwinia",
"       </i>",
"       ), pegaspargase",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Elspar&reg; may be confused with Elaprase&reg;, Erwinaze&trade;, Oncaspar&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F137034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Immediate effects: Fever, chills, nausea, and vomiting occur in 50% to 60% of patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue, fever, chills, depression, agitation, seizure (10% to 60%),  somnolence, stupor, confusion, coma (25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia/glucose intolerance (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting (50% to 60%), anorexia, abdominal cramps (70%), acute pancreatitis (15%, may be severe in some patients)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hypofibrinogenemia and depression of clotting factors V and VIII, variable decrease in factors VII and IX, severe protein C deficiency and decrease in antithrombin III (may be dose limiting or fatal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases, bilirubin, and alkaline phosphatase increased (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypersensitivity: Acute allergic reactions (fever, rash, urticaria, arthralgia, hypotension, angioedema, bronchospasm, anaphylaxis (15% to 35%); may be dose limiting in some patients, may be fatal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Azotemia (66%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperuricemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Stomatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction (including anaphylaxis), antibody formation/immunogenicity (~25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening) and/or frequency not defined: Acute renal failure, albumin decreased, cerebrovascular hemorrhage, cerebrovascular thrombosis, disorientation, fatty liver, fibrinogen decreased, glucosuria, hallucinations, headache, hemorrhagic pancreatitis, hyper-/hypolipidemia, hyperthermia, hypocholesterolemia, hypotension, insulin-dependent diabetes, intracranial hemorrhage, irritability, ketoacidosis, laryngospasm, malabsorption syndrome, myelosuppression (mild&ndash;to-moderate anemia, leukopenia, and thrombocytopenia; onset: 7 days; nadir: 14 days; recovery: 21 days), pancreatic pseudocyst, Parkinsonian symptoms (including tremor and increased muscle tone), partial thromboplastin time increased, peripheral edema, polyuria, proteinuria, prothrombin time increased, pruritus, rash, renal insufficiency, serum ammonia increased, serum cholesterol decreased, sagittal sinus thrombosis, stroke (hemorrhagic and thrombotic), thrombosis, urticaria, venous thrombosis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F136983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     History of serious allergic reaction to asparaginase or any",
"     <i>",
"      E. coli",
"     </i>",
"     -derived L-asparaginase; history of serious thrombosis, pancreatitis, or serious hemorrhagic events with prior L-asparaginase treatment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F136965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reactions: Severe allergic reactions may occur; monitor; immediate treatment for hypersensitivity reactions should be available during administration. Risk factors for allergic reactions include: I.V. administration, doses &gt;6000-12,000 units/m",
"     <sup>",
"      2",
"     </sup>",
"     , patients who have received previous cycles of asparaginase, and intervals of even a few days between doses. Up to 33% of patients who have an allergic reaction to",
"     <i>",
"      E. coli",
"     </i>",
"     asparaginase will also react to the",
"     <i>",
"      Erwinia",
"     </i>",
"     form or pegaspargase. A test dose may be administered prior to the first dose of asparaginase, or prior to restarting therapy after a hiatus of several days.",
"     <b>",
"      False-negative rates of up to 80% to test doses of 2-50 units are reported.",
"     </b>",
"     Desensitization may be performed in patients found to be hypersensitive by the intradermal test dose or who have received previous courses of therapy with the drug.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coagulopathy: Increased prothrombin time, partial thromboplastin time, and hypofibrinogenemia may occur; cerebrovascular hemorrhage has been reported; monitor coagulation parameters. Use with caution in patients with an underlying coagulopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperglycemia: May cause hyperglycemia/glucose intolerance (may be irreversible); monitor blood glucose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: May cause serious and possibly fatal pancreatitis; promptly evaluate patients with abdominal pain; discontinue permanently if pancreatitis develops.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombotic events: Serious thrombosis, including sagittal sinus thrombosis may occur; discontinue with serious thrombotic events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome: Appropriate measures must be taken to prevent tumor lysis syndrome and subsequent hyperuricemia and uric acid nephropathy; monitor, consider allopurinol, hydration and urinary alkalization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with pre-existing hepatic impairment; may alter function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F136970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexamethasone (Systemic): Asparaginase (E. coli) may increase the serum concentration of Dexamethasone (Systemic). This is thought to be due to an asparaginase-related decrease in hepatic proteins responsible for dexamethasone metabolism.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F136973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F136986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreased weight gain, resorptions, gross abnormalities, and skeletal abnormalities were observed in animal studies. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F137011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2245364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Elspar Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10000 unit (1): $73.09",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F136975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, urinalysis, amylase, liver function prior to and frequently during therapy, liver enzymes, coagulation parameters (baseline and periodic), renal function tests, urine dipstick for glucose, blood glucose, uric acid. Monitor for allergic reaction, be prepared to treat anaphylaxis at each administration; monitor for onset of abdominal pain and mental status changes. Monitor vital signs during administration.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F136987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Asparaginase medac (PL);",
"     </li>",
"     <li>",
"      Crasnitin (AT, CH, HN, PT);",
"     </li>",
"     <li>",
"      Elspar (BR, MX);",
"     </li>",
"     <li>",
"      Erwinase (DE, DK, FI, GB, GR, NL, NO, NZ, SE, SG);",
"     </li>",
"     <li>",
"      Kidrolase (AR, BG, CO, CZ, EG, FR, IL, PE, PL, UY);",
"     </li>",
"     <li>",
"      Laspar (ZA);",
"     </li>",
"     <li>",
"      Leunase (AU, BD, CL, HK, ID, IN, JP, KP, MY, NZ, PH, PK, SG, TH, TW);",
"     </li>",
"     <li>",
"      Oncaspar (DE);",
"     </li>",
"     <li>",
"      Paronal (BE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F136964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Asparaginase inhibits protein synthesis by hydrolyzing asparagine to aspartic acid and ammonia. Leukemia cells, especially lymphoblasts, require exogenous asparagine; normal cells can synthesize asparagine. Asparaginase is cycle-specific for the G",
"     <sub>",
"      1",
"     </sub>",
"     phase.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F136982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: Produces peak blood levels 50% lower than those from I.V. administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 4-5 L/kg; 70% to 80% of plasma volume; &lt;1% CSF penetration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Systemically degraded",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.M.: 39-49 hours; I.V.: 8-30 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: I.M.: 14-24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Avramis VI, Sencer S, Periclou AP, et al, &ldquo;A Randomized Comparison of Native Escherichia Coli Asparaginase and Polyethylene Glycol Conjugated Asparaginase for Treatment of Children With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia: A Children's Cancer Group Study,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2002, 99(6):1986-94.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capizzi RL, &ldquo;Asparaginase Revisited,&rdquo;",
"      <i>",
"       Leukemia &amp; Lymphoma",
"      </i>",
"      , 1993, 10(Suppl):147-50.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Duval M, Suciu S, Ferster A, et al, &ldquo;Comparison of",
"      <i>",
"       Escherichia Coli",
"      </i>",
"      -Asparaginase With",
"      <i>",
"       Erwinia",
"      </i>",
"      -Asparaginase in the Treatment of Childhood Lymphoid Malignancies: Results of a Randomized European Organisation for Research and Treatment of Cancer &minus; Children's Leukemia Group Phase 3 Trial,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2002, 99(8):2734-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ettinger LJ, Ettinger AG, Avramis VI, et al, &ldquo;Acute Lymphoblastic Leukemia: A Guide to Asparaginase and Pegaspargase Therapy,&rdquo;",
"      <i>",
"       BioDrugs",
"      </i>",
"      , 1997, 7:30-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gallagher MP, Marshall RD, and Wilson R, &ldquo;Asparaginase as a Drug for Treatment of Acute Lymphoblastic Leukemia,&rdquo;",
"      <i>",
"       Essays Biochem",
"      </i>",
"      , 1989, 24:1-40.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoelzer D, G&ouml;kbuget N, Digel W, et al, &ldquo;Outcome of Adult Patients With T-Lymphoblastic Lymphoma Treated According to Protocols for Acute Lymphoblastic Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2002; 99(12):4379-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/20/10567/abstract-text/12036865/pubmed\" id=\"12036865\" target=\"_blank\">",
"        12036865",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larson RA, Dodge RK, Burns P, et al, &ldquo;A Five-Drug Remission Induction Regimen With Intensive Consolidation for Adults With Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8811,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1995, 85(8):2025-37.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lazarus HM, Richards SM, Chopra R, et al, &ldquo;Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia at Diagnosis: Results from the International ALL Trial MRC UKALL XII/ECOG E2993,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2006, 108(2):465-72.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/20/10567/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Muller HJ and Boos J, &ldquo;Use of L-Asparaginase in Childhood ALL,&rdquo;",
"      <i>",
"       Crit Rev Oncol Hematol",
"      </i>",
"      , 1998, 28(2):97-113.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pession A, Valsecchi MG, Masera G, et al, &ldquo;Long-Term Results of a Randomized Trial on Extended Use of High Dose L-Asparaginase for Standard Risk Childhood Acute Lymphoblastic Leukemia,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(28):7161-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stecher AL, de Deus PM, Polikarpov I, et al, &ldquo;Stability of L-Asparaginase: An Enzyme Used in Leukemia Treatment,&rdquo;",
"      <i>",
"       Pharm Acta Helv",
"      </i>",
"      , 1999, 74(1):1-9.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8901 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-A7B94B43F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_20_10567=[""].join("\n");
var outline_f10_20_10567=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136999\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137000\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137036\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137004\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137023\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137005\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673217\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673218\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136977\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136961\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136980\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137042\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136978\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3881595\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137045\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137034\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136983\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136965\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298780\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136970\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136973\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136986\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137011\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2245364\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323002\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136975\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136987\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136964\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136982\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8901\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8901|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/37/39508?source=related_link\">",
"      E. coli asparaginase: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/1/16405?source=related_link\">",
"      E. coli asparaginase: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_20_10568="Epinephrine (adrenaline) (systemic therapy and oral inhalation): Pediatric drug information";
var content_f10_20_10568=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Epinephrine (adrenaline) (systemic therapy and oral inhalation): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?11/4/11337?source=see_link\">",
"    see \"Epinephrine (adrenaline) (systemic therapy and oral inhalation): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/24/10630?source=see_link\">",
"    see \"Epinephrine (adrenaline) (systemic therapy and oral inhalation): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8084976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Adrenalin&reg;;",
"     </li>",
"     <li>",
"      Asthmanefrin&trade; [OTC];",
"     </li>",
"     <li>",
"      Auvi-Q&trade;;",
"     </li>",
"     <li>",
"      EpiPen 2-Pak&reg;;",
"     </li>",
"     <li>",
"      EpiPen Jr 2-Pak&reg;;",
"     </li>",
"     <li>",
"      S2&reg; [OTC];",
"     </li>",
"     <li>",
"      Twinject&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8084977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adrenalin&reg;;",
"     </li>",
"     <li>",
"      Epi E-Z Pen&reg;;",
"     </li>",
"     <li>",
"      EpiPen&reg;;",
"     </li>",
"     <li>",
"      EpiPen&reg; Jr;",
"     </li>",
"     <li>",
"      Twinject&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10484212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenergic Agonist Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Hypersensitivity Reactions",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Bronchodilator",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sympathomimetic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12864279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Cardiopulmonary resuscitation [Kattwinkel (AAP/AHA), 2010]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: 0.01-0.03 mg/kg (0.1-0.3 mL/kg of",
"     <b>",
"      1:10,000",
"     </b>",
"     solution) every 3-5 minutes as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endotracheal:",
"     <b>",
"      Note:",
"     </b>",
"     I.V. route preferred: E.T.: 0.05-0.1 mg/kg (0.5-1 mL/kg of",
"     <b>",
"      1:10,000",
"     </b>",
"     solution) every 3-5 minutes until I.V. access established or return of spontaneous circulation",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10485044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/4/11337?source=see_link\">",
"      see \"Epinephrine (adrenaline) (systemic therapy and oral inhalation): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Asthma, bronchodilation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Nebulization: Racemic epinephrine (2.25% solution): Children &ge;4 years and Adolescents: Manufacturer labeling:  0.5 mL diluted with 3-5 mL of NS; administer with jet nebulizer over ~15 minutes every 3-4 hours as needed.",
"     <b>",
"      Note:",
"     </b>",
"     Not recommended for routine management and treatment of asthma (NAEPP, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Asystole or pulseless arrest",
"     </b>",
"     (AHA, 2010):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V., I.O.: 0.01 mg/kg (0.1 mL/kg of",
"     <b>",
"      1:10,000",
"     </b>",
"     solution) (maximum single dose: 1 mg); every 3-5 minutes until return of spontaneous circulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Endotracheal: 0.1 mg/kg (0.1 mL/kg of",
"     <b>",
"      1:1000",
"     </b>",
"     solution) (maximum single dose: 2.5 mg) every 3-5 minutes until return of spontaneous circulation or I.V./I.O. access established.",
"     <b>",
"      Note:",
"     </b>",
"     Recent clinical studies suggest that lower epinephrine concentrations delivered by endotracheal administration may produce transient &beta;-adrenergic effects which may be detrimental (eg, hypotension, lower coronary artery perfusion pressure). I.V. or I.O. are the preferred methods of administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Bradycardia",
"     </b>",
"     (AHA, 2010):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V., I.O.: 0.01 mg/kg (0.1 mL/kg of",
"     <b>",
"      1:10,000",
"     </b>",
"     solution) (maximum dose: 1 mg or 10 mL); may repeat every 3-5 minutes as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Endotracheal: 0.1 mg/kg (0.1 mL/kg of",
"     <b>",
"      1:1000",
"     </b>",
"     solution) (maximum single dose: 2.5 mg); doses as high as 0.2 mg/kg may be effective; may repeat every 3-5 minutes as needed until I.V./I.O. access established",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Continuous infusion: I.V., I.O.: 0.1-1 mcg/kg/minute; titrate dosage to desired effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Croup (laryngotracheobronchitis), airway edema:",
"     </b>",
"     Nebulization: Infants, Children, and Adolescents:",
"     <b>",
"      Note:",
"     </b>",
"     Typically relief of symptoms occurs within 10-30 minutes and lasts 2-3 hours; patients should be observed for rapid symptom recurrence and possible repeat treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Racemic epinephrine (2.25% solution): 0.05-0.1 mL/kg (maximum dose: 0.5 mL) diluted in 2 mL NS, may repeat dose every 20 minutes; others have reported use of  0.5 mL as a fixed dose for all patients; use lower end of dosing range for younger infants (Hegenbarth, 2008;  Rosekrans, 1998; Rotta, 2003; Wright, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     L-epinephrine: 0.5 mL/kg of",
"     <b>",
"      1:1000",
"     </b>",
"     solution (maximum dose: 5 mL) diluted in NS, may repeat dose every 20 minutes;",
"     <b>",
"      Note:",
"     </b>",
"     Racemic epinephrine 10 mg = 5 mg L-epinephrine (Hegenbarth, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypersensitivity reactions:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     SubQ administration results in slower absorption and is less reliable. I.M. administration in the anterolateral aspect of the middle third of the thigh is preferred in the setting of anaphylaxis (ACLS guidelines, 2010; Kemp, 2008). For self-administration following severe allergic reactions (eg, insect stings, food), the World Health Organization (WHO) and Anaphylaxis Canada recommend the availability of one dose for every 10-20 minutes of travel time to a medical emergency facility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., SubQ: 0.01 mg/kg (0.01 mL/kg/dose of",
"     <b>",
"      1:1000",
"     </b>",
"     solution) not to exceed 0.3-0.5 mg every 5-15 minutes (Hegenbarth, 2008; Kemp, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Autoinjector dose: I.M. (Kemp, 2008; Sicherer, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     10-25 kg: 0.15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &gt;25 kg: 0.3 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Autoinjectors (EpiPen&reg; Jr, EpiPen&reg;, Twinject&reg;): I.M. Manufacturer recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     15-29 kg: 0.15 mg; if anaphylactic symptoms persist, dose may be repeated in 5-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ge;30 kg: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated in 5-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 0.01 mg/kg (0.1 mL/kg of",
"     <b>",
"      1:10,000",
"     </b>",
"     solution) not to exceed 0.5 mg every 20 minutes; may use continuous infusion (0.1 mcg/kg/minute) to prevent frequent doses in more severe reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypotension/shock, fluid-resistant:",
"     </b>",
"     Continuous I.V. infusion: 0.1-1 mcg/kg/minute; doses up to 5 mcg/kg/minute may rarely be necessary, may be combined with inotropic support (Hegenbarth, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     SubQ: 0.01 mg/kg (0.01 mL/kg of 1:1000 solution) (maximum single dose: 0.5 mg) every 20 minutes for 3 doses (Hegenbarth, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Inotropic support:",
"     </b>",
"     Continuous I.V. infusion rate: 0.1-1 mcg/kg/minute; titrate dosage to desired effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Postresuscitation infusion to maintain cardiac output or stabilize:",
"     </b>",
"     Continuous I.V./I.O. infusion rate: 0.1-1 mcg/kg/minute; doses &lt;0.3 mcg/kg/minute generally produce &beta;-adrenergic effects and higher doses (&gt;0.3 mcg/kg/minute) generally produce alpha-adrenergic vasoconstriction; titrate dosage to desired effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Asystole/pulseless arrest, pulseless VT/VF",
"     </b>",
"     (ACLS, 2010):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V., I.O.: 1 mg every 3-5 minutes until return of spontaneous circulation; if this approach fails, higher doses of epinephrine (up to 0.2 mg/kg) have been used for treatment of specific problems (eg, beta-blocker or calcium channel blocker overdose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Endotracheal: 2-2.5 mg every 3-5 minutes until I.V./I.O. access established or return of spontaneous circulation; dilute in 5-10 mL NS or sterile water.",
"     <b>",
"      Note:",
"     </b>",
"     Absorption may be greater with sterile water (Naganobu, 2000).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Bradycardia (symptomatic; unresponsive to atropine or pacing):",
"     </b>",
"     I.V. infusion: 2-10 mcg/minute",
"     <b>",
"      or",
"     </b>",
"     0.1-0.5 mcg/kg/minute (7-35 mcg/minute in a 70 kg patient); titrate to desired effect (ACLS, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Bronchodilator:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Nebulization: S2&reg; (racemic epinephrine, OTC labeling): 0.5 mL: Repeat no more frequently than every 3-4 hours as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     SubQ: 0.3-0.5 mg (",
"     <b>",
"      1:1000",
"     </b>",
"     solution) every 20 minutes for 3 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypersensitivity reactions:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     SubQ administration results in slower absorption and is less reliable. I.M. administration in the anterolateral aspect of the middle third of the thigh is preferred in the setting of anaphylaxis (ACLS guidelines, 2010; Kemp, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M., SubQ: 0.2-0.5 mg (",
"     <b>",
"      1:1000",
"     </b>",
"     solution) every 5-15 minutes in the absence of clinical improvement (ACLS, 2010; Kemp, 2008; Lieberman, 2010). If clinician deems appropriate, the 5-minute interval between injections may be shortened to allow for more frequent administration (Lieberman, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 0.1 mg (",
"     <b>",
"      1:10,000",
"     </b>",
"     solution) over 5 minutes; may infuse at 1-4 mcg/minute to prevent the need to repeat injections frequently",
"     <b>",
"      or",
"     </b>",
"     may initiate with an infusion at 5-15 mcg/minute (with crystalloid administration) (ACLS, 2010; Brown, 2004). In general, I.V. administration should only be done in patients who are profoundly hypotensive or are in cardiopulmonary arrest refractory to volume resuscitation and several epinephrine injections (Lieberman, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Self-administration following severe allergic reactions (eg, insect stings, food):",
"     <b>",
"      Note:",
"     </b>",
"     The World Health Organization (WHO) and Anaphylaxis Canada recommend the availability of one dose for every 10-20 minutes of travel time to a medical emergency facility. More than 2 doses should only be administered under direct medical supervision.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Twinject&reg;: I.M., SubQ: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated in 5-15 minutes using the same device after partial disassembly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     EpiPen&reg;: I.M., SubQ: 0.3 mg; if anaphylactic symptoms persist, dose may be repeated in 5-15 minutes using an additional EpiPen&reg;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypotension/shock, severe and fluid resistant:",
"     </b>",
"     I.V. infusion: Initial: 0.1-0.5 mcg/kg/minute (7-35 mcg/minute in a 70 kg patient); titrate to desired response (ACLS, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8085180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 0.1 mg/mL (10 mL) [1:10,000 solution]; 1 mg/mL (1 mL) [1:1000 solution]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Auvi-Q&trade;: 0.15 mg/0.15 mL (0.76 mL) [contains sodium bisulfite; 1:1000 solution; delivers 0.15 mL per injection]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Auvi-Q&trade;: 0.3 mg/0.3 mL (0.76 mL) [contains sodium bisulfite; 1:1000 solution; delivers 0.3 mL per injection]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EpiPen 2-Pak&reg;: 0.3 mg/0.3 mL (2 mL) [contains sodium metabisulfite; 1:1000 solution; delivers 0.3 mg per injection]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     EpiPen Jr 2-Pak&reg;: 0.15 mg/0.3 mL (2 mL) [contains sodium metabisulfite; 1:2000 solution; delivers 0.15 mg per injection]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Twinject&reg;: 0.15 mg/0.15 mL (1.1 mL [DSC]) [contains chlorobutanol, sodium bisulfite; 1:1000 solution; delivers 0.15 mg per injection]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Twinject&reg;: 0.3 mg/0.3 mL (1.1 mL [DSC]) [contains chlorobutanol, sodium bisulfite; 1:1000 solution; delivers 0.3 mg per injection]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 1 mg/mL (30 mL) [1:1000 solution]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adrenalin&reg;: 1 mg/mL (30 mL) [contains chlorobutanol, sodium bisulfite; 1:1000 solution]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adrenalin&reg;: 1 mg/mL (1 mL) [contains sodium bisulfite; 1:1000 solution]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 1 mg/mL (1 mL) [1:1000 solution]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, for oral inhalation [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Asthmanefrin&trade;: Racepinephrine 2.25% (0.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     S2&reg;: Racepinephrine 2.25% (0.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8085003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Solution for injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10485064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endotracheal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: Use 0.1 mg/mL (",
"     <b>",
"      1:10,000",
"     </b>",
"     ) solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants, Children, and Adolescents: Use 1 mg/mL solution (",
"     <b>",
"      1:1000",
"     </b>",
"     ); administer and flush with a minimum of 5 mL NS, followed by 5 manual ventilations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nebulization: Dilute in 2-3 mL NS; if using jet nebulizer: Administer over ~15 minutes; must be diluted. If using handheld rubber bulb nebulizer; dilution is not required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Direct I.V. or I.O. administration: Dilute to a maximum concentration of 100 mcg/mL (if using",
"     <b>",
"      1:10,000",
"     </b>",
"     concentration, no dilution is necessary); pH: 2.5-5.0",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous I.V. infusion: Rate of infusion (mL/hour) = dose (mcg/kg/minute) x weight (kg) x 60 minutes/hour divided by the concentration (mcg/mL); maximum concentration: 64 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M. (EpiPen&reg;, EpiPen&reg; Jr, and Twinject&reg;): Intramuscularly into anterolateral aspect of the middle third of the thigh; EpiPen&reg; products are single-use products and a new device should be used for each dose; Twinject&reg; device can be used  for subsequent doses after partial disassembly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ: Use only",
"     <b>",
"      1:1000",
"     </b>",
"     solution",
"    </p>",
"   </div>",
"   <div class=\"block uicn drugH1Div\" id=\"F14471808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     10",
"     <b>",
"      mcg",
"     </b>",
"     /mL, 16",
"     <b>",
"      mcg",
"     </b>",
"     /mL, 32",
"     <b>",
"      mcg",
"     </b>",
"     /mL, or 64",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14471807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     16",
"     <b>",
"      mcg",
"     </b>",
"     /mL, 32",
"     <b>",
"      mcg",
"     </b>",
"     /mL, or 64",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8085063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     R, D",
"     <sub>",
"      2.5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     NS, LR, NS, Ringer's injection;",
"     <b>",
"      incompatible",
"     </b>",
"     with sodium bicarbonate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alcohol (ethyl), amiodarone, anidulafungin, atracurium, bivalirudin, caffeine citrate, calcium chloride, calcium gluconate, caspofungin, ceftazidime, cisatracurium, clonidine, dexmedetomidine, diltiazem, dobutamine, dopamine, famotidine, fenoldopam, fentanyl, furosemide, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, inamrinone, labetalol, levofloxacin, lorazepam, midazolam, milrinone, morphine, nicardipine, nitroglycerin, nitroprusside, norepinephrine, pancuronium,  phytonadione, potassium chloride, propofol, ranitidine, remifentanil, terbutaline, tigecycline, tirofiban, vasopressin, vecuronium, vitamin B complex with C, warfarin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Ampicillin, micafungin, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Drotrecogin alfa, nesiritide, pantoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Caffeine citrate, doxapram, heparin, hyaluronidase, inamrinone, iohexol, iopamidol, iothalamate meglumine 60%, ioxaglate meglumine 39.3% and ioxaglate sodium 19.6%, milrinone.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Lidocaine.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F11432244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Epinephrine is sensitive to light and air. Protection from light is recommended. Oxidation turns drug pink, then a brown color.",
"     <b>",
"      Solutions should not be used if they are discolored or contain a precipitate.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Store between 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); do not freeze. Protect from light. The 1:1000 solution should be discarded 30 days after initial use; stability of injection in parenteral admixture at room temperature (25&deg;C) or refrigeration (4&deg;C) is 24 hours; incompatible with alkaline solutions (sodium bicarbonate); compatible when coadministered with dopamine, dobutamine, inamrinone (amrinone), atracurium, pancuronium, and vecuronium",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral (autoinjectors):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Twinject&reg;: Store between 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not  freeze or refrigerate. Protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     EpiPen&reg; and EpiPen&reg; Jr: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze or refrigerate. Protect from light by storing in carrier tube provided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Inhalation [solution (S2&reg;)]: Store between 2&deg;C to 20&deg;C (36&deg;F to 68&deg;F). Protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10485025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Treatment of bronchospasms, bronchial asthma, anaphylactic reactions, cardiac arrest and attacks of transitory atrioventricular (AV) heart block with syncopal seizures (Stokes-Adams Syndrome); added to local anesthetics to decrease systemic absorption of intraspinal and local anesthetics and increase duration of action [FDA approved in pediatric patients (age not specified) and adults]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalation (nebulization): Treatment of bronchial asthma, upper airway obstruction, and croup (racemic epinephrine) (FDA approved in ages &ge;4 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8084974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       EPINEPHrine may be confused with ePHEDrine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Epifrin&reg; may be confused with ephedrine, EpiPen&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Medication errors have occurred due to confusion with epinephrine products expressed as ratio strengths (eg, 1:1000 vs 1:10,000).",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Epinephrine 1:1000 = 1 mg/mL and is most commonly used I.M.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Epinephrine 1:10,000 = 0.1 mg/mL and is used I.V.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Medication errors have occurred when topical epinephrine 1 mg/mL (1:1000) has been inadvertently injected. Vials of injectable and topical epinephrine look very similar. Epinephrine should always be appropriately labeled with the intended administration.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       EpiPen [U.S., Canada, and multiple international markets] may be confused with Epigen brand name for glycyrrhizinic acid [Argentina, Mexico, Russia] and Epopen brand name for epoetin alfa [Spain]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8085040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, cardiac arrhythmia, chest pain, flushing, hypertension, pallor, palpitation, sudden death, tachycardia (parenteral), vasoconstriction, ventricular ectopy, ventricular fibrillation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety (transient), apprehensiveness, cerebral hemorrhage, dizziness, headache, insomnia, lightheadedness, nervousness, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Dry throat, loss of appetite, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Acute urinary retention in patients with bladder outflow obstruction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Allergic lid reaction, burning, corneal endothelial damage (intraocular use), eye pain, ocular irritation, precipitation of or exacerbation of narrow-angle glaucoma, transient stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, pulmonary edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10485026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     There are no absolute contraindications to the use of injectable epinephrine (including EpiPen&reg;, EpiPen&reg; Jr, and Twinject&reg;) in a life-threatening situation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypersensitivity to epinephrine or any component; patients anesthetized with agents, such as cyclopropane or halothane; narrow angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10485028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with diabetes mellitus or cardiovascular disease (coronary artery disease, hypertension, diabetes mellitus, Parkinson&rsquo;s disease, thyroid disease, or cerebrovascular disease. Use with extreme caution in patients taking MAO inhibitors and tricyclic antidepressants; effects of epinephrine may be potentiated. Accidental injection into digits, hands, or feet may result in local reactions including injection site pallor, coldness, and hypoesthesia or injury resulting in bruising, bleeding, discoloration, erythema, or skeletal injury. Patient should seek immediate medical attention if occurs.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10485027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products contain sulfites as preservatives which may cause allergic reactions in susceptible individuals; the presence of sulfites in some products (eg, EpiPen&reg; and Twinject&reg;) should not deter administration during a serious allergic or other emergency situation even if the patient is sulfite-sensitive. Due to direct catecholamine effect, administration of epinephrine may cause high arterial blood pressure (may cause angina pectoris, aortic rupture, or cerebral hemorrhage); induce potentially serious cardiac arrhythmias; and produce constriction of renal blood vessels and decrease urine formation initially (with parenteral administration)",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of COMT",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8085042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems. Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May decrease the metabolism of COMT Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the vasoconstricting effect of Alpha-/Beta-Agonists. Management: Avoid the use of hyaluronidase to enhance dispersion or absorption of alpha-/beta-agonists.  Use of hyaluronidase for other purposes in patients receiving alpha-/beta-agonists may be considered as clinically indicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Inhalational Anesthetics: May enhance the arrhythmogenic effect of EPINEPHrine (Systemic, Oral Inhalation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: EPINEPHrine (Systemic, Oral Inhalation) may enhance the hypotensive effect of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Promethazine: May diminish the vasoconstricting effect of EPINEPHrine (Systemic, Oral Inhalation). Management: When vasoconstrictive effects are desired in patients receiving promethazine, consider alternatives to epinephrine. Consider use of norepinephrine or phenylephrine, and avoid epinephrine, when treating hypotension associated with promethazine overdose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8085007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8085008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animal reproduction studies. Epinephrine crosses the placenta and may cause fetal anoxia. Use during pregnancy when the potential benefit to the mother outweighs the possible risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10485065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ECG, heart rate, blood pressure, site of infusion for excessive blanching/extravasation, rebound respiratory symptoms",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10485031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stimulates alpha-, beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic receptors resulting in relaxation of smooth muscle of the bronchial tree, cardiac stimulation, and dilation of skeletal muscle vasculature; small doses can cause vasodilation via beta",
"     <sub>",
"      2",
"     </sub>",
"     -vascular receptors; large doses may produce constriction of skeletal and vascular smooth muscle; decreases production of aqueous humor and increases aqueous outflow; dilates the pupil by contracting the dilator muscle",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10485032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Local vasoconstriction (topical):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Onset of action: 5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Duration: &lt;1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of bronchodilation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Inhalation: Within 1 minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     SubQ.: Within 5-10 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10485033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Orally ingested doses are rapidly metabolized in GI tract and liver; pharmacologically active concentrations are not achieved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Crosses placenta but not blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensive in the liver and other tissues by the enzymes catechol-o-methyltransferase and monoamine oxidase",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F13907501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/24/10630?source=see_link\">",
"      see \"Epinephrine (adrenaline) (systemic therapy and oral inhalation): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Avoid other stimulants to avoid serious overdose reactions. May cause dizziness, blurred vision, restlessness, or difficulty urinating. Report excessive nervousness or excitation, inability to sleep, facial flushing, pounding heartbeat, muscle tremors or weakness, chest pain or palpitations, or increased sweating.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brown SG, Blackman KE, Stenlake V, et al, &ldquo;Insect Sting Anaphylaxis; Prospective Evaluation of Treatment With Intravenous Adrenaline and Volume Resuscitation,&rdquo;",
"      <i>",
"       Emerg Med J",
"      </i>",
"      , 2004, 21(2):149-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/20/10568/abstract-text/14988337/pubmed\" id=\"14988337\" target=\"_blank\">",
"        14988337",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (Suppl 3):640-56.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA and the American Academy of Pediatrics Committee on Drugs, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/20/10568/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practices (ISMP), \"Standard Concentrations of Neonatal Drug Infusions,\"",
"      <i>",
"       ISMP",
"      </i>",
"      , 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kattwinkel J, Perlman JM, Aziz K, et al, \"Neonatal Resuscitation: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 126(5):e1400-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/20/10568/abstract-text/20956432 /pubmed\" id=\"20956432 \" target=\"_blank\">",
"        20956432",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kemp SF, Lockey RF, Simons FE, et al, &ldquo;Epinephrine: The Drug of Choice for Anaphylaxis. A Statement of the World Allergy Organization,&rdquo;",
"      <i>",
"       Allergy",
"      </i>",
"      , 2008, 63(8):1061-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/20/10568/abstract-text/18691308/pubmed\" id=\"18691308\" target=\"_blank\">",
"        18691308",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):876-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/20/10568/abstract-text/20956230/pubmed\" id=\"20956230\" target=\"_blank\">",
"        20956230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lieberman P, Nicklas RA, Oppenheimer J, et al, &ldquo;The Diagnosis and Management of Anaphylaxis Practice Parameter: 2010 Update,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2010, 126(3):477-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/20/10568/abstract-text/20692689/pubmed\" id=\"20692689\" target=\"_blank\">",
"        20692689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Naganobu K, Hasebe Y, Uchiyama Y, et al, &ldquo;A Comparison of Distilled Water and Normal Saline as Diluents for Endobronchial Administration of Epinephrine in the Dog,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2000, 91(2):317-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/20/10568/abstract-text/10910841/pubmed\" id=\"10910841\" target=\"_blank\">",
"        10910841",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Peberdy MA, Callaway CW, Neumar RW, et al, &ldquo;Part 9: Post Cardiac Arrest Care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):768-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/20/10568/abstract-text/20956225/pubmed\" id=\"20956225\" target=\"_blank\">",
"        20956225",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, \"Standardizing I.V. Infusion Concentrations: National Survey Results,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/20/10568/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosekrans JA, \"Viral Croup: Current Diagnosis and Treatment,\"",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1998, 73(11):1102-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/20/10568/abstract-text/9818047/pubmed\" id=\"9818047\" target=\"_blank\">",
"        9818047",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rotta AT and Wiryawan B, \"Respiratory Emergencies in Children,\"",
"      <i>",
"       Respir Care",
"      </i>",
"      , 2003, 48(3):248-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/20/10568/abstract-text/12667275/pubmed\" id=\"12667275\" target=\"_blank\">",
"        12667275",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sicherer S, Simons F, et al, &ldquo;Self-Injectable Epinephrine for First-Aid Management of Anaphylaxis,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007,119(3):638-46.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vanden Hoek TL, Morrison LJ, Shuster M, et al, &ldquo;Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):829-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/20/10568/abstract-text/20956228/pubmed\" id=\"20956228\" target=\"_blank\">",
"        20956228",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Waisman Y, Klein BL, Boenning DA, et al, &ldquo;Prospective Randomized Double-Blind Study Comparing L-Epinephrine and Racemic Epinephrine Aerosols in the Treatment of Laryngotracheitis (Croup),&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1992, 89(2):302-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/20/10568/abstract-text/1734400/pubmed\" id=\"1734400\" target=\"_blank\">",
"        1734400",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wright RB, Pomerantz WJ, and Luria JW, \"New Approaches to Respiratory Infections in Children. Bronchiolitis and Croup,\"",
"      <i>",
"       Emerg Med Clin North Am",
"      </i>",
"      , 2002, 20(1):93-114.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/20/10568/abstract-text/11826639/pubmed\" id=\"11826639\" target=\"_blank\">",
"        11826639",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15975 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.146-C1CFDD43C6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_20_10568=[""].join("\n");
var outline_f10_20_10568=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084976\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084977\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484212\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12864279\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485044\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085180\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085003\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485064\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471808\">",
"      Usual Infusion Concentrations: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471807\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085063\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11432244\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485025\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8084974\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085040\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485026\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485028\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485027\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299272\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085042\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085007\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085008\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485065\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485031\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485032\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10485033\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13907501\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15975\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15975|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/34/3620?source=related_link\">",
"      Epinephrine (adrenaline) (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/59/4020?source=related_link\">",
"      Epinephrine (adrenaline) (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/14/40163?source=related_link\">",
"      Epinephrine (adrenaline) (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/4/11337?source=related_link\">",
"      Epinephrine (adrenaline) (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/24/10630?source=related_link\">",
"      Epinephrine (adrenaline) (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_20_10569="HSTL tumor cells immunophenotype";
var content_f10_20_10569=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatosplenic T cell lymphoma tumor cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 617px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hepatosplenic T cell lymphoma tumor cells express CD2 (panel A) and surface CD3 (panel B). In most cases, CD5 (panel C) and CD 8 (panel D) are not expressed. The cytotoxic granule protein TIA-1 (panel E) is expressed, but perforin (panel F) and granzyme B (panel G) are absent, features consistent with a non-activated cytotoxic T cell phenotype. Mitotic activity (panel H) is generally low.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Kindly provided by German Pihan, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_20_10569=[""].join("\n");
var outline_f10_20_10569=null;
var title_f10_20_10570="Complications and long-term outcomes of a severe burn";
var content_f10_20_10570=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complications and long-term outcomes of a severe burn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/20/10570/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/20/10570/contributors\">",
"     Gerd G Gauglitz, MMS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/20/10570/contributors\">",
"     Felicia N Williams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/20/10570/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/20/10570/contributors\">",
"     Marc G Jeschke, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/20/10570/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/20/10570/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/20/10570/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H37436937\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite major advances in therapeutic strategies for the management of patients with severe burns, including improved resuscitation, enhanced wound coverage, infection control, and management of inhalation injuries, the consequences of a severe burn are profound and result in complex metabolic changes that can adversely affect every organ system [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The definition of a severe burn injury (",
"    <a class=\"graphic graphic_table graphicRef74855 \" href=\"UTD.htm?2/13/2268\">",
"     table 1",
"    </a>",
"    ) and the management of such patients are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35478?source=see_link\">",
"     \"Overview of the management of the severely burned patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37436945\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37433371\">",
"    <span class=\"h2\">",
"     Multiple organ dysfunction syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple organ dysfunction syndrome (MODS) is a progressive disorder that commonly occurs in acutely ill patients, regardless of etiology of the injury or illness. MODS exists in a continuum with the systemic inflammatory response syndrome (SIRS) which affects most patients with a severe burn, with or without an infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. The risk of MODS increases with burn wounds &gt;20 percent TBSA, increasing age, male gender, sepsis, hypoperfusion, and underresuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Approximately 50 percent of patients who succumbed to the burn injury had been diagnosed with MODS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/6\">",
"     6",
"    </a>",
"    ]. Most patients with MODS have an inability to attenuate the inflammatory response to injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link&amp;anchor=H10#H10\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\", section on 'Multiple organ dysfunction syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=see_link&amp;anchor=H5#H5\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\", section on 'Systemic inflammatory response syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, the burn wound or lungs are the most likely sites for an infection in the severely burned patient that subsequently develops MODS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/1\">",
"     1",
"    </a>",
"    ]. The release of endotoxins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exotoxins from an infective process initiates a cascade of inflammatory mediators that leads to organ damage and ultimately organ failure. Targeting the different cascade systems involved in the pathogenesis of burn-induced MODS is often not a feasible option [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/8\">",
"     8",
"    </a>",
"    ]. Prevention of sepsis from burn wound infection is the most promising approach, as illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wound-associated inflammation is limited by immediate debridement of devitalized tissue and tangential excision of burn tissue and wound closure, primarily by skin grafts, within 48 hours of a full-thickness burn [",
"      <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/1,9-14\">",
"       1,9-14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link&amp;anchor=H16#H16\">",
"       \"Hypermetabolic response to severe burn injury: Recognition and treatment\", section on 'Early wound closure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21417?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of burn wound sepsis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients should be weaned from the ventilator and ambulated as soon as clinically feasible to minimize the risk of pulmonary complications. &nbsp;",
"     </li>",
"     <li>",
"      Early enteral nutrition in severely burned patients is associated with decreased bacterial translocation and aids in attenuating the immune response post-injury [",
"      <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Severely burned patients develop MODS primarily at two different distinct points: early, due to hypoperfusion and underresuscitation, or late, due to sepsis. In general, MODS begins in the renal or pulmonary system, and progresses systematically to the liver, gastrointestinal system, hematologic system, and central nervous system. Once the diagnosis of MODS is established, the management is goal-directed to re-establishing end-organ perfusion (such as lungs or kidneys), with resuscitation or supportive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37433378\">",
"    <span class=\"h2\">",
"     Specific organ failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an early and late cascade of organ failure following a severe burn. The early clinical sequence is characterized by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Resuscitation failure",
"     </li>",
"     <li>",
"      Acute respiratory distress syndrome",
"     </li>",
"     <li>",
"      Hemodynamic failure",
"     </li>",
"     <li>",
"      Renal failure",
"     </li>",
"     <li>",
"      Liver failure",
"     </li>",
"     <li>",
"      Gastrointestinal failure",
"     </li>",
"     <li>",
"      Infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The later clinical sequence is characterized by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulmonary failure",
"     </li>",
"     <li>",
"      Hemodynamic instability",
"     </li>",
"     <li>",
"      Renal failure",
"     </li>",
"     <li>",
"      Gastrointestinal failure",
"     </li>",
"     <li>",
"      Liver failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Often, multisystem organ failure and death occurs at the end of both cascades. Mortality increases with increasing numbers of failed organ systems. When three organs have failed, mortality approaches 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37433385\">",
"    <span class=\"h3\">",
"     Acute tubular necrosis and acute kidney injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute tubular necrosis and acute kidney injury (AKI) are caused by a reduction of cardiac output and blood volume along with an increased secretion of stress mediators (eg, angiotensin, aldosterone, and vasopressin). AKI is associated with a high mortality rate for severely burned adults and children (88 percent and 56 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=see_link\">",
"     \"Definition of acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=see_link\">",
"     \"Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immediate fluid resuscitation upon admission to the emergency department is the fundamental approach to preventing AKI [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/21\">",
"     21",
"    </a>",
"    ]. Early renal failure can occur as a consequence of underperfusion and underresuscitation. A second period of risk occurs 2 to 14 days after the initial resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/1\">",
"     1",
"    </a>",
"    ], and is most likely related to sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/22\">",
"     22",
"    </a>",
"    ]. In a retrospective review of 238 severely burned patients admitted to an intensive care unit (ICU), AKI occurred in 39 percent, and one in three patients with AKI required renal replacement therapy (RRT) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/23\">",
"     23",
"    </a>",
"    ]. The percent of total body surface area (TBSA) burned was significantly higher for patients who developed AKI compared with patients without AKI (40.2 versus 25.7 percent TBSA). The mortality rate was significantly higher for patients with AKI compared with patients without AKI (44.1 percent [41 of 93 patients] versus 6.9 percent [10 of 145 patients]). In addition, for patients requiring RRT (n = 32), the mortality rate was higher for patients with early AKI due to underresuscitation or hypoperfusion compared with patients with late AKI (66.7 versus 57.1 percent). &nbsp;",
"   </p>",
"   <p>",
"    Management of AKI includes correcting electrolyte abnormalities, volume status (depletion or overload), and metabolic acidosis. Dialysis is performed in the clinical setting when patients are not responsive to these conservative measures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=see_link\">",
"     \"Definition of acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30425?source=see_link\">",
"     \"Overview of the management of acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37433392\">",
"    <span class=\"h3\">",
"     Pulmonary failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary failure is the result of decreased oxygenation, and occurs both initially with the burn injury and within four to eight days after the initial injury due to progression of the inhalation injury",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fulminant ARDS. The pathophysiology, clinical presentation, and diagnostic evaluation for ARDS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=see_link\">",
"     \"Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Continuous oximetry measurements are critical, as a decrease in oxygen saturation to less than 92 percent is indicative of respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/1\">",
"     1",
"    </a>",
"    ]. Increasing concentrations of inspired oxygen are needed, and when ventilation begins to fail, indicated by growing respiratory rates and hypercarbia, intubation is warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, extubation should be performed as soon as possible, since patients can perform their own pulmonary toilet better than through an endotracheal tube or tracheostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Retrospective studies have suggested that patients treated with a tracheostomy are at risk of tracheostomy site infections and an associated greater risk of pneumonia and death [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While a tracheostomy is safe, provides a secure airway, and may improve ventilator management. The timing of performing a tracheostomy is controversial, and should be decided on a patient-by-patient basis, as illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of 44 acutely burned adults randomized to early tracheostomy (ET) within the first week or conventional therapy (endotracheal intubation), patients undergoing ET had significant improvement in the ratio of arterial oxygen pressure to inspired oxygen concentration ratio",
"      <span class=\"nowrap\">",
"       (Pa0",
"       <sub>",
"        2",
"       </sub>",
"       /Fi0",
"       <sub>",
"        2",
"       </sub>",
"       )",
"      </span>",
"      within 24 hours following the procedure (139 &plusmn; 15 versus 190 &plusmn; 12 mmHg) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/26\">",
"       26",
"      </a>",
"      ]. However, patients treated with ET were less likely to undergo extubation on postburn day 14 compared with conventional management (one versus six patients). There were no significant differences in ventilator days, length of stay, incidence of pneumonia, or survival.",
"     </li>",
"     <li>",
"      A retrospective review of 38 severely burned children undergoing a tracheostomy within the first week of a severe burn found no statistical difference in pre-tracheostomy oxygenation or ventilation compared with post-tracheostomy ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/27\">",
"       27",
"      </a>",
"      ]. Peak inspiratory pressures were lower after tracheostomy, accompanied by higher ventilatory volumes and pulmonary compliance, and higher",
"      <span class=\"nowrap\">",
"       Pa0",
"       <sub>",
"        2",
"       </sub>",
"       /Fi0",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      ratios. There were no tracheostomy site infections, tracheostomy-related deaths, or tracheal stenoses in the 30 burn survivors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37433399\">",
"    <span class=\"h3\">",
"     Cardiac failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two clinical responses to a severe burn: the ebb and flow states. The ebb state is one of low cardiac output. The flow state is hyperdynamic, in which patients have significantly elevated heart rates and cardiac outputs. These cardiac perturbations occur in nearly all patients with a &ge;40 percent TBSA burn. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link&amp;anchor=H7#H7\">",
"     \"Hypermetabolic response to severe burn injury: Recognition and treatment\", section on 'Patterns of metabolic regulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immediately following a severe burn, patients typically have low cardiac function indices that are characteristic for early shock (",
"    <a class=\"graphic graphic_table graphicRef73000 \" href=\"UTD.htm?17/34/17963\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/28\">",
"     28",
"    </a>",
"    ]. At 72 to 96 hours postburn, cardiac output was 150 percent higher than predicted for healthy adults, and remained abnormal at the time of discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/29\">",
"     29",
"    </a>",
"    ]. The heart rate was 160 to 170 percent higher than predicted and remained elevated for up to two years post burn. In addition, myocardial oxygen consumption remained elevated into the rehabilitation phase [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/30\">",
"     30",
"    </a>",
"    ], and increased cardiac stress was associated with myocardial depression [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective review of optimal management of severely burned patients, cardiac stress and myocardial dysfunction may be main contributors to mortality in large burns, implying the therapeutic need to improve cardiac stress and function [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/34\">",
"     34",
"    </a>",
"    ]. Underresuscitation followed by over-resuscitation leads to pulmonary edema and right heart failure. In infants, right heart failure is a common contributor to burn-related death. Infant hearts may be less compliant, and low filling pressures may plateau stroke volumes, thereby causing the heart to be more sensitive to volume overload [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/21,35\">",
"     21,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link&amp;anchor=H5#H5\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Cardiogenic'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42901?source=see_link&amp;anchor=H10#H10\">",
"     \"Physiology and classification of shock in children\", section on 'Cardiogenic shock'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To reduce the risk of cardiac failure, judicious fluid resuscitation should be performed upon the patient&rsquo;s arrival to the hospital. For the cardiac dysfunction or hyperdynamic state that occurs in almost all patients with burns &gt;40 percent TBSA, we also use a nonselective beta blocker to block catecholamine receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link&amp;anchor=H31#H31\">",
"     \"Hypermetabolic response to severe burn injury: Recognition and treatment\", section on 'Propranolol'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37433406\">",
"    <span class=\"h3\">",
"     Hepatic failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic failure following a severe burn is generally proportional to the severity of the burn [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/38\">",
"     38",
"    </a>",
"    ]. Immediately following a severe burn and continuing for approximately one week, generalized edema and hepatic hypertrophy occur [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In a retrospective review of 102 severely burned children, the mean liver size and weight increased during the first week and peaked at two weeks following the burn (mean &plusmn; standard error, 85 &plusmn; 5 percent and 126 &plusmn; 19 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/40\">",
"     40",
"    </a>",
"    ]. Twelve months after the burn, the liver remained 50 percent larger than the predicted liver size.",
"   </p>",
"   <p>",
"    Hepatic protein synthesis is also impaired after a severe burn. As a result of the cellular damage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    altered membrane permeability, hepatic edema induces an increased release of hepatic enzymes into the circulation. Elevated circulating levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), glutamate dehydrogenase, or alkaline phosphatase (ALKP) are reliable indicators of hepatocyte injury [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/29,40,41\">",
"     29,40,41",
"    </a>",
"    ]. However, ALT is a more specific test for hepatocyte injury following a severe burn. Serum levels of the circulating enzymes as high as 200 percent above normal for age have been reported for patients with severe burns.",
"   </p>",
"   <p>",
"    Serum markers peak early following a severe burn; AST and ALT peak during the first postburn day, and ALKP during the second day, and often normalize prior to discharge. Although these enzymes are elevated as a direct result of the burn injury, additional physiologic processes may be amplifying their expression, including the elevation of ALKP occurring during growth spurts or alongside massive bone resorption. Treatment of acute hepatic failure is supportive, and may include replacement of factors II, VII, IX, and X and albumen until the liver recovers. Management of acute liver failure is discussed separately. Prothrombin time (PT) is a useful marker of hepatic synthetic function, and specifically coagulation. Coupled with the clinical examination, PT can be helpful in the interpretation of other serum liver function tests, especially if abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=see_link\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=see_link\">",
"     \"Acute liver failure in adults: Management and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6777?source=see_link\">",
"     \"Acute liver failure in children: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37433413\">",
"    <span class=\"h3\">",
"     Hematologic failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematologic failure expressed as a coagulopathy may be caused by depletion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impaired synthesis of coagulation factors or by thrombocytopenia. Disseminated intravascular coagulation may be effectively treated by infusion of fresh frozen plasma and cryoprecipitate in order to sustain plasma levels of coagulation factors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23242?source=see_link\">",
"     \"Coagulopathy associated with trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Trauma-induced coagulopathy can be present in up to 30 percent of severe trauma victims. This may lead to multisystem organ dysfunction that increases morbidity and mortality. (See",
"    <a class=\"local\" href=\"#H37433371\">",
"     'Multiple organ dysfunction syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Risk factors for developing hematologic failure or trauma-induced coagulopathy include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/21,43,44\">",
"     21,43,44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Delay in resuscitation",
"     </li>",
"     <li>",
"      Under-resuscitation",
"     </li>",
"     <li>",
"      Acidosis",
"     </li>",
"     <li>",
"      Hypothermia",
"     </li>",
"     <li>",
"      Massive blood loss",
"     </li>",
"     <li>",
"      High volume transfusion",
"     </li>",
"     <li>",
"      Thrombocytopenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Management is supportive in nature will be based on the etiology of the coagulopathy (eg, warming patient, correcting acidosis, resuscitation). While hematologic failure may occur in the absence of hepatic failure, it is worsened by hepatic failure. Thrombocytopenia with platelet counts lower than 50,000 represents a common finding in severe burn patients and does not require any treatment, except in the clinical setting of diffuse bleeding, when administration of exogenous platelets may be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/21\">",
"     21",
"    </a>",
"    ]. Overall, prognosis is poor if left untreated, with a mortality rate approaching 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severely burned patients are at risk for thrombotic and embolic complications, which are likely related to immobilization. Complications of deep venous thrombosis were associated with increasing age, weight, and TBSA burned [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/43\">",
"     43",
"    </a>",
"    ], indicating a need for deep venous thrombosis prophylaxis in the absence of bleeding complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35478?source=see_link&amp;anchor=H1607614#H1607614\">",
"     \"Overview of the management of the severely burned patient\", section on 'Acute management in the ICU'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37433420\">",
"    <span class=\"h3\">",
"     Central nervous system failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obtundation is one of the hallmarks of sepsis, and burn patients are no exception. A new onset of mental status changes not attributed to sedative medications in a severely burned patient should incite a search for a septic source [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/1\">",
"     1",
"    </a>",
"    ]. One significant cause of altered mental status in severely burned patients is anoxic brain injury due to",
"    <span class=\"nowrap\">",
"     hypoperfusion/under-resuscitation",
"    </span>",
"    or cerebral edema secondary to over-resuscitation. Anoxic brain injury contributes up to 7 percent of fatalities from severe burn injury. Adequate resuscitation in these patients may have been preventative [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/6,45\">",
"     6,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurologic evaluation, including coma syndromes, and management are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=see_link\">",
"     \"Stupor and coma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28136?source=see_link\">",
"     \"Evaluation of stupor and coma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37433427\">",
"    <span class=\"h3\">",
"     Gastrointestinal system failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal system failure may be associated with loss of gut barrier function and enteric bacterial translocation following a severe burn injury [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/46\">",
"     46",
"    </a>",
"    ]. This results in a profound hyperinflammatory response, leading to gastrointestinal organ failure.",
"   </p>",
"   <p>",
"    In the clinical setting of low flow states that can occur with inadequate fluid resuscitation following a severe burn, mesenteric blood flow is compromised or inadequate, and gut mucosal integrity is compromised. This is best prevented by following goal-directed fluid resuscitation and maintaining optimal hemodynamics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link&amp;anchor=H22#H22\">",
"     \"Emergency care of moderate and severe thermal burns in children\", section on 'Fluid resuscitation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link&amp;anchor=H10#H10\">",
"     \"Emergency care of moderate and severe thermal burns in adults\", section on 'Fluid resuscitation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44377?source=see_link&amp;anchor=H17#H17\">",
"     \"Acute mesenteric ischemia\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gut mucosal atrophy occurs in the absence of intraluminal feeds and is another cause of gastrointestinal failure after severe burn injury [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Early enteral nutrition, started 24 to 48 hours after burn injury, is one of the only therapies shown to decrease this complication. Early enteral nutrition is well tolerated after severe burn injury [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4215?source=see_link\">",
"     \"Overview of nutritional support for moderate to severe burn patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15716?source=see_link\">",
"     \"Evaluating nutritional support for moderate to severe burn patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11401?source=see_link\">",
"     \"Nutritional demands and enteral formulas for moderate to severe burn patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are some data to support the contention that enteral feedings have beneficial effects on outcome in injured patients when compared with parenteral feedings, possibly via an enhancement of gastrointestinal barrier integrity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/51\">",
"     51",
"    </a>",
"    ]. However, these data require confirmation prior to general application.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37434932\">",
"    <span class=\"h1\">",
"     LONG-TERM OUTCOMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37434940\">",
"    <span class=\"h2\">",
"     Metabolic alterations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partial-thickness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    full-thickness burns covering more than 40 percent TBSA are associated with a significant stress response, inflammation, and severe hypermetabolism, resulting in hyperdynamic circulation, augmented body temperature regulation, proteolysis, glycolysis, lipolysis, and inefficient substrate cycling [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/2,52-57\">",
"     2,52-57",
"    </a>",
"    ]. Enhanced catecholamine, glucocorticoid, glucagon, and dopamine secretion account for the initiation of the acute hypermetabolic response and the associated catabolic state [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/52,58-64\">",
"     52,58-64",
"    </a>",
"    ]. Release of insulin is increased in response to glucose load when compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/65,66\">",
"     65,66",
"    </a>",
"    ] and glucose levels remain elevated, indicating an insulin-resistant state [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. The hypermetabolic response can persist for three years following a severe burn [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/52,58,64,68-70\">",
"     52,58,64,68-70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=see_link\">",
"     \"Hypermetabolic response to severe burn injury: Recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37434947\">",
"    <span class=\"h2\">",
"     Hypertrophic scars",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic scarring is defined as a scar raised above the skin level but within the confines of the original skin lesion and may result from an overproduction of collagen and an imbalance between the anabolic and catabolic phases of healing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. In contrast, keloid scars overextend the margins of the wound. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1847?source=see_link\">",
"     \"Keloids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypertrophic scars occur in approximately 25 to 90 percent of burns, with a longer time to heal as the most important risk factor [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/73-77\">",
"     73-77",
"    </a>",
"    ]. For example, in a retrospective review of 59 children and 41 adult burn patients, when the time to heal was between 14 and 21 days, one-third developed hypertrophic scars [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/74\">",
"     74",
"    </a>",
"    ]. However, when the burn wound healed after 21 days, 78 percent of patients developed hypertrophic scars. Other risks for hypertrophic scarring include deep full-thickness burns, darker color of skin, and genetic predisposition.",
"   </p>",
"   <p>",
"    Preventive strategies that may diminish the occurrence or severity of cosmetically disfiguring or functionally limiting hypertrophic scars include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/73,74,78-86\">",
"     73,74,78-86",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Early wound closure",
"      </strong>",
"      &mdash; Wound closure should be performed within the first five days of the burn.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Skin grafting",
"      </strong>",
"      &ndash; Use of sheet or mesh skin grafts with a small expansion ratio (1:2) are preferable to grafts with a wider expansion. However, in patients with extensive burns, coverage is the priority, and meshed skin grafts with a wide expansion ratio may be required to provide adequate early coverage.",
"     </li>",
"     <li>",
"      <strong>",
"       Dermal substitutes",
"      </strong>",
"      &ndash; Use of dermal regeneration templates, such as Integra or Matriderm, can be used in the acute and reconstructive phases to improve aesthetic and functional outcomes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The principles of early skin closure, coverage, and reconstruction, including a discussion on types of grafts and dermal substitutes, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link&amp;anchor=H8044867#H8044867\">",
"     \"Principles of burn reconstruction: Overview of surgical procedures\", section on 'Burn reconstruction procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pressure therapy",
"      </strong>",
"      &ndash; Pressure therapy, applied as continuous wearing of pressure garments, is typically used to prevent hypertrophic burn scar formation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/79,87\">",
"       79,87",
"      </a>",
"      ]. Pressure therapy is effective in 60 to 85 percent of patients, possibly by decreasing collagen synthesis as a result of limiting the supply of blood, oxygen, and nutrients to the scar tissue",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increasing apoptosis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/87-90\">",
"       87-90",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Continuous pressure of 15 to 40 mmHg is applied for at least 23",
"      <span class=\"nowrap\">",
"       h/day",
"      </span>",
"      for more than six months while the scar is still active is currently recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/89,91\">",
"       89,91",
"      </a>",
"      ]. However, compression therapy is limited by the ability to adequately fit the garment to the wounded area, and patient discomfort frequently reduces compliance.",
"     </li>",
"     <li>",
"      <strong>",
"       Silicone gel sheeting",
"      </strong>",
"      &ndash; Silicone gel sheeting, a soft, slightly adherent and semi-occlusive covering, may prevent or reduce the formation of hypertrophic scars by decreasing the collagen remodeling phase of wound healing, although the exact mechanism is unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/73,92-94\">",
"       73,92-94",
"      </a>",
"      ]. Randomized trials that included 559 patients at risk for hypertrophic scarring imply that silicone gel may reduce the incidence of hypertrophic scars; however, the trials were judged to be of poor quality and subject to bias [",
"      <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/95\">",
"       95",
"      </a>",
"      ]. Side effects of silicone sheeting include local skin reactions, such as maceration and pruritus.",
"     </li>",
"     <li>",
"      <strong>",
"       Investigational therapies",
"      </strong>",
"      &ndash; Investigational approaches include the use of gene transfer technology to promote wound healing to stimulate the granulation process, vascularization, and reepithelialization or the scar quality [",
"      <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/96,97\">",
"       96,97",
"      </a>",
"      ]. Additional studies are needed to define growth factor levels in different phases of wound healing and to elucidate the precise timing of gene expression or down-regulation required to better augment wound healing and control scar formation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/98\">",
"       98",
"      </a>",
"      ]. Other investigational approaches include onion extract containing scar creams as well as injections with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      acetonide or 5-Fluorouacil in circumscribed areas [",
"      <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/73,99\">",
"       73,99",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Management options for hypertrophic scars and keloids are reviewed separately. (See",
"    <span class=\"nowrap\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1847?source=see_link&amp;anchor=H4#H4\">",
"      \"Keloids\", section on 'Treatment'",
"     </a>",
"     .)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37434954\">",
"    <span class=\"h2\">",
"     Psychological aspects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychiatric/psychologic",
"    support of the burn patient should be an early and routine component of management. With improvements in mortality from severe burn injury, outcomes are focused on measures of function, adjustment, and community integration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/100-103\">",
"     100-103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35478?source=see_link&amp;anchor=H1470803#H1470803\">",
"     \"Overview of the management of the severely burned patient\", section on 'Survival'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Burn Specific Health Scale (BSHS) was designed to assess heat sensitivity, affect, hand function, treatment regimens, work, sexuality, interpersonal relationships, simple abilities, and body image in burn patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/104\">",
"     104",
"    </a>",
"    ]. Severely burned patients can return to the community and adjust well; however, some burn patients do develop clinically significant psychological disturbances such as somatization and phobic anxiety.",
"   </p>",
"   <p>",
"    Depression and post-traumatic stress disorder (PTSD) are the most common psychologic problems, occurring in 13 to 23 percent and 13 to 45 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/78\">",
"     78",
"    </a>",
"    ]. Risk factors related to depression include pre-burn depression and female gender in combination with facial disfigurement. Risk factors related to PTSD include pre-burn depression, type and severity of baseline depressive symptoms, anxiety related to pain, and visibility of burn injury. Social problems include difficulties with sexual activity and social interactions, although quality of life appears to improve with time. Children with severe burns were found to have similar somatization problems as well as sleep disturbances, but, in general, were reasonably adjusted [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/100,101,105\">",
"     100,101,105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therapeutic interventions in long-term psychosocial rehabilitation following a major burn injury include optimizing social functioning and adjustment, therapies directed towards the specific conditions (eg, depression, PTSD, anxiety) encountered, and exercise to improve health-related quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/101,106,107\">",
"     101,106,107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37434961\">",
"    <span class=\"h2\">",
"     Return to work",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ultimate goal of rehabilitation following a burn injury is reintegration into society, including gainful employment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/108\">",
"     108",
"    </a>",
"    ]. In a retrospective review of 363 adults employed prior to the burn, 66 and 90 percent of patients returned to work at 6 and 24 months postburn, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/109\">",
"     109",
"    </a>",
"    ]. However, only 37 percent returned to the same job and employer without injury-related accommodations.",
"   </p>",
"   <p>",
"    The percent of total body surface area (TBSA) burned was the most important predictor of time away from work [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/109\">",
"     109",
"    </a>",
"    ]. Other predictors of employment after a burn injury include burn site (eg, hands), length of hospitalization, psychiatric history, personality characteristics, and demographic factors including age, marital status, and employment status at the time of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/110-113\">",
"     110-113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Return to work can be delayed by the functional limitations of a burn. The management of the long-term functional limitations of burn scars and resultant contractures is reviewed separately and includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=see_link\">",
"       \"Principles of burn reconstruction: Overview of surgical procedures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29625?source=see_link\">",
"       \"Principles of burn reconstruction: Face, scalp, and neck\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10456?source=see_link\">",
"       \"Principles of burn reconstruction: The female breast\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15882?source=see_link\">",
"       \"Principles of burn reconstruction: Extremities and regional nodal basins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14263?source=see_link\">",
"       \"Principles of burn reconstruction: Perineum and genitalia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37434968\">",
"    <span class=\"h2\">",
"     Associated medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with extensive burns require attention to specific long-term complications, including sensory loss, hyperpigmentation, and hypertrophic scars [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/114\">",
"     114",
"    </a>",
"    ]. The depth of injury (partial thickness versus full thickness) determines specific long-term complications (eg, sensory loss due to nerve damage and full-thickness injury leading to impairment of sweat glands) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/115,116\">",
"     115,116",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Survival from severe burns is no longer the exception, but the rule (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35478?source=see_link&amp;anchor=H1470803#H1470803\">",
"     \"Overview of the management of the severely burned patient\", section on 'Survival'",
"    </a>",
"    ). Quality of life is now a major outcome measure since acute management has greatly improved the survival of patients with severe burns. The price of survival is the risk of total disability, and the location of major injuries (eg, hands, face) determines one&rsquo;s ability to adapt. Psychosocially, patients are able to adapt in society with physical disabilities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/100,117-120\">",
"     100,117-120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Available epidemiologic data support that burn patients are",
"    <strong>",
"     not",
"    </strong>",
"    at a higher risk of developing skin cancers, particularly melanoma or squamous cell carcinomas, despite data from earlier case reports and small series [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/121-123\">",
"     121-123",
"    </a>",
"    ]. In a retrospective cohort study of 16,903 patients with a thermal or chemical burn that required hospitalization, only 139 burn patients developed skin cancers compared with an expected 189 cases in the general population (standardized incidence ratio 0.7, 95% CI 0.6-0.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/121\">",
"     121",
"    </a>",
"    ]. This was independent of severity of burn or duration of observation. A second cohort study of 12,783 burn patients found no causal association of a burn injury and risk of developing skin cancer with 20 to 30 years of observation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/122\">",
"     122",
"    </a>",
"    ]. However, female gender-specific skin cancer risk was identified (standardized incidence ratio 1.39, 95% CI 1.16-1.69) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/20/10570/abstract/124\">",
"     124",
"    </a>",
"    ]. Burn wounds are a chronic condition and require extended surveillance and follow-up beyond the acute hospitalization and acute inflammatory stage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37436261\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple organ dysfunction syndrome (MODS) is a progressive disorder that commonly occurs in acutely ill patients and exists in a continuum with the systemic inflammatory response syndrome (SIRS) which affects most patients with a severe burn, with or without an infection. The risk of MODS increases with burn wounds &gt;20 percent TBSA, increasing age, male gender, sepsis, hypoperfusion, and underresuscitation. (See",
"      <a class=\"local\" href=\"#H37433371\">",
"       'Multiple organ dysfunction syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immediate fluid resuscitation upon admission to the emergency department is the fundamental approach to preventing acute kidney injury. Early renal failure can occur as a consequence of underperfusion and underresuscitation. A second period of risk occurs 2 to 14 days after the initial resuscitation, and is most likely related to sepsis. (See",
"      <a class=\"local\" href=\"#H37433385\">",
"       'Acute tubular necrosis and acute kidney injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gut mucosal atrophy occurs in the absence of intraluminal feeds and is another cause of gastrointestinal failure after severe burn injury. Early enteral nutrition, started 24 to 48 hours after burn injury, is one of the only therapies shown to decrease this complication. (See",
"      <a class=\"local\" href=\"#H37433427\">",
"       'Gastrointestinal system failure'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4215?source=see_link\">",
"       \"Overview of nutritional support for moderate to severe burn patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Depression and post-traumatic stress disorder (PTSD) are the most common psychologic problems, occurring in 13 to 23 percent and 13 to 45 percent of patients, respectively. (See",
"      <a class=\"local\" href=\"#H37434954\">",
"       'Psychological aspects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Jeschke MG, Williams FN, Gauglitz GG, Herndon DN. Burns. In: Sabiston Textbook of Surgery, Townsend M, Beauchamp RD, Evers MB, Kenneth ML (Eds), Elsevier, Philadelphia, PA 2012. Vol 19, p.521.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/2\">",
"      Herndon DN, Tompkins RG. Support of the metabolic response to burn injury. Lancet 2004; 363:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/3\">",
"      McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care Clin 2001; 17:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/4\">",
"      Greenhalgh DG, Saffle JR, Holmes JH 4th, et al. American Burn Association consensus conference to define sepsis and infection in burns. J Burn Care Res 2007; 28:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/5\">",
"      Cumming J, Purdue GF, Hunt JL, O'Keefe GE. Objective estimates of the incidence and consequences of multiple organ dysfunction and sepsis after burn trauma. J Trauma 2001; 50:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/6\">",
"      Williams FN, Herndon DN, Hawkins HK, et al. The leading causes of death after burn injury in a single pediatric burn center. Crit Care 2009; 13:R183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/7\">",
"      Meakins JL. Etiology of multiple organ failure. J Trauma 1990; 30:S165.",
"     </a>",
"    </li>",
"    <li>",
"     Chung K, Steven Wolf. Critical care in the severely burned :  Organ support and management of complications. In: Total Burn Care, 4th ed, Herndon DN.  (Ed), 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/9\">",
"      Janzekovic Z. The burn wound from the surgical point of view. J Trauma 1975; 15:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/10\">",
"      Atiyeh BS, Dham R, Kadry M, et al. Benefit-cost analysis of moist exposed burn ointment. Burns 2002; 28:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/11\">",
"      Lofts JA. Cost analysis of a major burn. N Z Med J 1991; 104:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/12\">",
"      Munster AM, Smith-Meek M, Sharkey P. The effect of early surgical intervention on mortality and cost-effectiveness in burn care, 1978-91. Burns 1994; 20:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/13\">",
"      Ramzy PI, Barret JP, Herndon DN. Thermal injury. Crit Care Clin 1999; 15:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/14\">",
"      Chan BP, Kochevar IE, Redmond RW. Enhancement of porcine skin graft adherence using a light-activated process. J Surg Res 2002; 108:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/15\">",
"      Magnotti LJ, Deitch EA. Burns, bacterial translocation, gut barrier function, and failure. J Burn Care Rehabil 2005; 26:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/16\">",
"      Goodwin CW. Multiple organ failure: clinical overview of the syndrome. J Trauma 1990; 30:S163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/17\">",
"      Huang YS, Yang ZC, Liu XS, et al. Serial experimental and clinical studies on the pathogenesis of multiple organ dysfunction syndrome (MODS) in severe burns. Burns 1998; 24:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/18\">",
"      Leblanc M, Thibeault Y, Qu&eacute;rin S. Continuous haemofiltration and haemodiafiltration for acute renal failure in severely burned patients. Burns 1997; 23:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/19\">",
"      Chrysopoulo MT, Jeschke MG, Dziewulski P, et al. Acute renal dysfunction in severely burned adults. J Trauma 1999; 46:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/20\">",
"      Jeschke MG, Barrow RE, Wolf SE, Herndon DN. Mortality in burned children with acute renal failure. Arch Surg 1998; 133:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/21\">",
"      Wolf SE, Rose JK, Desai MH, et al. Mortality determinants in massive pediatric burns. An analysis of 103 children with &gt; or = 80% TBSA burns (&gt; or = 70% full-thickness). Ann Surg 1997; 225:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/22\">",
"      Ichai C, Passeron C, Carles M, et al. Prolonged low-dose dopamine infusion induces a transient improvement in renal function in hemodynamically stable, critically ill patients: a single-blind, prospective, controlled study. Crit Care Med 2000; 28:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/23\">",
"      Mustonen KM, Vuola J. Acute renal failure in intensive care burn patients (ARF in burn patients). J Burn Care Res 2008; 29:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/24\">",
"      Barret JP, Desai MH, Herndon DN. Effects of tracheostomies on infection and airway complications in pediatric burn patients. Burns 2000; 26:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/25\">",
"      Hunt JL, Purdue GF, Gunning T. Is tracheostomy warranted in the burn patient? Indications and complications. J Burn Care Rehabil 1986; 7:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/26\">",
"      Saffle JR, Morris SE, Edelman L. Early tracheostomy does not improve outcome in burn patients. J Burn Care Rehabil 2002; 23:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/27\">",
"      Palmieri TL, Jackson W, Greenhalgh DG. Benefits of early tracheostomy in severely burned children. Crit Care Med 2002; 30:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/28\">",
"      Cuthbertson D. Post-shock metabolic response. Lancet 1942; :433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/29\">",
"      Jeschke MG, Chinkes DL, Finnerty CC, et al. Pathophysiologic response to severe burn injury. Ann Surg 2008; 248:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/30\">",
"      Baron PW, Barrow RE, Pierre EJ, Herndon DN. Prolonged use of propranolol safely decreases cardiac work in burned children. J Burn Care Rehabil 1997; 18:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/31\">",
"      Sambol JT, White J, Horton JW, Deitch EA. Burn-induced impairment of cardiac contractile function is due to gut-derived factors transported in mesenteric lymph. Shock 2002; 18:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/32\">",
"      Willis MS, Carlson DL, Dimaio JM, et al. Macrophage migration inhibitory factor mediates late cardiac dysfunction after burn injury. Am J Physiol Heart Circ Physiol 2005; 288:H795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/33\">",
"      Yang J, Yang Z, Chen F. [Myocardial contractile and calcium transport function after severe burn injury]. Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi 1998; 14:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/34\">",
"      Pereira C, Murphy K, Herndon D. Outcome measures in burn care. Is mortality dead? Burns 2004; 30:761.",
"     </a>",
"    </li>",
"    <li>",
"     Lee JO, Norbury WB, Herndon DN. Special considerations of age: The pediatric burned patient. In: Total Burn Care, 4th, Herndon DN.  (Ed), Saunders Elsevier, Philadelphia 2012. p.405.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/36\">",
"      Williams FN, Herndon DN, Kulp GA, Jeschke MG. Propranolol decreases cardiac work in a dose-dependent manner in severely burned children. Surgery 2011; 149:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/37\">",
"      Williams FN, Herndon DN, Suman OE, et al. Changes in cardiac physiology after severe burn injury. J Burn Care Res 2011; 32:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/38\">",
"      Barret JP, Jeschke MG, Herndon DN. Fatty infiltration of the liver in severely burned pediatric patients: autopsy findings and clinical implications. J Trauma 2001; 51:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/39\">",
"      Jeschke MG, Low JF, Spies M, et al. Cell proliferation, apoptosis, NF-kappaB expression, enzyme, protein, and weight changes in livers of burned rats. Am J Physiol Gastrointest Liver Physiol 2001; 280:G1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/40\">",
"      Jeschke MG, Micak RP, Finnerty CC, Herndon DN. Changes in liver function and size after a severe thermal injury. Shock 2007; 28:172.",
"     </a>",
"    </li>",
"    <li>",
"     Jeschke MG, Celeste Finnerty. The hepatic response to thermal injury. In: Total Burn Care, Herndon DN.  (Ed), 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/42\">",
"      Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002; 123:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/43\">",
"      Harrington DT, Mozingo DW, Cancio L, et al. Thermally injured patients are at significant risk for thromboembolic complications. J Trauma 2001; 50:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/44\">",
"      Xu SX, Wang L, Zhou GJ, et al. Risk factors and clinical significance of trauma-induced coagulopathy in ICU patients with severe trauma. Eur J Emerg Med 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/45\">",
"      Gore DC, Hawkins HK, Chinkes DL, et al. Assessment of adverse events in the demise of pediatric burn patients. J Trauma 2007; 63:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/46\">",
"      Deitch EA. Intestinal permeability is increased in burn patients shortly after injury. Surgery 1990; 107:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/47\">",
"      Wu X, Woodside KJ, Song J, Wolf SE. Burn-induced gut mucosal homeostasis in TCR delta receptor-deficient mice. Shock 2004; 21:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/48\">",
"      Spies M, Chappell VL, Dasu MR, et al. Role of TNF-alpha in gut mucosal changes after severe burn. Am J Physiol Gastrointest Liver Physiol 2002; 283:G703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/49\">",
"      Chung DH, Herndon DN. Multiple converging mechanisms for postburn intestinal barrier dysfunction. Crit Care Med 2004; 32:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/50\">",
"      McDonald WS, Sharp CW Jr, Deitch EA. Immediate enteral feeding in burn patients is safe and effective. Ann Surg 1991; 213:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/51\">",
"      Gupta R, Patel K, Calder PC, et al. A randomised clinical trial to assess the effect of total enteral and total parenteral nutritional support on metabolic, inflammatory and oxidative markers in patients with predicted severe acute pancreatitis (APACHE II &gt; or =6). Pancreatology 2003; 3:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/52\">",
"      Hart DW, Wolf SE, Mlcak R, et al. Persistence of muscle catabolism after severe burn. Surgery 2000; 128:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/53\">",
"      REISS E, PEARSON E, ARTZ CP. The metabolic response to burns. J Clin Invest 1956; 35:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/54\">",
"      Yu YM, Tompkins RG, Ryan CM, Young VR. The metabolic basis of the increase of the increase in energy expenditure in severely burned patients. JPEN J Parenter Enteral Nutr 1999; 23:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/55\">",
"      Hart DW, Wolf SE, Chinkes DL, et al. Effects of early excision and aggressive enteral feeding on hypermetabolism, catabolism, and sepsis after severe burn. J Trauma 2003; 54:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/56\">",
"      Hart DW, Wolf SE, Ramzy PI, et al. Anabolic effects of oxandrolone after severe burn. Ann Surg 2001; 233:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/57\">",
"      Przkora R, Herndon DN, Suman OE, et al. Beneficial effects of extended growth hormone treatment after hospital discharge in pediatric burn patients. Ann Surg 2006; 243:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/58\">",
"      Mlcak RP, Jeschke MG, Barrow RE, Herndon DN. The influence of age and gender on resting energy expenditure in severely burned children. Ann Surg 2006; 244:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/59\">",
"      Przkora R, Barrow RE, Jeschke MG, et al. Body composition changes with time in pediatric burn patients. J Trauma 2006; 60:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/60\">",
"      Dolecek R. Endocrine changes after burn trauma--a review. Keio J Med 1989; 38:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/61\">",
"      Jeffries MK, Vance ML. Growth hormone and cortisol secretion in patients with burn injury. J Burn Care Rehabil 1992; 13:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/62\">",
"      Klein GL, Bi LX, Sherrard DJ, et al. Evidence supporting a role of glucocorticoids in short-term bone loss in burned children. Osteoporos Int 2004; 15:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/63\">",
"      Coombes EJ, Batstone GF. Urine cortisol levels after burn injury. Burns Incl Therm Inj 1982; 8:333.",
"     </a>",
"    </li>",
"    <li>",
"     Norbury WB, Herndon DN. Modulation of the hypermetabolic response after burn injury. In: Total Burn Care, 3rd ed, Herndon DN (Ed), Saunders &amp; Elsevier, New York 2007. p.420.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/65\">",
"      Galster AD, Bier DM, Cryer PE, Monafo WW. Plasma palmitate turnover in subjects with thermal injury. J Trauma 1984; 24:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/66\">",
"      Cree MG, Aarsland A, Herndon DN, Wolfe RR. Role of fat metabolism in burn trauma-induced skeletal muscle insulin resistance. Crit Care Med 2007; 35:S476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/67\">",
"      Childs C, Heath DF, Little RA, Brotherston M. Glucose metabolism in children during the first day after burn injury. Arch Emerg Med 1990; 7:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/68\">",
"      Jeschke MG, Mlcak RP, Finnerty CC, et al. Burn size determines the inflammatory and hypermetabolic response. Crit Care 2007; 11:R90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/69\">",
"      Jeschke MG, Gauglitz GG, Kulp GA, et al. Long-term persistance of the pathophysiologic response to severe burn injury. PLoS One 2011; 6:e21245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/70\">",
"      Gauglitz GG, Herndon DN, Kulp GA, et al. Abnormal insulin sensitivity persists up to three years in pediatric patients post-burn. J Clin Endocrinol Metab 2009; 94:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/71\">",
"      Brown JJ, Bayat A. Genetic susceptibility to raised dermal scarring. Br J Dermatol 2009; 161:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/72\">",
"      Peacock EE Jr, Madden JW, Trier WC. Biologic basis for the treatment of keloids and hypertrophic scars. South Med J 1970; 63:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/73\">",
"      Bloemen MC, van der Veer WM, Ulrich MM, et al. Prevention and curative management of hypertrophic scar formation. Burns 2009; 35:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/74\">",
"      Deitch EA, Wheelahan TM, Rose MP, et al. Hypertrophic burn scars: analysis of variables. J Trauma 1983; 23:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/75\">",
"      Lewis WH, Sun KK. Hypertrophic scar: a genetic hypothesis. Burns 1990; 16:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/76\">",
"      Cubison TC, Pape SA, Parkhouse N. Evidence for the link between healing time and the development of hypertrophic scars (HTS) in paediatric burns due to scald injury. Burns 2006; 32:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/77\">",
"      Berman B, Viera MH, Amini S, et al. Prevention and management of hypertrophic scars and keloids after burns in children. J Craniofac Surg 2008; 19:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/78\">",
"      Van Loey NE, Van Son MJ. Psychopathology and psychological problems in patients with burn scars: epidemiology and management. Am J Clin Dermatol 2003; 4:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/79\">",
"      Gauglitz GG, Korting HC, Pavicic T, et al. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med 2011; 17:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/80\">",
"      van Zuijlen PP, Angeles AP, Kreis RW, et al. Scar assessment tools: implications for current research. Plast Reconstr Surg 2002; 109:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/81\">",
"      Archer SB, Henke A, Greenhalgh DG, Warden GD. The use of sheet autografts to cover extensive burns in patients. J Burn Care Rehabil 1998; 19:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/82\">",
"      Haslik W, Kamolz LP, Nathschl&auml;ger G, et al. First experiences with the collagen-elastin matrix Matriderm as a dermal substitute in severe burn injuries of the hand. Burns 2007; 33:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/83\">",
"      Ryssel H, Gazyakan E, Germann G, Ohlbauer M. The use of MatriDerm in early excision and simultaneous autologous skin grafting in burns--a pilot study. Burns 2008; 34:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/84\">",
"      Dantzer E, Queruel P, Salinier L, et al. Dermal regeneration template for deep hand burns: clinical utility for both early grafting and reconstructive surgery. Br J Plast Surg 2003; 56:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/85\">",
"      Branski LK, Herndon DN, Pereira C, et al. Longitudinal assessment of Integra in primary burn management: a randomized pediatric clinical trial. Crit Care Med 2007; 35:2615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/86\">",
"      Clayman MA, Clayman SM, Mozingo DW. The use of collagen-glycosaminoglycan copolymer (Integra) for the repair of hypertrophic scars and keloids. J Burn Care Res 2006; 27:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/87\">",
"      Ren&ograve; F, Sabbatini M, Lombardi F, et al. In vitro mechanical compression induces apoptosis and regulates cytokines release in hypertrophic scars. Wound Repair Regen 2003; 11:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/88\">",
"      Baur PS, Larson DL, Stacey TR, et al. Ultrastructural analysis of pressure-treated human hypertrophic scars. J Trauma 1976; 16:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/89\">",
"      Macintyre L, Baird M. Pressure garments for use in the treatment of hypertrophic scars--a review of the problems associated with their use. Burns 2006; 32:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/90\">",
"      Kelly AP. Medical and surgical therapies for keloids. Dermatol Ther 2004; 17:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/91\">",
"      Van den Kerckhove E, Stappaerts K, Fieuws S, et al. The assessment of erythema and thickness on burn related scars during pressure garment therapy as a preventive measure for hypertrophic scarring. Burns 2005; 31:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/92\">",
"      Kuhn MA, Moffit MR, Smith PD, et al. Silicone sheeting decreases fibroblast activity and downregulates TGFbeta2 in hypertrophic scar model. Int J Surg Investig 2001; 2:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/93\">",
"      Musgrave MA, Umraw N, Fish JS, et al. The effect of silicone gel sheets on perfusion of hypertrophic burn scars. J Burn Care Rehabil 2002; 23:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/94\">",
"      Perkins K, Davey RB, Wallis KA. Silicone gel: a new treatment for burn scars and contractures. Burns Incl Therm Inj 1983; 9:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/95\">",
"      O'Brien L, Pandit A. Silicon gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst Rev 2006; :CD003826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/96\">",
"      Petrie NC, Vranckx JJ, Hoeller D, et al. Gene delivery of PDGF for wound healing therapy. J Tissue Viability 2005; 15:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/97\">",
"      Rogers B, Lineaweaver WC. Skin wound healing and cell-mediated DNA transport. J Long Term Eff Med Implants 2002; 12:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/98\">",
"      Gauglitz GG, Jeschke MG. Combined gene and stem cell therapy for cutaneous wound healing. Mol Pharm 2011; 8:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/99\">",
"      Karagoz H, Yuksel F, Ulkur E, Evinc R. Comparison of efficacy of silicone gel, silicone gel sheeting, and topical onion extract including heparin and allantoin for the treatment of postburn hypertrophic scars. Burns 2009; 35:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/100\">",
"      Blakeney PE, Rosenberg L, Rosenberg M, Faber AW. Psychosocial care of persons with severe burns. Burns 2008; 34:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/101\">",
"      Corry N, Pruzinsky T, Rumsey N. Quality of life and psychosocial adjustment to burn injury: social functioning, body image, and health policy perspectives. Int Rev Psychiatry 2009; 21:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/102\">",
"      Engrav LH, Covey MH, Dutcher KD, et al. Impairment, time out of school, and time off from work after burns. Plast Reconstr Surg 1987; 79:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/103\">",
"      Anzarut A, Chen M, Shankowsky H, Tredget EE. Quality-of-life and outcome predictors following massive burn injury. Plast Reconstr Surg 2005; 116:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/104\">",
"      Kildal M, Andersson G, Fugl-Meyer AR, et al. Development of a brief version of the Burn Specific Health Scale (BSHS-B). J Trauma 2001; 51:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/105\">",
"      Browne G, Byrne C, Brown B, et al. Psychosocial adjustment of burn survivors. Burns Incl Therm Inj 1985; 12:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/106\">",
"      Grisbrook TL, Wallman KE, Elliott CM, et al. The effect of exercise training on pulmonary function and aerobic capacity in adults with burn. Burns 2012; 38:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/107\">",
"      Grisbrook TL, Reid SL, Edgar DW, et al. Exercise training to improve health related quality of life in long term survivors of major burn injury: a matched controlled study. Burns 2012; 38:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/108\">",
"      Schneider JC, Bassi S, Ryan CM. Employment outcomes after burn injury: a comparison of those burned at work and those burned outside of work. J Burn Care Res 2011; 32:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/109\">",
"      Brych SB, Engrav LH, Rivara FP, et al. Time off work and return to work rates after burns: systematic review of the literature and a large two-center series. J Burn Care Rehabil 2001; 22:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/110\">",
"      Bowden ML, Thomson PD, Prasad JK. Factors influencing return to employment after a burn injury. Arch Phys Med Rehabil 1989; 70:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/111\">",
"      Dyster-Aas J, Kildal M, Willebrand M. Return to work and health-related quality of life after burn injury. J Rehabil Med 2007; 39:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/112\">",
"      Moi AL, Wentzel-Larsen T, Salemark L, Hanestad BR. Long-term risk factors for impaired burn-specific health and unemployment in patients with thermal injury. Burns 2007; 33:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/113\">",
"      Schneider JC, Bassi S, Ryan CM. Barriers impacting employment after burn injury. J Burn Care Res 2009; 30:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/114\">",
"      Holavanahalli RK, Helm PA, Kowalske KJ. Long-term outcomes in patients surviving large burns: the skin. J Burn Care Res 2010; 31:631.",
"     </a>",
"    </li>",
"    <li>",
"     Lewis GM, Heimback DM, Gibran NS. Evaluation of the burn wound. In: Total Burn Care, 4th, Herndon DN.  (Ed), Saunders Elsevier, Philadelphia 2012. p.125.",
"    </li>",
"    <li>",
"     Barret J. Cost-containment and outcome measures. In: Total Burn Care, Herndon DN.  (Ed), Saunders Elsevier, Philadepphia 2012. p.706.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/117\">",
"      Verity PA. Burn injuries in children. The emotional and psychological effects on child and family. Aust Fam Physician 1995; 24:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/118\">",
"      Nguyen TJ, Thaller S. Psychological rehabilitation of pediatric burn patients. J Craniofac Surg 2008; 19:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/119\">",
"      Paratz JD, Stockton K, Plaza A, et al. Intensive exercise after thermal injury improves physical, functional, and psychological outcomes. J Trauma Acute Care Surg 2012; 73:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/120\">",
"      Baker CP, Russell WJ, Meyer W 3rd, Blakeney P. Physical and psychologic rehabilitation outcomes for young adults burned as children. Arch Phys Med Rehabil 2007; 88:S57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/121\">",
"      Mellemkjaer L, H&ouml;lmich LR, Gridley G, et al. Risks for skin and other cancers up to 25 years after burn injuries. Epidemiology 2006; 17:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/122\">",
"      Lindel&ouml;f B, Krynitz B, Granath F, Ekbom A. Burn injuries and skin cancer: a population-based cohort study. Acta Derm Venereol 2008; 88:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/123\">",
"      Wallingford SC, Olsen CM, Plasmeijer E, Green AC. Skin cancer arising in scars: a systematic review. Dermatol Surg 2011; 37:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/20/10570/abstract/124\">",
"      Duke J, Rea S, Semmens J, et al. Burn and cancer risk: a state-wide longitudinal analysis. Burns 2012; 38:340.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87444 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-9B44C2D3FB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_20_10570=[""].join("\n");
var outline_f10_20_10570=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37436261\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37436937\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37436945\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37433371\">",
"      Multiple organ dysfunction syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37433378\">",
"      Specific organ failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37433385\">",
"      - Acute tubular necrosis and acute kidney injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37433392\">",
"      - Pulmonary failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37433399\">",
"      - Cardiac failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37433406\">",
"      - Hepatic failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37433413\">",
"      - Hematologic failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37433420\">",
"      - Central nervous system failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37433427\">",
"      - Gastrointestinal system failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37434932\">",
"      LONG-TERM OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37434940\">",
"      Metabolic alterations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37434947\">",
"      Hypertrophic scars",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37434954\">",
"      Psychological aspects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37434961\">",
"      Return to work",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37434968\">",
"      Associated medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37436261\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/87444\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/87444|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/13/2268\" title=\"table 1\">",
"      American Burn Association grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/34/17963\" title=\"table 2\">",
"      Types of shock",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=related_link\">",
"      Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38538?source=related_link\">",
"      Acute liver failure in adults: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6777?source=related_link\">",
"      Acute liver failure in children: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44377?source=related_link\">",
"      Acute mesenteric ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=related_link\">",
"      Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/58/21417?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of burn wound sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/44/23242?source=related_link\">",
"      Coagulopathy associated with trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42773?source=related_link\">",
"      Definition of acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/54/12138?source=related_link\">",
"      Etiology and diagnosis of prerenal disease and acute tubular necrosis in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/22/15716?source=related_link\">",
"      Evaluating nutritional support for moderate to severe burn patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28136?source=related_link\">",
"      Evaluation of stupor and coma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/51/22330?source=related_link\">",
"      Hypermetabolic response to severe burn injury: Recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1847?source=related_link\">",
"      Keloids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11401?source=related_link\">",
"      Nutritional demands and enteral formulas for moderate to severe burn patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4215?source=related_link\">",
"      Overview of nutritional support for moderate to severe burn patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30425?source=related_link\">",
"      Overview of the management of acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35478?source=related_link\">",
"      Overview of the management of the severely burned patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42901?source=related_link\">",
"      Physiology and classification of shock in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/32/15882?source=related_link\">",
"      Principles of burn reconstruction: Extremities and regional nodal basins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/59/29625?source=related_link\">",
"      Principles of burn reconstruction: Face, scalp, and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20346?source=related_link\">",
"      Principles of burn reconstruction: Overview of surgical procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/59/14263?source=related_link\">",
"      Principles of burn reconstruction: Perineum and genitalia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10456?source=related_link\">",
"      Principles of burn reconstruction: The female breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_20_10571="Presenting symptoms lung ca";
var content_f10_20_10571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76229&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Symptoms of lung cancer in over 3500 patients at presentation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Symptom",
"       </td>",
"       <td class=\"subtitle1\">",
"        Patients (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cough",
"       </td>",
"       <td>",
"        45-74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight loss",
"       </td>",
"       <td>",
"        46-68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dyspnea",
"       </td>",
"       <td>",
"        37-58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest pain",
"       </td>",
"       <td>",
"        27-49",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemoptysis",
"       </td>",
"       <td>",
"        27-29",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone pain",
"       </td>",
"       <td>",
"        20-21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hoarseness",
"       </td>",
"       <td>",
"        8-18",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Hyde, L, Hyde, CI. Chest 1974; 65:299-306 and Chute CG, et al. Cancer 1985; 56:2107-2111.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_20_10571=[""].join("\n");
var outline_f10_20_10571=null;
var title_f10_20_10572="Dx criteria for cutaneous and systemic mastocytosis";
var content_f10_20_10572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F82827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F82827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for cutaneous and systemic mastocytosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cutaneous mastocytosis (CM)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin lesions demonstrating the typical clinical findings of urticaria pigmentosa/maculopapular cutaneous mastocytosis, diffuse cutaneous mastocytosis or solitary mastocytoma, and typical histological infiltrates of mast cells in a multifocal or diffuse pattern in an adequate skin biopsy. In addition, a diagnostic prerequisite for the diagnosis of CM is the absence of features/criteria sufficient to establish the diagnosis of SM.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Systemic mastocytosis (SM)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The diagnosis of SM can be made when the major criterion and one minor criterion or at least three minor criteria are present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Major criterion:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multifocal, dense infiltrates of mast cells (&ge;15 mast cells in aggregates) detected in sections of bone marrow and/or other extracutaneous organ(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Minor criteria:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ol>",
"         <li>",
"          In biopsy sections of bone marrow or other extracutaneous organs, &gt;25 percent of the mast cells in the infiltrate are spindle-shaped or have atypical morphology or, of all mast cells in bone marrow aspirate smears, &gt;25 percent are immature or atypical",
"         </li>",
"         <li>",
"          Detection of an activating point mutation at codon 816 of",
"          <em>",
"           KIT",
"          </em>",
"          in bone marrow, blood or another extracutaneous organ",
"         </li>",
"         <li>",
"          Mast cells in bone marrow, blood or other extracutaneous organs express CD2 and/or CD25 in addition to normal mast cell markers",
"         </li>",
"         <li>",
"          Serum total tryptase persistently exceeds 20 ng/mL (unless there is an associated clonal myeloid disorder, in which case this parameter is not valid)",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Horny HP, Metcalfe DD, Bennet JM, et al. Mastocytosis. In: WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed, Swerdlow SH, Camp E, Harris NL, et al (Eds), IARC, Lyon 2008. Copyright &copy; 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_20_10572=[""].join("\n");
var outline_f10_20_10572=null;
var title_f10_20_10573="Organ donation rates by country";
var content_f10_20_10573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80579&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Organ donation decision defaults, donation agreement rates, and actual donation rated by country",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Country",
"      </td>",
"      <td class=\"subtitle1\">",
"       Default",
"      </td>",
"      <td class=\"subtitle1\">",
"       Effective consent rate",
"      </td>",
"      <td class=\"subtitle1\">",
"       Year registry established",
"      </td>",
"      <td class=\"subtitle1\">",
"       Actual rate of donation 2001",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Austria",
"      </td>",
"      <td>",
"       Opt out",
"      </td>",
"      <td>",
"       99.99",
"      </td>",
"      <td>",
"       1995",
"      </td>",
"      <td>",
"       23.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Belgium",
"      </td>",
"      <td>",
"       Opt out",
"      </td>",
"      <td>",
"       98",
"      </td>",
"      <td>",
"       1987",
"      </td>",
"      <td>",
"       21.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Czech Republic",
"      </td>",
"      <td>",
"       Opt out",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       16.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Denmark",
"      </td>",
"      <td>",
"       Opt in",
"      </td>",
"      <td>",
"       4.25",
"      </td>",
"      <td>",
"       1990",
"      </td>",
"      <td>",
"       12.9",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Finland",
"      </td>",
"      <td>",
"       Opt out",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       17.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       France",
"      </td>",
"      <td>",
"       Opt out",
"      </td>",
"      <td>",
"       99.91",
"      </td>",
"      <td>",
"       1998",
"      </td>",
"      <td>",
"       17.8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Germany",
"      </td>",
"      <td>",
"       Opt in",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       13.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Greece",
"      </td>",
"      <td>",
"       Opt out",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       3.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hungary",
"      </td>",
"      <td>",
"       Opt out",
"      </td>",
"      <td>",
"       99.997",
"      </td>",
"      <td>",
"       1999",
"      </td>",
"      <td>",
"       13.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ireland",
"      </td>",
"      <td>",
"       Opt in",
"      </td>",
"      <td>",
"       NS",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       17.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Netherlands",
"      </td>",
"      <td>",
"       Opt in",
"      </td>",
"      <td>",
"       28.79",
"      </td>",
"      <td>",
"       1998",
"      </td>",
"      <td>",
"       11.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Norway",
"      </td>",
"      <td>",
"       Opt out",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       17.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Poland",
"      </td>",
"      <td>",
"       Opt out",
"      </td>",
"      <td>",
"       99.95",
"      </td>",
"      <td>",
"       1996",
"      </td>",
"      <td>",
"       11.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Portugal",
"      </td>",
"      <td>",
"       Opt out",
"      </td>",
"      <td>",
"       99.65",
"      </td>",
"      <td>",
"       1994",
"      </td>",
"      <td>",
"       20.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Spain",
"      </td>",
"      <td>",
"       Opt out",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       32.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sweden",
"      </td>",
"      <td>",
"       Opt out",
"      </td>",
"      <td>",
"       91.73",
"      </td>",
"      <td>",
"       1996",
"      </td>",
"      <td>",
"       12.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       United Kingdom",
"      </td>",
"      <td>",
"       Opt in",
"      </td>",
"      <td>",
"       16.9",
"      </td>",
"      <td>",
"       1994",
"      </td>",
"      <td>",
"       18.1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    All results are based on data from G&auml;bel [G&auml;bel and Rehnqvist. Transplant Proc 1997; 29:3093], supplemented by additional contacts with the donation registries in France, the Netherlands, Portugal, and the United Kingdom. Data from Germany represent information from a transplant organization and the results of a national poll which inquired about whether the respondent held a donor card and their attitude toward donation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eric Johnson, MD. From: Johnson, E, Goldstein, D. Do Defaults Save Lives? Science 2003; 302:1338.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_20_10573=[""].join("\n");
var outline_f10_20_10573=null;
var title_f10_20_10574="Contents: Gastroenterology and Hepatology calculators";
var content_f10_20_10574=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/12/3278\">",
"       Gastroenterology and Hepatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Gastroenterology and Hepatology calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Gastroenterology and Hepatology calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Clinical Criteria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/56/19329\">",
"           Calculator: Blatchford score for gastrointestinal bleeding",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/26/28065\">",
"           Calculator: Child Pugh classification for severity of liver disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/28/29121\">",
"           Calculator: Child Pugh classification for severity of liver disease (SI units)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/61/6098\">",
"           Calculator: Crohn's disease activity index (CDAI)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/9/43152\">",
"           Calculator: Glasgow alcoholic hepatitis score",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/33/19985\">",
"           Calculator: Harvey-Bradshaw index of Crohn's disease activity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/29/15825\">",
"           Calculator: Hepatitis discriminant function for corticosteroid therapy in alcoholic hepatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/46/8929\">",
"           Calculator: Mayo score for assessing ulcerative colitis activity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/16/7425\">",
"           Calculator: Ranson criteria for pancreatitis prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/11/27838\">",
"           Calculator: Rockall score for upper gastrointestinal bleeding",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/25/37264\">",
"           Calculator: Bedside Index of Severity in Acute Pancreatitis (BISAP) score",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/23/21874\">",
"           Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/2/18466\">",
"           Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12) (SI units)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/39/14962\">",
"           Calculator: MELDNa score for end-stage liver disease (not appropriate for patients under the age of 12)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/38/11874\">",
"           Calculator: MELDNa score for end-stage liver disease (not appropriate for patients under the age of 12) (SI units)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/26/32162\">",
"           Calculator: Mortality risk in post-operative patients with cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/40/9860\">",
"           Calculator: PELD score for end-stage liver disease (patients less than 12 years old)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/42/9890\">",
"           Calculator: Stool osmolal gap",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-C9C412E4A8-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f10_20_10574=[""].join("\n");
var outline_f10_20_10574=null;
var title_f10_20_10575="Merkel relative survival by stage";
var content_f10_20_10575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F82500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F82500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Relative survival for 2856 Merkel cell carcinoma patients by stage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 306px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relative survival for 2856 Merkel cell carcinoma patients by stage. Percent relative survival was calculated for cases in the National Cancer Database using age- and sex-matched control data from the Centers for Disease Control and Prevention. Stages are indicated in the figure except for Stage IIIA* which could not be derived using this dataset. Total number of patients with 2856, and individual substages were as follows: IA = 266, IB = 754, IIA = 124, IIB = 414, IIC = 84, IIIA = 794, IIIB = 143, IV = 277.",
"    <div class=\"footnotes\">",
"     * The IIIA curve shown represents pathologically node positive patients, with the clinical node status unknown or negative. It is anticipated that true Stage IIIA patients (clinical node status negative) have better survival than the IIIA line in this graph shows.",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_20_10575=[""].join("\n");
var outline_f10_20_10575=null;
